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Nucleotide excision repair (NER) is one of the major repair systems for removal of 
DNA lesions. The NER pathway has evolved mainly to repair UV-induced DNA 
damage and is also active against a broad range of endogenously generated oxidative 
lesions. Defects in NER result in the human inherited disorder xeroderma pigmentosum 
(XP), which is characterised by UV hypersensitivity and a 1000-fold increased risk of 
skin cancer. ERCC1 is essential for the NER pathway where it acts in a complex with 
the XPF protein to make the incision 5' to the DNA lesion. The normal 1.1kb Ercc1 
transcript is expressed in all tissues. Our group has discovered a second larger 1.5 kb 
transcript, which initiates from an alternative promoter, and is the most abundant Ercc1 
transcript in mouse skin.  
 
The aims of this project were: 1, To investigate the role of ERCC1 and of the 1.5kb skin 
specific Ercc1 transcript in protecting the skin against UV-induced DNA damage. 2, To 
study the importance of ERCC1 in melanoma skin cancer and investigate ERCC1as a 
possible target for therapy against melanoma.  
 
Using a panel of Ercc1 wild-type and deficient cells, we established a quantitative 
western blotting system to study the expression of ERCC1 in a range of mouse tissues 
and mouse and human cell types. Although the skin-specific Ercc1 transcript was found 
to be present at much higher levels in the skin of albino compared to pigmented mouse 
strains, this did not result in an elevated level of ERCC1 protein. We were also unable to 
demonstrate that UV-irradiation, or other stress-inducing treatments resulted in 
increased levels of ERCC1 protein in cultured mouse keratinocytes. We investigated the 





upstream promoter regions that were candidates for the source of the 1.5kb skin-specific 
Ercc1 transcript. We found no evidence that they were the source and, instead, used 5' 
RACE analysis to locate the skin-specific promoter to a polymorphic region 500bp 
upstream of the normal initiation site. In albino strains this region contains a SINE 
element, which we hypothesize could be involved in the production of the skin-specific 
Ercc1 transcript.   
 
We also investigated the protein level of ERCC1 and other DNA repair proteins, 
including XPF, MSH2, MSH6 and MLH1 in human melanoma cells and ovarian tumour 
cells. Significantly elevated protein levels of ERCC1 and XPF, as well as the mismatch 
repair protein MLH1 were found in melanoma cells. This could possibly contribute to 
the higher resistance to chemotherapy in melanoma, although the melanoma cell lines 
we tested did not show increased resistance to UV and cisplatin compared to the ovarian 
cancer cells tested. When Ercc1 proficient mouse melanoma cells were xenografted into 
nude mice the xenografts grew rapidly. Cisplatin treatment caused an initial shrinkage of 
the tumours, but re-growth rapidly followed. Cells re-isolated into culture from cisplatin 
treated xenografts had significantly higher levels of ERCC1 protein than either input 
cells, or cells re-isolated from untreated xenografts. An isogenic Ercc1 deficient 
derivative of the Ercc1 proficient mouse melanoma cell line grew as rapidly as the 
parent line in vitro, but grew much more slowly as xenografts. In addition, the 
xenografts shrank completely following cisplatin treatment and did not recover. This 
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1.1 DNA damage and repair 
 
Correct genetic and epigenetic information is essential for proper cellular functioning. 
However, DNA damage, which can result in the introductions of mutation into the 
genome, is an extremely common event in a cell's lifetime. Miscellaneous errors occur 
and accumulate in the genome during cell division as the machinery of DNA replication 
is not 100% efficient. On top of this, endogenous sources of DNA damage and 
exposures to environmental carcinogens, such as chemical contacts, tobacco smoke and 
ultraviolet (UV) radiation, can also result in various types of DNA lesions. The 
accumulation of DNA changes may eventually activate proto-oncogenes and inactivate 
tumour suppressor genes leading to an increased risk of tumourigenesis. Therefore, 
efficient repair of DNA damage and maintenance of genome integrity is fundamental to 
species survival. 
 
To protect the information stored within the genome, cells have evolved various 
complex mechanisms to detect and repair DNA damage, and most of the time a cell 
repairs its damaged DNA properly. Depending upon the mutagenic agents involved, 
different DNA repair mechanisms are operative, including the direct reversal pathway 
(DR), mismatch repair (MMR), nucleotide excision repair (NER), base excision repair 
(BER), non-homologous end joining (NHEJ), homologous recombination repair (HR)  
and inter-strand cross-link (ICL) repair (Figure 1.1). DNA adducts, such as those created 
by alkylating agents, may be repaired by the direct reversal of the DNA alkylation (DR). 
The DNA lesions could also be excised and repaired before they are confronted by the 
replication machinery. This is achieved by BER (Sharma and Dianov 2007), which 
excises a single damaged DNA base, or a short strand containing the damaged base, or 
by NER, which excises a single-stranded DNA molecule of approximately 24-30 












Several DNA repair pathways exist and deal with various types of DNA insults. These pathways include 
the direct reversal pathway, the MMR pathway, the NER pathway, the BER pathway, the NHEJ pathway, 
the HRR pathway, and the ICL pathway.  DNA strands are shown in black lines and different nucleotides 






breaks (DSB) are mainly repaired by NHEJ, whereas replication-associated DSBs are 
repaired by homologous recombination  (HR) and related replication repair pathways 
(Sargent et al. 1997; Arnaudeau et al. 2001). Interstrand cross-links (ICLs), which are a 
complex lesion that covalently link duplex DNA molecules, can be repaired by a 
combination of NER, HR and lesion bypass mechanisms (Wang et al. 2001; Zheng et al. 
2003). 
 
Direct reversal of DNA damage is not a multistep process and does not involve multiple 
proteins (Sedgwick et al. 2007). Catalyzed by enzymes such as ABH2 (also known as 
ALKBH2), ABH3 (also known as ALKBH3) and O6-methylguanine DNA methyl 
transferase (MGMT), DNA adducts are repaired in a process that directly reverses the 
DNA alkylation. MGMT, also known as AGT, removes the DNA adducts by 
transferring the alkyl group from the oxygen in the guanine ring to a cysteine residue in 
its active site (Lindahl et al. 1982). DNA dioxygenases ABH2 and ABH3 revert 1-
methyladenine and 3-methylcytosine back to adenine or cytosine respectively (Duncan 
et al. 2002).  
 
Mismatch repair, a system for recognizing and repairing erroneous insertion, deletion 
and mis-incorporation of bases during DNA replication and recombination, is a highly 
conserved process from prokaryotes to eukaryotes. MMR plays a key role in maintaining 
genomic integrity (Li 2008). Mismatch repair is strand-specific and has a number of 
cues which distinguish the newly synthesized strand from the template strand. 
Mismatches are recognized by the MutS homologue, which in conjunction with a MutL 
homologue initiates the repair. The incorporated base is replaced with the correct 
nucleotide on the newly synthesized strand by an excision repair mechanism. The 
consequences of defective MMR are associated with genome-wide instability, 





cancer, resistance to certain chemotherapeutic agents, and abnormalities in meiosis and 
infertility in mammalian systems (de la Chapelle 2004).  
 
Base excision repair (BER) is a cellular mechanism that removes non-bulky adducts 
from the DNA throughout the cell cycle and is the primary mechanism for repair of 
oxidative base lesions (Sancar 1996; David et al. 2007). Other base modifications 
repaired by BER include uracil that results from cytosine deamination and 3-
methyladenine caused by alkylating agents. The cut of the N-glycosyl bond between the 
sugar and the base is made by DNA glycosylase and an apurinic/apyrimidinic (AP) site 
is created, then the abasic sugar is released by AP lyase and endonucleases, before an 
undamaged nucleoside is inserted to fill the gap. Defects in human BER proteins can 
reduce cellular tolerance to oxidative DNA base damage caused by endogenous and 
exogenous sources, such as exposure to toxins and ionizing radiation, and increase the 
chance of cell dysfunction and mutagenesis, consequently leading to cancer, disease, and 
aging (Sokhansanj and Wilson 2006; Maynard et al. 2009). 
 
The NER pathway is a multistep process that has evolved primarily to repair UV-
induced DNA damage and is also active against a broad range of endogenously 
generated oxidative lesions (de Boer and Hoeijmakers 2000). NER consists of two 
subpathways in mammals, global genome repair (GGR) and transcription-coupled repair 
(TCR), which differ according to the initial recognition stage. GGR can remove DNA 
lesions throughout the genome while TCR mainly deals with lesions in the transcribed 
strand of actively transcribed genes (Leadon and Lawrence 1991; Lombard et al. 2005). 
Incisions are made in the damaged strand of DNA by endonucleases, upstream of the 
lesion by ERCC1/XPF complex and downstream by XPG, and then an oligonucleotide 






Double-strand breaks (DSBs), primarily caused by ionising radiation, certain chemicals 
and arrested replication, are repaired by homologous recombination (HR) and non-
homologous end joining (NHEJ) (Pardo et al. 2009). The primary HR mechanism 
consists of two categories: the most important category is gene conversion, which 
requires that sequences surrounding the break can find their homology anywhere else in 
the genome. The non-damaged homologous sequence then acts as a template for repair 
synthesis. The second HR category is the non-conservative process of single-strand 
annealing (SSA), which utilizes direct repeats flanking the DSB. The secondary 
mechanism NHEJ, also called illegitimate recombination or non-homologous 
recombination, permits joining of ends even if there is no sequence similarity between 
them (Hefferin and Tomkinson 2005). NHEJ requires the broken ends to be physically 
closely aligned, before NHEJ proteins bind the broken ends together.  This re-ligation 
process could simply restore the original sequence perfectly, or in an error-prone fashion 
by adding a few nucleotides or removing sequences ranging from 1 nucleotide up to a 
few Kb. 
  
Inter-strand crosslinks (ICL), normally caused by cisplatin, mitomycin C, derivatives of 
nitrogen mustard, and other bifunctional alkylating agents, covalently join both DNA 
strands, preventing their separation and blocking DNA and RNA polymerases and 
therefore constituting and extremely toxic class of DNA damage. As most of the cross-
linking agents are among the frequently used drugs in cancer chemotherapy the repair 
mechanisms of ICLs in cells are not just important to the maintenance of genome 
integrity, but can be also related to the resistance of tumour cells against chemotherapy. 
Although the repair of ICL is believed to be a complex process which recruits proteins 
from other DNA repair pathways as well as ICL repair specific enzymes, the detailed 
molecular mechanism of cross-link repair in humans is still not well characterized. It is 
reported that the ICL repair is initiated by FANC (Fanconi anaemia) gene products, then 





(Wang et al. 2001; Zheng et al. 2003). The cisplatin-induced DNA ICLs are reported to 
be recognized by replication protein A (RPA) (Patrick et al. 2008). The NER 
endonuclease-complex ERCC1/XPF is reported to be crucial for the repair of ICLs by 




1.2 Nucleotide excision repair 
 
1.2.1 Overview of NER 
 
Nucleotide excision repair (NER) is one of the major repair systems for removal of 
DNA lesions. The NER pathway has evolved mainly to repair UV-induced DNA 
damage, and is also active against a broad range of endogenously generated oxidative 
lesions (Wood 1999; de Boer and Hoeijmakers 2000). UV radiation mainly induces two 
mutagenic and cytotoxic DNA lesions, cyclobutane–pyrimidine dimers (CPDs) and 6–4 
photoproducts (6–4PPs), which both distort the DNA helix (Sinha and Hader 2002). The 
majority of proteins involved in the NER pathway are well characterised and are 
reviewed extensively (de Laat et al. 1999; Hoeijmakers 2001). 
 
The NER pathway excises damaged nucleotides, along with adjacent undamaged DNA, 
in the form of oligomers that are 25-32 nucleotides long. Defects in NER will be 
discussed in more detail later in this chapter, but generally, they result in the human 





hypersensitivity, pigmentation abnormalities and a 1000-fold increased risk of skin 
cancer (Friedberg 2003). Sun exposure of XP patients can also lead to progressive 
degenerative alterations of the skin and eyes (Bootsma et al. 2002). Defects of 
components of the NER pathway are also associated with an increased incidence of 
internal tumours and neurological abnormalities. Additionally, some NER defects lead 
to premature ageing phenotypes. 
 
 
1.2.2 The steps in NER 
 
The NER pathway is biochemically complicated and involves about 30 distinct proteins 
in human cells, including ERCC1 (the excision repair cross complementing-group 1), 
ERCC2 (XPD), ERCC3 (XPB), ERCC4 (XPF), ERCC5 (XPG), ERCC6 (CSB), XPA, 
XPC, XPE, PCNA (proliferating cell nuclear antigen) and the TFIIH-complex (Wood 
1999).  
 
NER consists of two subpathways in mammals, global genome repair (GGR) and 
transcription-coupled repair (TCR), according to the initial recognition stage (Figure 
1.2). GGR can remove DNA lesions throughout the genome (Lombard et al. 2005), 
while TCR deals with lesions in the transcribed strand of actively transcribed genes 
which lead to stalling of RNA polymerase II (Leadon and Lawrence 1991). Common 







NER consists of the following 4 steps: 
 
1) Recognition of DNA damage and binding of a multi-protein complex at the 
damaged site. As described before, the two sub-pathways, GGR and TCR, are 
different in this step only. In GGR, the proteins XPC and HHR23B are recruited to 
compose the first NER complex which recognizes and binds to the site of the DNA 
lesion. The binding to DNA lesions by the XPC/HHR23B complex is not only 
essential for the lesion recognition but is also essential for the recruitment of all 
subsequent NER components, including transcription factor TFIIH (Volker et al. 
2001). XPC/HHR23B is a structure-specific DNA binding factor which 
preferentially recognizes and binds to double-stranded/single-stranded DNA lesions 
that induce a higher degree of DNA helix distortion (Sugasawa et al. 2002). 
XPC/HHR23B recognizes 6-4PPs efficiently but doesn't recognizes CPDs as 
competently (Sugasawa et al. 2002). The XPC-HHR23B complex is also reported to 
recognize DNA ICLs by interaction with another NER complex XPA-RPA (Thoma 
et al. 2005). The XPE protein is also involved with damage-specific DNA binding 
(DDB) activity, and is reported to recognize DNA lesions. The DDB complex 
consists a p48/p127 heterodimer which has high affinity for UV induced DNA 
lesions (Nichols et al. 2000). p48, also known as DDB2, is the XPE gene product 
and is involved in cell cycle checkpoints as well as NER (Rapic-Otrin et al. 2003; 
Kulaksiz et al. 2005). Furthermore, DDB2 has been recently reported to be linked 
with the modification of histone H2A by ubiquitination and the cause of a 
conformational change which enables DNA lesion binding by the NER machinery 
(Kapetanaki et al. 2006). 
 
 
By contrast, in the TCR subpathway, the stalled RNA polymerase II fulfills the 














CSB (Matsumura and Ananthaswamy 2002). The CSA protein contains a WD-40  
repeat motif known to be involved in protein-protein interactions (Henning et al. 
1995). It has been reported that CSA is part of an E3-ubiquitin ligase complex 
(Groisman et al. 2003; Fousteri et al. 2006). The CSB protein has nucleosome 
remodelling activity and binds to core histone proteins in vitro (Citterio et al. 2000). 
CSB does not remove the stalled polymerase but its ability to bind to repair proteins 
suggests that CSB protein plays a role in recruiting repair proteins to complexes 
formed at damage sites (Selby and Sancar 1997). 
 
 
2) DNA helix unwinding. Once the DNA lesion is identified, GGR and TCR use a 
common mechanism to excise the damage. TFIIH is recruited to the damage site 
through interactions with XPC-HHR23B or CSB and CSA. TFIIH is a protein 
complex which has multiple enzymatic activities and is involved in initiation of 
RNA polymerase II transcription, NER and possibly in cell cycle regulation (de 
Laat et al. 1999). The multi-subunit TFIIH complex consists of ten polypeptides, 
including one recently identified trichothiodystrophy group A (TTDA)/ hTFB5 
protein, which is not essential for cell viability but could potentially be an NER-
specific factor. (Giglia-Mari et al. 2004; 2006). In NER, two essential subunits of 
TFIIH, known as XPB and XPD, exhibit DNA-dependent ATPase and helicase 
functions (Sancar 1996). XPB can unwind DNA in a 3' to 5' direction, and XPD in 
the opposite direction.  
 
 
Once the damaged DNA-helix is unwound, the DNA lesion is exposed for the 
upcoming repair work. XPA and RPA are recruited to the site not only to stabilize 
this open repair intermediate but also to coordinate the following repair work. XPA 
is considered to verify NER lesions and to play a central role in positioning the 





complex (de Laat et al. 1999). RPA also interacts with ERCC1-XPF, presumably 
via XPF, to position the nuclease at the DNA lesion (Matsunaga et al. 1996). 
 
 
3) Incision of damaged DNA. During this step, two structure-specific endonucleases 
XPG and XPF/ERCC1 access the damaged site to make the dual incision. XPG, 
which is closely related to the flap structure-specific endonuclease 1 (FEN-1) that 
participates in base excision repair, has a cleavage polarity that always make 
incisions in one strand of duplex DNA at the 3' side of a junction with ssDNA. 
Consistent with this cleavage polarity, XPG makes the 3' incision during NER  
(O'Donovan et al. 1994). XPG is not only required for the 3' incision but also for 
full open-complex formation, indicating a structural role in the core NER reaction 
(Evans et al. 1997). ERCC1-XPF makes the 5' side incision in NER (Mu et al. 
1996). However, unlike the XPG protein, ERCC1-XPF can be omitted for full open 
complex formation suggesting that they don't have an architectural function in the 
NER protein-DNA complex (Evans et al. 1997; Mu et al. 1997). It has been reported 
that the XPG-mediated 3' incision precedes the 5' incision made by ERCC1-XPF 
(Mu et al. 1996). The cut made by XPG is 2-8 nucleotides from the lesion, and the 
cut made by XPF/ERCC1 is 15-24 nucleotides away (Sancar 1996). 
 
 
4) Lesion excision and de novo synthesis. The excised fragment is around 30 
nucleotides in length. Part of the repair complex remains in the gap made by 
excision to protect the ssDNA. Once the lesion has been removed, the gap is filled 
by two DNA polymerases Polymerase δ and Polymerase ε. Both of the polymerases 
are proliferation cell nuclear antigen (PCNA) dependent, so that PCNA is also 
involved in this step, which adds nucleotides in a 5' to 3' direction. Replication 
factor-C (RF-C) and RPA are both involved as well. The final closure occurs with 






1.2.3 ERCC1 and ERCC1-XPF complex 
 
As described in the previous section, the ERCC1-XPF complex is an essential 
component of the NER pathway for making incision to the 5' side of the lesions. The 
complex also has additional, NER-independent roles in the repair of interstrand DNA 
crosslinks (ICL) and homologous recombination (HR) (Busch et al. 1997; Kuraoka et al. 
2000; Niedernhofer et al. 2004). Although the details of the ICL repair pathway are still 
not well-characterised, a suggested model indicates that the endonuclease function of 
ERCC1-XPF is essential to make the 5' end incision and remove the blocking ICL 
during repair (Niedernhofer et al. 2004). In the HR pathway, the ERCC1-XPF 
endonuclease was reported to be required for both gene conversion and SSA in 
mammalian cells (Al-Minawi et al. 2008).  
 
Several structural studies have been done to better understand the ERCC1-XPF 
complex. In archaebacteria, the XPF homolog acts as a homodimer without the presence 
of ERCC1 (Nishino et al. 2003; Newman et al. 2005). However, in eukaryotic cells, 
formation of the ERCC1-XPF complex, by interaction of their C terminal regions is 
required for the stability of both components (de Laat et al. 1998) (Figure 1.3). Three-
dimensional structural analysis of human ERCC1-XPF complex showed that the core of 
the complex, comprising residues 234–294 of ERCC1 and residues 836–895 of XPF, has 
a global pseudosymmetry with a very similar architecture of the associated partners 
(Tripsianes et al. 2005). In particular, a characteristic example of the double helix-
hairpin-helix (HhH)2 motif was detected in the ERCC1 protein fold, while a very similar 
fold was detected in XPF as well. This (HhH)2 motif is present in a variety of protein 












The heterodimeric (HhH)2 motif interaction of the ERCC1-XPF complex is shown within a circle. Other 
main domains are shown in ellipse shapes. N and C terminus of each protein is indicated with red letters.  






heterodimeric (HhH)2 motif from the ERCC1-XPF complex, containing two 
independent DNA-binding surfaces, was reported to be functional in ssDNA binding 
(Tripsianes et al. 2005; Tsodikov et al. 2005). The N-terminal helicase-like domain of 
XPF may contribute to the DNA binding and hydrolyzing activity (McCutchen-Maloney 
et al. 1999). The central domain of ERCC1 binds ssDNA/dsDNA junctions with a 
defined polarity, preferring a 5' single-stranded overhang (Tsodikov et al. 2005). 
 
Functional domains of ERCC1 and XPF were initially investigated by deletional 
analyses. Deletion of the N-terminal 92 amino acids of ERCC1 had no major effect on 
ERCC1 in terms of DNA repair in vivo. However, disruption of the N-terminal 103 
residues of ERCC1 completely destroyed the repair capacity (de Laat et al. 1998). The 
XPA binding domain was mapped to residues 93–120 in ERCC1. The ERCC1 C-
terminus was directly linked with complex formation ability and repair capacity as a five 
amino acid deletion from the ERCC1 C-terminus completely destroyed both the XPF 
binding ability and the DNA repair capacity in vivo (Sijbers et al. 1996; de Laat et al. 
1998). In XPF, residues 814–905 were mapped to be the region responsible for initial 
and stable complex formation between ERCC1 and XPF (de Laat et al. 1998). 
 
1.2.4 ERCC1 gene expression 
 
 
ERCC1 is highly conserved like many other DNA repair genes. It is homologous to 
RAD10 in Saccharomyces cerevisiae, SWI10 in Schizosaccharomyces pombe, and 





1987; Rodel et al. 1992). In both human and mouse, the normal 1.1kb Ercc1 transcript 
contains 10 exons and is believed to be driven by a promoter region lacking the 
“classical” promoter regulatory elements such as the TATA box and GC box 
immediately upstream of the transcription initiation site (van Duin et al. 1987). 
However, comparisons of the entire gene from mammalian species suggests that some 
potential regulatory regions may exist further upstream of the putative ERCC1 promoter 
region (Wilson et al. 2001). A conserved GC-rich region 5 kb upstream of ERCC1, 
which contains a conserved TATA box and a GC box, as well as some additional 
conserved segments such as LINE/L1 and LINE/L2 elements, indicate that the upstream 
region may also be involved in ERCC1 transcription (Wilson et al. 2001). 
 
Comparative transcript analysis of human ERCC1 ESTs has revealed alternative splicing 
events involving exons 1, 2, 3, 7, 8 and 9 (reviewed by Wilson et al. 2001). A 5' variant 
containing a differentially spliced exon 1 has been reported that spans the entire region 
of the previously believed promoter (van Duin et al. 1987).  Furthermore, a transcript 
with alternative polyadenylation, which reads through exon 9 and appears to utilize the 
polyadenylation signal on an adjacent Alu element was identified (Wilson et al. 2001). 
 
A novel 1.5kb skin-specific Ercc1 transcript was characterized by our previous group 
work using a panel of tissues from an Ercc1 wild type mouse (Selfridge et al. 2001). 
According to the northern blotting using an Ercc1 probe, the normal 1.1kb Ercc1 
transcript was evident in all tissues examined. In addition to the normal Ercc1 transcript, 
a second larger transcript of 1.5kb was evident in skin. The novel 1.5kb transcript 






An RT-PCR assay using primers in exon 2 and exon 10 of the Ercc1 cDNA indicated 
that the coding region from both novel and normal transcripts have the same size. Also 
3' RACE analysis revealed the difference in size was not due to differential 
polyadenylation. As a result, the additional 400bp in the novel transcript should be due 
to initiation of transcription upstream of the normal transcription start site, driven by an 
alternative upstream promoter not utilized in other tissues. This hypothesis was 
supported using 5' RACE analysis. A 400bp larger product was obtained from skin than 
from embryonic stem cells (Jim Selfridge, unpublished observations). An investigation 




1.2.5   Human inherited NER deficiency syndromes 
 
The phenotypic consequences caused by NER defects in humans are mainly three 
distinct diseases: xeroderma pigmentosum (XP), Cockayne syndrome (CS) and 
trichothiodystrophy (TTD). 
 
Xeroderma pigmentosum (OMIM: 278700) is an autosomal recessive genetic disorder of 
DNA repair in which the ability to repair damage caused by ultraviolet (UV) radiation is 
deficient. This disorder in patients leads to extreme photosensitivity, excessive 
pigmentation in response to UV and a significant increased chance of UV induced skin 
cancer. Physically, the XP disease passes through 3 stages. The first stage typically 
appears after the age of 6 months and is characterized by diffuse erythema, scaling, and 
freckle-like areas of increased pigmentation. The second stage is characterized by 





hyperpigmentation and hypopigmentation. The third stage is heralded by the appearance 
of numerous malignancies, including squamous cell carcinomas, malignant melanoma, 
basal cell carcinoma, and fibrosarcoma. Two most common causes of death for XP 
victims are metastatic malignant melanoma and squamous cell carcinoma (Li 2007). XP 
patients get the initial development of skin cancer at the mean age of 8 compared with 
the age of 50 in the general population (Kraemer 1997). It has been identified through 
complementation studies that XP is caused by mutations in seven different NER genes, 
XPA to XPG, while an additional XP variant group, XPV, is caused by mutation in the 
lesion bypass DNA polymerase polη, which can contribute to DNA replication over the 
damage site and is needed when cells enter S-phase in the presence of unrepaired DNA 
damage. A small number of XP patients with more severe NER defects also develop 
neurological symptoms and cognitive dysfunction, which is believed to be due to the 
accumulation of oxidative lesions in neurons (Anttinen et al. 2008). 
 
Cockayne syndrome, also known as Weber-Cockayne syndrome or Neill-Dingwall 
syndrome, is a rare autosomal recessive congenital disorder characterized by growth 
failure, impaired development of the nervous system, hypersensitivity to sunlight, and 
premature aging (Bertola et al. 2006). CS patients have hearing loss, eye abnormalities 
and some other common features like small head size, short stature and a prematurely 
aged appearance. However, problems with any or all of the internal organs are also 
possible (reviewed by de Boer and Hoeijmakers, 2000). Genetically, Type A CS 
(OMIM: 216400) is caused by mutations in the NER gene CSA and Type B CS (OMIM: 
133540) is caused by the NER gene CSB, while the cause of Type C CS (OMIM: 
216411) is still not clear. As described in the previous section, CSA and CSB proteins 
are involved in NER via the transcription-coupled repair mechanism. Compared to XP 
patients, CS patients are sensitive to sunshine but have a low risk of developing skin 
cancer. This is likely to be because the GGR pathway, which is still functional in CS 






Trichothiodystrophy (TTD) (OMIM: 601675) is a heterogeneous group of autosomal 
recessive disorders, characterised by brittle hair due to the lack of sulphur matrix rich 
proteins and accompanied by ichthyosis and other manifestations (Gillespie and 
Marshall 1983). In TTD patients, the hair appears dry, short and sparse. Existing hair is 
extremely fragile and splits longitudinally in to small fibres due to the poor viscoelastic 
parameters compared to controls. Physically, TTD patients generally have retarded 
overall growth and facial appearance with unusual protruding ears and receding chin. 
About half of the patients show abnormalities in NER of ultraviolet damaged DNA. 
Genetically, TTD is caused by mutations in one of the TFIIH subunits XPB, XPD or 
TTDA. Beyond deficiency in the NER pathway, it is hypothesized that basal 
transcription may also be altered leading to decreased transcription of specific genes 
(Itin et al. 2001; Nakamura et al. 2001). 
 
Some other rare diseases are also linked with NER defects. For example, DeSanctis-
Cacchione syndrome, which has been reported to be due to mutation in CSB, is an 
extremely rare disease with features of XP as well as a severe neurological phenotype 
(Colella et al. 2000). Another very rare disease combined xeroderma pigmentosum 
associated with Cockayne's syndrome (XP/CS), showing symptoms of both disorders 
has been identified to be linked with mutations in XPD (Lehmann 2001). The Cerebro-
Oculo-Facio-Skeletal (COFS) (OMIM: 214150) syndrome, showing an autosomal, 
recessively inherited and rapidly progressive, neurologic disorder, also appears to be 
linked with mutations in CSB, XPG and XPD (Graham et al. 2001).  
 
Different mutations in the same NER gene can lead to different syndromes. For instance, 
mutations in XPD or XPB can lead to XP, XP/CS, or TTD, while mutations in XPG can 





that function in both NER and transcription can result in either repair syndromes (such 
as NER), transcription syndromes (such as CS, or TTD) or a combination of the two 
(such as XP/CS). 
 
ERCC1 defects have not seen associated with XP, CS or TTD. A case of human 
inherited ERCC1 deficiency was firstly reported to be associated with Cerebro-Oculo-
Facio-Skeletal (COFS) syndrome with a mild defect in NER and severe developmental 
failure (Jaspers et al. 2007). The patient was born from nonconsanguineous Italian white 
parents and had microcephaly with premature closure of fontanels, bilateral 
microphthalmia, blepharophimosis, high nasal bridge, short filtrum, micrognathia, low-
set and posterior-rotated ears. The patient didn't show spine abnormalities by X-ray scan, 
but a simplified gyral pattern and cerebellar hypoplasia were detected in the brain by 
nuclear magnetic resonance. These combined symptoms were compatible with a clinical 
diagnosis of a severe form of COFS syndrome. The patient failed to pass any 
developmental milestones and died at the age of 14 months due to respiratory failure 
from bilateral pneumonia. Sequencing analysis of both ERCC1 cDNA and genomic 
locus from cells from the patient and his parents revealed that a C to T transition in 
ERCC1 exon 5 on one allele inherited from the mother converted the amino acid 
glutamine codon to a translational stop signal (Q158). This was predicted as the main 
cause of the patient's ERCC1 deficiency. The truncated ERCC1 protein encoded by this 
allele lacks the entire C-terminal (HhH)2 domain, which is required for the interaction 
with ERCC1's partner XPF to form a stable complex as described before. A C to G 
transversion, which changes the Phe231 to a Leu, was detected on the other allele. This 
residue lies within the XPF binding domain of ERCC1 and is fully conserved among 
mammals and the transversion is likely to interrupt the binding activity. Comparative 







1.2.6   Mouse models of NER deficiency 
 
Defective repair of various types of mutagenic DNA damage is a significant risk factor 
for diseases, especially cancer. However, difficulties such as limited access to tissues, 
lack of adequate clinical follow up, and failure to obtain complete autopsy information, 
complicate the use of human subjects for disease pathogenesis studies. Therefore, the 
availability of genetically-engineered mouse models becomes a powerful tool for 
understanding the molecular pathology of these diseases. Currently, several mouse 
mutants with defects in NER genes have been generated for further investigation of 
disease pathogenesis arising from NER deficiency. 
 
XPA-deficient mice were generated using gene targeting in embryonic stem cells to 
study the function of the Xpa gene in vivo (de Vries et al. 1995; Nakane et al. 1995). 
The Xpa-/- mice appear normal, at least until the age of 13 months. Xpa-/- mice are highly 
susceptible to UVB-induced skin and eye tumours and to 7,12-dimethylbenz-
[a]anthracene (DMBA)-induced skin tumours (de Vries et al. 1995). The skin cancer 
proneness displayed by XPA-deficient mice is highly comparable to that observed in 
human XP-A (Berg et al. 1997). Following treatment wih UVB radiation from a lower 
dose of 32J/m2/day to a higher dose of 80J/m2/day for up to 144 days, 100% of Xpa-/- 
mutants developed skin tumours. None of the UVB-exposed Xpa+/+ or Xpa+/- mice 
developed tumors, nor did non-exposed Xpa-/- mice. Also, results indicate the 
development of different tumour types in Xpa-deficient mice is UVB dose dependent 
(Berg et al. 1997; de Vries et al. 1998). Histopathological observations of tumours show 
that irradiated hairless Xpa null mice developed papillomas, actinic keratosis (AK) and 







A mouse homologue of the human gene for XP group C was isolated and XPC-deficient 
mice were generated by using embryonic stem cell technology to study the function of 
XPC in vivo (Sands et al. 1995). Mice homozygous for the Xpc mutant allele 
(xpcmut/xpcmut) were viable and do not exhibit an increased susceptibility to spontaneous 
tumour generation at one year of age. However, xpcmut/xpcmut mice were found to be 
highly susceptible to ultraviolet-induced carcinogenesis compared with mice 
heterozygous for the mutant allele (xpcmut/+) and wild-type controls. Homozygous 
xpcmut mutant mice also display a spectrum of ultraviolet-exposure-related pathological 
skin and eye changes consistent with the human disease xeroderma pigmentosum group 
C (Sands et al. 1995). Investigations showed cells from Xpc mutants are highly sensitive 
to UV radiation. Mouse embryonic fibroblasts (MEFs) isolated from Xpc mutant mice 
are severely defective in overall NER (Cheo et al. 1997; Reardon et al. 1997; Friedberg 
and Meira 1999). Studies show that Xpc mutant mice are highly predisposed to skin 
cancer (Sands et al. 1995). All Xpc-/- mutant mice develop skin cancer on shaved skin by 
25 weeks after daily exposure to UVB radiation. Comparatively, no cancerous 
symptoms are observed in normal or Xpc+/- heterozygotes during this time. However, a 
significant increase in predisposition to skin cancer is observed in Xpc+/- mice compared 
to wild-type controls following more extended periods of UVB radiation, as 80% of 
Xpc+/- heterozygotes developed skin cancer compared to 40% in the wild type group. 
These observations suggest that loss of one Xpc allele predisposes to UV radiation-
induced skin cancer because of a partial defect of NER (Cheo et al. 1997). Additionally, 
further study suggests that defective p53 function accelerates the progression of benign 
liver tumours in Xpc-/- mice (Cheo et al. 1999).  
 
Xpd null mice are embryonic lethal (de Boer et al. 1998). A viable mouse model 
carrying the XPDR772W allele mimicking a point mutation from a TTD patient showed a 





Further investigations showed that this mouse was also susceptible to UV and chemical 
induced carcinogenesis, although not as much as Xpa mice (de Boer et al. 1999). 
Furthermore, the TTD mouse model has recently been determined to have a segmental 
progeroid or premature ageing phenotype, which is also evident in human TTD patients 
(Wijnhoven et al. 2005). 
 
An Xpb mouse model for combined XP/CS has been reported very recently (Andressoo 
et al. 2009). Severe alterations in Xpb caused embryonic lethality while knock-in mice 
closely mimicking an XP/CS patient-derived XPB mutation were viable. Xpb mice 
showed XP features like UV sensitivity but no CS features unless the DNA repair 
capacity was further challenged by crossing to the NER-deficient Xpa background, 
which suggests that accumulation of DNA damage is an important determinant of 
clinical diversity in NER syndromes. Furthermore, Xpb and Xpd double mutant mice 
were healthy at birth but display neonatal lethality, indicating that transcription 
efficiency is sufficient to permit embryonal development even when both TFIIH 
helicases are deficient (Andressoo et al. 2009). 
 
Xpe mice, also known as DDB mice, have been generated by deletion of exons 4 and 5. 
This mouse model showed a high susceptibility to internal tumours, particularly of the 
lymphoid tissue and UV induced skin cancers (Yoon et al. 2005). 
 
An Xpf model mouse was created by modelling a point mutation from an XPF patient, 
which introduced a stop coden to exon 8 of the Xpf gene (Tian et al. 2004). Although the 
patient didn't suffer extremely severe symptoms, all Xpf mice died at three weeks 






Xpg mice were created by using a neo insertion into exon3 of the gene which abolished 
the Xpg mRNA (Harada et al. 1999). The Xpg mouse model showed features of 
impaired growth, dramatically reduced lifespan and cerebellar abnormalities, which was 
reminiscent of Xpf or Ercc1 deficiency (Harada et al. 1999; Sun et al. 2001). 
 
Mouse models have also been generated to investigate the mutations in Csa and Csb. 
The Csa model was created by interrupting exon 2 of the Csa gene with a hygromycin 
insert, while the Csb model was generated by mimicking a gene truncation found in a 
CSB patient (van der Horst et al. 1997; 2002). These mice showed mild CS-like features 
such as photosensitivity and slightly retarded growth but the fertility and lifespan were 
found to be normal (van der Horst et al. 1997; 2002).  
 
Investigation of ERCC1/XPF defective animals is still on-going. Our lab generated the 
first mouse with an Ercc1 knockout allele and has done several studies with the Ercc1 
mutant animals (McWhir et al. 1993). The original knockout Ercc1 allele was generated 
by insertion of a Neo cassette into exon 5 of the wild type Ercc1 allele (Selfridge et al. 
1992) (Figure 1.4).  
 
Interestingly, the phenotype of Ercc1-/- mice is more severe and quite distinct from most 
other NER-deficient mice. Ercc1 knockout mice die before weaning, around three weeks 
of age, because of the extensive physiological abnormalities (McWhir et al. 1993).  
These animals were severely runted with a weight around only 20% of their control 
littermates.  Investigations showed that Ercc1 null mice with the original Ercc1 
knockout allele suffer from severe liver failure, which was supposed to be the main 
cause of the premature death (Selfridge et al. 2001). Highly polyploid cells were found 













Schematic diagram of targeted Ercc1 alleles. White boxes show exons. Horizontal black boxes show 





feature of ageing. The Ercc1 null mice showed ploidy levels at about twenty days of age 
that were reminiscent of two years old mice. The p53 level was also found to be elevated 
in our Ercc1 null mice. In addition, an independent Ercc1 mutant mouse exhibited an 
absence of subcutaneous fat, early onset of ferritin deposition in the spleen and 
compromised NER and cross-link repair (Weeda et al. 1997). Unlike cells from mice 
with only an NER defect, ERCC1 mutant cells undergo premature replicative 
senescence, which may contribute to the premature ageing phenotype (Weeda et al. 
1997). 
 
Because the premature mortality of our Ercc1 null mice has effectively precluded studies 
on the role of Ercc1 in older mice, another Ercc1 knockout mouse model was created 
with an Ercc1 proficient liver using an Ercc1 transgene under the control of a liver-
specific promoter (Selfridge et al. 2001). The Ercc1 null mice expressing the liver 
transgene had a weight around 60% of their littermates and a lifespan ranging from 9 to 
12 weeks. Although the liver function was corrected, it didn't revert these mice to a 
normal wild type phenotype. Some kidney abnormalities including slightly increased 
plasma creatinine level, increased 8-oxo-guanine DNA adducts, some histopathology 
and an increasd level of ploidy arose in the transgene-positive Ercc1 knockout mice. 
Polyploid nuclei of kidney proximal tubule cells were revealed by FACS from 10-week-
old transgene-positive nulls, similar to the polyploidy seen in the liver of 3-week-old 
Ercc1 nulls. These abnormalities finally led to the death of the liver corrected Ercc1 
knockout animals (Selfridge et al. 2001). Further study revealed that the Ercc1 liver-
corrected null mice suffered from proteinuria from a young age and had brain 
abnormalities and swollen brains consistent with uraemic disease (Lawrence et al. 2008). 
 
Many of these features of the Ercc1 null mouse phenotype were reminiscent of a 





syndrome was suggested to be a consequence of genotoxic stress suppressing the 
somatotroph axis, which is one of the major hormonal systems regulating postnatal 
growth in mammals, and has now been characterised more extensively in Ercc1-
deficient mice and has also been found in a patient with a severe XPF mutation 
(Niedernhofer et al. 2006). Close parallels were also found between the clinical course in 
the ERCC1 deficient patient, which was reported to be associated with COFS syndrome, 
as described in the section 1.2.5 (Jaspers et al. 2007) and the phenotype of Ercc1-
deficient mice.   
 
The lifespan of the liver-corrected animals with the Ercc1 transgene was still not ideal 
for some long-term investigations such as sensitivity to UV radiation. Therefore, an 
Ercc1 floxed allele has been engineered using the Cre-lox system, which enables us to 
inactivate Ercc1 in specific tissues (Figure 1.4). In the Cre-lox system, bacterial Cre 
recombinase is controlled by a tissue-specific or development-specific promoter 
sequence. With the expression of Cre recombinase, two loxP sites in the engineered 
Ercc1 gene are recognised and then the sequence between these two loxP sites is excised 
by recombination. A transgenic mouse line expressing Cre recombinase under the 
control the keratin K5 promoter was used in our group to generate the epidermal specific 
Ercc1 knockout (Ramirez et al. 2004). Hairless mice with Ercc1-deficient skin were 
hypersensitive to the short-term effects of UV irradiation, showing a very low minimal 
erythemal dose and a dramatic hyperproliferative response. Ultraviolet-irradiated mice 
with Ercc1-deficient skin developed epidermal skin tumours much more rapidly than 
controls (Doig et al. 2006). 
  
The minimal erythemal dose (MED) for Ercc1 skin-specific knockouts was lower and 
the 20-fold difference from control mice was greater than reported for other NER 





fold more sensitive than controls to UV-induced skin cancer, while Xpa mice were only 
4-fold more sensitive than controls and Csb mice only 2-fold more sensitive  (Berg et al. 
1997; Berg et al. 2000). Thus, Ercc1 skin-specific knockouts appear more sensitive to 
UV irradiation than other NER knockouts and the resulting tumours also showed more 
raped actinic progression than controls. This has not been reported previously for other 





1.3.1 General introduction to melanoma 
 
Melanoma is one of the rarer types of skin cancer but causes the majority of skin cancer 
related deaths. It is a malignant tumour of melanocytes which are cells of neural-crest 
lineage that are evenly distributed in the basal epidermal layer of human skin.  
 
There are about 160,000 new cases of melanoma diagnosed worldwide each year, and it 
is more frequent in males and Caucasians (Tsao et al. 2004). Cutaneous melanoma is the 
eighth most common cancer in the UK and the second commonest in young people aged 
from 20 to 39. In Scotland the incidence of melanoma is rising rapidly, from 1979 to 
1998 it increased 300% for men and 180% for women (MacKie et al. 2002). A further 
73% rise is predicted over the next 10 to 15 years in terms of melanoma cases in 





A family history of melanoma will greatly increase the risk of an individual developing 
this disease. Chromosome 9p21 was identified as the site of a familial melanoma gene 
(Tsao 2000). About 8% to 12% of all melanoma cases are familial and 25% to 40% of 
inherited cases of melanoma carry mutations in the CDKN2A (which encodes p16 and 
ARF proteins and is located at 9p21) or CDK4 loci (Kamb et al. 1994). This will be 
addressed in more detail in section 1.3.2. Melanoma risk is highest in those with fair 
skin and inability to tan, particularly in those with red hair (Marrett et al. 1992). 
Freckling and blue eyes are also associated with modest increase in melanoma risk 
(Bliss et al. 1995). The melanocortin-1 receptor (MC1R) gene plays an important role in 
determining if a person has red hair, fair skin, and sensitivity to UV radiation. An 
increased UV sensitivity and a 2-4 fold elevation in melanoma risk is linked with some 
inherited variants of the MC1R gene (Hayward 2003). The presence of multiple naevi in 
an individual is a strong marker for melanoma risk irrespective of family history 
(Berwick and Halpern 1997). Coinheritance of variants of the MC1R gene seen in red-
haired patients, along with CDKN2A mutations, further increases the risk of melanoma 
in melanoma-prone families (Goldstein et al. 2005). 
 
There are several phase in the development of melanoma (reviewed by Gray-Schopfer et 
al. 2007). In the skin, melanocytes reside in the basal layer of the epidermis (Fig. 1.5.a) 
and in the hair follicles. In response to ultraviolet (UV) radiation, epidermal 
keratinocytes regulate the homeostasis of melanocytes by secreting factors that regulate 
melanocyte survival, differentiation, proliferation and motility, also stimulating 
melanocytes to produce melanin and resulting in the tanning response. Thereby, 
melanocytes are essential in protecting the skin from the UV radiation induced 
damaging effects and in preventing skin cancer. Melanin production occurs mainly in a 
lysosome-like structure known as the melanosome. Generally, there are two types of 
melanin and both derive from a common tyrosinase-dependent pathway with the same 





hair, while the red-yellow pheomelanin is mainly found in red hair and freckled 
individuals. The production of melanin in the hair and skin is tightly regulated by the 
MC1R. Binding of melanocyte stimulating hormone to a functional MC1R leads to an 
increase in intracellular cAMP levels. This stimulates the conversion of red/yellow 
pheomelanin to black/brown eumelanin. This conversion does not occur in individuals 
homozygous for "red hair" mutations in the MC1R gene (Cone et al. 1996). 
 
Mutations in critical growth regulatory genes disrupt the intracellular signalling in 
melanocytes and allow them to escape their tight regulation by keratinocytes (Haass et 
al. 2004). Consequently, melanocytes can proliferate and spread, leading to the 
formation of a naevus or common mole (Figure 1.5.b).  Although the majority of naevi 
are benign, a small number can progress to radial-growth-phase (RGP) melanoma, 
which is an intra-epidermal lesion and can involve some local microinvasion of the 
dermis (Figure 1.5.c). The RGP cells can then progress to the vertical-growth phase 
(VGP) which is a more dangerous stage due to its metastatic potential, with nodules or 
nests of cells invading the dermis (Figure 1.5.d). Not all melanomas pass through each 
of these individual phases. RGP or VGP can both develop directly from isolated 
melanocytes or naevi and progress directly to metastatic malignant melanoma (Miller 
and Mihm 2006). 
 
 
Many melanomas metastasize because of their propensity for vertical growth with deep 
invasion. The majority of patients with early-stage melanoma following simple surgical 
resection could have a long-term survival (5 year survival rate > 90%) but patients with 
metastatic case would normally have a dismal prognosis (5 year survival rate < 30%). 
This emphasises the importance of early diagonosis. Most melanoma can be identified 





Fig 1.5 Progression of melanocyte transformation 
 
 
Various stages of melanocytic lesion. a, Normal skin. Evenly distributed dendritic melanocytes are shown 
within the basal layer of the epidermis. b, Naevus. Naevus cells are shown. Naevi are termed either 
junctional, dermal or compound according to their localization. c, Radial-growth-phase (RGP) melanoma, 
which is considered to be the primary malignant stage. d, Vertical-growth-phase (VGP) melanoma, which 
is the first stage that is considered to have malignant potential and leads directly to metastatic malignant 





irregularity, colour Change and Diameter greater than 6mm, an ABCD system of 
diagnosis (Friedman et al. 1985). Clinical suspicion should also be aroused by any 
significant change in an existing nevus or skin lesion.  
 
Melanoma is a disease with high metastatic potential and is highly resistant to 
chemotherapy. This is likely to be explained by melanocytes originating from highly 
motile cells that have enhanced survival properties. Melanoma cells have low levels of 
spontaneous apoptosis in vivo compared with other tumour cell types, and are relatively 
resistant to drug-induced apoptosis in vitro (Soengas and Lowe 2003). Currently there is 
no effective therapeutic regime to improve the survival of patients with advanced 
melanoma in randomized trials. 
 
Patients with intermediate or high risk of recurrence could potentially benefit from 
eradication of micrometastatic disease through the use of effective systemic adjuvant 
therapy. Currently high dose intravenous interferon-alpha is the only drug that has been 
shown reproducibly to have some impact on patients according to large randomised 
trials (Hersey 2003). A pooled analysis of trials in median follow-up times of 2.1 to 12.6 
years showed that high dose intravenous interferon-alpha treatment was linked with a 
significant improvement of about 10% at 5 years in relapse-free survival for patients but 
no obvious benefit in terms of overall survival (Kirkwood et al. 2004). 
 
For patients with metastatic melanoma, there is no evidence to show a significant 
survival advantage with use of any specific drug or combination of drugs (Brown and 
Kirkwood 2003). Dacarbazine (DTIC) is one approved chemotherapeutic agent for the 
treatment of advanced melanoma. DTIC produces a response rate in 15-20% with a 





using a combination of DTIC and other cytotoxic agents such as tamoxifen or interferon-
alpha have shown promising response rates in single-institution phase 2 trials but no 
survival advantage in randomised phase 3 studies (Tsao et al. 2004). The cytokine 
interleukin 2 has approval for use in the US for treating metastatic melanoma but its 
overall response rate is low (16%) and systemic toxicity is high. 
 
 
1.3.2 Melanoma and its cell signalling pathways 
 
As melanoma is a complex and refractory genetic disease, a clear understanding of the 
biology underlying its initiation and progression is required to contribute to the refining 
of the classification system, the design of better therapeutic agents and approaches. 
Therefore, a number of cell signalling pathways related to melanoma pathogenesis and 
development of effective drugs to treat melanoma have been investigated, which are 
described below (Figure 1.6). 
 
Inactivation of the p16INK4a/cyclin dependent kinases 4 and 6/retinoblastoma protein 
(p16INK4a/CDK4,6/pRb) and p14ARF/human double minute 2/p53 (p14ARF/HDM2/p53) 
tumor suppressor pathways has been shown to be strongly associated with melanoma 
development. These pathways are involved in the control of the G1/S phase transition of 
the cell cycle and are most often inhibited via mutations or deletion in the cyclin-
dependent kinase inhibitor 2A (CDKN2A) locus on chromosome 9p21, which encodes 2 
tumour suppressors, p16INK4a and p14ARF (Chin 2003; Sharpless et al. 2003). p16INK4 is a 
CDK inhibitor that binds to and inhibits CDK4 and CDK6, which otherwise 










Several of the main pathways involved in melanoma initiation, progression and maintenance are 






p14ARF acts through a distinct pathway which stabilizes p53 by preventing murine 
double minute-2 (MDM2) induced p53 degradation (Pomerantz et al. 1998). The 
importance of the CDKN2A gene in melanoma susceptibility was confirmed by studies 
showing that the penetrance of CDKN2A mutations varies with melanoma population 
incidence rates (Bishop et al. 2002) and that CDKN2A mutation carriers have increased 
total nevus number and total nevus density, both known as risk factors for melanoma, 
compared with noncarriers within the same family (Florell et al. 2004). 
 
The Ras/Raf/MEK(mitogen-activated protein kinase/ERK kinase)/ERK(extracellular-
signal-regulated kinase) pathway regulates proliferation, differentiation and cell 
survival. In this pathway, the small G protein Ras works upstream of a core module 
consisting of three kinases: the MAPK (mitogen-activated protein kinase)  kinase kinase 
(MAPKKK) Raf that phosphorylates and activates the MAPK kinase (MAPKK) MEK, 
which in turn activates the MAPK ERK (Kolch 2000). The Ras/Raf/MEK/ERK pathway 
is a key regulator of melanoma cell proliferation. ERK is hyperactivated in up to 90% of 
human melanoma. NRAS, one of the three Ras genes in human, is mutated at the rate of 
15% to 30%. BRAF, which together with ARAF and CRAF are the three human RAF 
genes, is the most commonly mutated component in this pathway with a mutation rate 
from 50% to 70% (Gray-Schopfer et al. 2007).  80% to 90% of the BRAF mutations 
involve a glutamic acid for valine substitution at position 600 (V600E) (Davies et al. 
2002). This V600E BRAF has a 10 times greater kinase activity compared to wild-type 
BRAF and constitutively stimulates ERK activity in vivo independent of Ras 
(Karasarides et al. 2004). Does UV-irradiation induce the BRAF mutation? The GTG to 
GAG change in the V600E is not a typical UVB-damaged DNA signature as the most 
characteristic signature mutation by UV is CC to TT or C to T (Davies et al. 2002). It is 
possible that the V600E mutation is not induced by UV irradiation directly but is a 
secondary consequence of exposure, arising from error prone translesion synthesis 






The phosphoinositide-3-OH kinase (PI3K) pathway, which regulates cell survival, 
proliferation, growth and motility, is another important pathway in melanoma and is 
often hyperactivated in melanoma. PI3K mutations occur in 3% of metastatic 
melanomas. One component in the PI3K pathway PTEN (phosphate and tensin 
homologue) is also found to have loss of function rates from 5% to 20% in late-stage 
melanomas (Gray-Schopfer et al. 2007), and the PI3K effector protein kinase B (PKB) is 
overexpressed in up to 60% of melanomas (Figure 1.6). Both ERK and PI3K signalling 
pathways must be inhibited to suppress cell growth in melanomas indicating that both 
pathways are important targets for drug development (Smalley et al. 2006). 
 
Microphthalmia-associated transcription factor (MITF) is considered to be the master 
regulator of melanocyte biology because of its regulation of the expression of 
melanogenic proteins (Levy et al. 2006). It also plays a key role in melanoma through its 
regulation of melanoblast survival and melanocyte lineage commitment. Continued 
MITF expression is essential for melanoma cell proliferation and survival (Levy et al. 
2006). MITF is expressed in most human melanomas and its target genes have already 
been used as diagnostic markers (Levy et al. 2006). However, the protein level of MITF 
must be carefully controlled. There is a significantly lower level of MITF in melanoma 
cells compared to the level in melanocytes. Increased MITF levels could reduce 
melanoma proliferation even in the presence of oncogenic BRAF, while critically low 
levels lead to cell cycle arrest and apoptosis (Wellbrock and Marais 2005). Although 
MITF alone cannot immortalize human melanocytes, it can achieve this by cooperating 
with the V600E BRAF to transform immortalized melanocytes (Garraway et al. 2005). 
 
Other signalling pathways involved in human melanoma development include the 





and Akt3. It is common in melanoma that mutations in these pathways contribute to 
reduce apoptosis and promote growth (Figure 1.6). Furthermore, as described before, it 
has been reported that many inherited cases of melanoma carry inactivating mutations in 




1.3.3 Melanoma and DNA repair 
 
1.3.3.1 DNA repair and melanoma susceptibility 
 
As described in the previous section, exposure to the ultraviolet component in sunlight is 
a key environmental risk factor for the incidence of cutaneous melanoma by inducing 
mutations in important genes involved in cell proliferation and apoptosis. UVB radiation 
at wavelengths of 290–320 nm causes damage in the form of cyclobutane pyrimidine 
dimers and pyrimidine 6-4 photoproducts, while UVA radiation at wavelengths of 320-
400nm normally induces single-stranded breaks, DNA-protein crosslinking, and 
generates free-radicals that cause oxidative damage. Multiple pathways are involved in 
repairing UV-DNA damage including the NER pathway, the BER pathway, the MMR 
pathway and the homologous double-stranded DNA repair pathways.  
 
The NER pathway plays the main role in the repair of UVB-induced DNA lesions. 
Thereby, polymorphisms in nucleotide excision repair genes that affect function are 





pathway lead to accumulation of photoproducts, which is associated with melanoma 
risk. This is exemplified by the NER deficiency disease XP. Based on a study with 596 
Scottish melanoma patients and 441 population-based controls, significant associations 
were found for the NER genes ERCC1 and XPF, with the strongest associations for 
melanoma cases aged 50 and under (ERCC1 OR 1.59, P = 0.008; XPF OR 1.69, P = 
0.003) (Povey et al. 2007).  
 
For other NER genes, there was no association found between the XPG exon 15 Asp 
1104 His polymorphism (rs17655) and melanoma. For the XPC gene, there was no 
association for three XPC polymorphisms, G1580A, T1601C and G2166A (Blankenburg 
et al. 2005), but association was found for three other XPC markers, intron 9 PAT, 
Intron 11-6A and Lys 939 Gln (Blankenburg et al. 2005). However, no association was 
found for XPC Lys 939 Gln, nor for two SNPs (Arg 1213 Gly, Arg 1230 Pro) in CSB 
and one SNP (Ala 249 Val) in HR23B (Millikan et al. 2006). For XPD, no association 
was found between the XPD exon 23 Lys 751 Gln polymorphism and melanoma (Povey 
et al. 2007). In other studies of the XPD gene, Baccarelli et al. reported an association 
between the Gln 751 allele and melanoma in older patients (OR 2.3, 95% CI 1.1-4.9, P = 
0.03) (Baccarelli et al. 2004). However, Han et al. reported an inverse association 
between the Gln 751 allele and melanoma (OR 0.63, 95% CI 0.38-1.05, P= 0.09) (Han et 
al. 2005). The genes environment and melanoma study found an association between the 
XPD 751 Gln/Gln genotype and melanoma (OR 1.4, 95% CI 1.1-1.7, P = 0.004) 
(Millikan et al. 2006). 
 
It is also possible that genes involved in other pathways for the repair of DNA damage 
may also contribute to the susceptibility to melanoma as not all melanomas arise on sun-






The XRCC3 gene encodes a member of the RecA/Rad51-related protein family that 
participates in homologous recombination to maintain chromosome stability and repair 
DNA damage. It has been reported that the XRCC3 gene is significantly associated with 
melanoma development based on a study with 125 individuals with malignant melanoma 
and 211 individuals in the control group. (P = 0.004; odds ratio, 2.36; relative risk, 1.74) 
(Winsey et al. 2000). However, our study didn't find any evidence to support that 
XRCC3 exon 7 Thr 241 Met (rs861539) polymorphism is associated with melanoma 
(Povey et al. 2007).  
 
Our previous study was also particularly interested in the possibility that genes in the 
BER pathway, which is responsible for the repair of UVA-induced oxidative DNA 
damage, might be genetic susceptibility factors for melanoma. However, no association 
was found for XRCC1 exon 10 Arg 339 Gln (rs25487), nor for OGG1 exon 7 Ser 326 
Lys (rs1052133), which has not been investigated before for a role in melanoma (Povey 
et al. 2007). 
 
 
1.3.3.2 DNA repair and melanoma metastasis 
 
Analysis of differential gene expression at the level of whole biological pathways, rather 
than individual genes was carried out using microarray to identify the gene-profile 
signature for human primary malignant melanoma associated with metastasis 
(Kauffmann et al. 2008). 48 DNA repair genes, among a list of 234 genes, were found to 
be associated with metastatic progression, in which 44 genes are overexpressed (Figure 









Standardized mean differences of log (ratio) for genes involved in DNA repair between non-recurrent 
primary melanomas and primaries that recurred within 4 years. A positive mean difference indicates 
overexpression in primary melanoma tumours that will metastasize within 4 years compared to those 






to 5-fold elevated expression in recurrent primary tumours. From the microarray 
investigation, only four NER genes including two TFIIH factors, GTF2H2 and GTF2H3, 
as well as the replication pathway proteins RFC and RPA are overexpressed in 
metastatic melanomas. Since the TFIIH factor is also involved in RNA transcription 
initiation, this result suggests that the NER pathway is not strongly implicated in 
metastasis induction (Kauffmann et al. 2008). 
 
In the BER pathway, two interesting genes were found to be overexpressed in recurrent 
primary melanomas. One is the hOGG1 gene, which encodes the main glycosylase 
involved in the repair of oxidized guanines, while another one is the NEIL3 gene which 
also codes for a DNA glycosylase which is able to repair oxidized purines (Kauffmann 
et al. 2008). 
 
Two MMR proteins, MSH6 and MSH2, are overexpressed in metastatic melanomas 
(Figure 1.7). These two proteins deal with DNA mismatches produced during normal 
DNA replication but also have the potential function of detecting bases mispaired with 
unrepaired DNA lesions to avoid mutagenesis during translesion synthesis (TLS) 
(Kauffmann et al. 2008). 
 
However, surprisingly the majority of the genes overexpressed in recurrent primaries 
were not key players in the NER, BER, or DSB repair pathways. Instead, many 
belonged to repair pathways allowing recovery of stalled replication forks as a result of 
spontaneous or DNA lesion-induced blockage, or correction of replication errors, while 
others were involved in more general pathways acting to preserve genome stability. This 





rapidly and accurately and could also contribute to their extreme resistance 
















2.1.1 General reagents and equipment 
Amersham: ECL fluorescence kit, Hyperfilm™ MP high performance autoradiography 
film, Storm 840 phosphorimager. 
 




BioRad: Gel Doc 2000 System with Quantity One 4.6 software, Mini-PROTEAN 
Electrophoresis System, Mini Trans-Blot Cell. 
 
DAKO: Secondary HRP-conjugated forms of goat anti-rabbit, swine anti-rabbit, rabbit 
anti-goat and rabbit anti-mouse antibodies. 
 
Fisher Scientific: 3M blotting paper, absolute alcohol, chloroform, Na2EDTA, filter 
paper haematoxylin, isoamyl alcohol, isopropanol (propan-2-ol), methanol, potassium 






Invitrogen: agarose, Benchmark™ prestained protein ladder, NuPAGE™ 4-12% Bis-
Tris gel, NuPAGE™ 10% Bis-Tris gel, NuPAGE™ transfer buffer, Subcloning 
Efficiency DH5α™ Competent Cells. 
 
Millipore (UK) Ltd: disposable sterile filter. Immobilon P PVDF membrane. 
 
New England Biolabs: restriction endonucleases and relevant buffers. 
 
Pierce Biotechnology: Bicinchoninic acid (BCA) protein assay kit. 
 
Promega: 25mM magnesium chloride, 10x PCR buffer, 5x PCR buffer, Taq DNA 
polymerase, Oligo dT, RNasin, pGEM-T Easy® Vector Systems. 
 
Qiagen Ltd: QIAprep Spin Miniprep Kit. QIAGEN Plasmid Maxi Kit. 
 
Roche: Protease Inhibitor cocktail tablets, Protein G Immunoprecipitation Kit, 3'/5' 
RACE kit (2nd Generation), High Pure PCR Product Purification Kit. 
 
Santa Cruz Biotechnology: bovine anti-goat IgG-HRP antibody, ERCC1 (D-16) goat 






Sigma-Aldrich: ammonium persulphate (APS), DMSO, DTT, Na2EDTA, glycerol, 
herring sperm DNA, MOPS, parafilm M, PBS tablets, propidium iodide, ribonuclease 
inhibitor, sodium chloride, sodium deoxycholate, sodium hydroxide, oligonucleotides, 
trypsin, trypsin inhibitor, Triton X-100, Tween 20. 
 
2.1.2 DNA manipulation reagents 
 
Loading dye: 20% glycerol, 100mM Na2EDTA, 0.1% bromophenol blue or orange G. 
 
CA: 24 parts chloroform, 1part isoamyl alcohol. 
 
DNA isolation buffer: 10mM Tris HCl pH8.0, 400mM NaCl, 3mM Na2EDTA, 1% (w/v) 
SDS. Stored at 4C. 
 
PCA: 25 parts redistilled phenol, 24 parts chloroform, 1 part isoamyl alcohol. 
 
Proteinase K: 2% proteinase K w/v in sterile distilled water. 
 






TAE electrophoresis buffer: 40mM Tris-acetate, 1mM Na2EDTA. 
 
TBE electrophoresis buffer: 90mM Tris-HCl, 90mM boric acid, 2mM Na2EDTA, pH 
8.3. 
 
2.1.3 RNA manipulation reagents 
 
Denaturation buffer: 0.5M NaOH, 1.5M NaCl. 
 
Formamide sample buffer (RNA sample buffer): 2.3X MOPS, 50% de-ionised 
formamide, 11% formaldehyde. 
 
Labelling buffer: 50ul solution A, 125ul solution B, 75ul solution C. 
 
10X MOPS: 200mM 3-(N-morpholino) propane-sulphonic acid (MOPS), 50mM sodium 
acetate, 10mM Na2EDTA, pH7.0. 
 






RNA loading buffer: 50% (v/v) glycerol, 1mM Na2EDTA pH 8.0, 0.4% (wt/v) 
bromophenol blue, 1mg/ml ethidium bromide. Stored at -20°C. 
 
RNAzolTMB: RNA isolation solvent. 
 
5X sample buffer: 20% (v/v) glycerol, 100mM Na2EDTA, 0.1% (wt/v) bromophenol 
blue 
 
Solution A: 1.25M Tris-HCl pH8.0, 0.125M MgCl2, 25mM beta-mercaptoethanol, 
0.5mM each of dGTP, dATP and dTTP. 
 
Solution B: 2M HEPES buffer adjusted to pH6.6 with NaOH. 
 
Solution C: Random hexadeoxyribonucleotides OD260nm=90units/ml in TE 
 
SSC (20X): 3M NaCl, 300mM tri-sodium citrate dihydrate pH 7.0. 
 






2.1.4 Protein manipulation reagents 
 
Immunoprecipitation washing buffer 1: 50mM Tris-HCl pH 7.5, 150mM NaCl, 1% 
Nonidet P40, 0.5% sodium deoxycholate, 1 protease inhibitor cocktail tablet (Roche 
Complete) / 25-50ml. 
 
Immunoprecipitation washing buffer 2: 50mM Tris-HCl pH 7.5, 500mM NaCl, 0.1% 
Nonidet P40, 0.05% sodium deoxycholate.  
 
Immunoprecipitation washing buffer 3: 10mM Tris-HCl pH 7.5, 0.1% Nonidet P40, 
0.05% sodium deoxycholate. 
 
Modified RIPA buffer: 50mM Tris-HCl pH 7.2, 1% (v/v) Triton X-100, 0.2% (w/v) 
sodium deoxycholate, 0.2% (wt/v) sodium dodecyl sulphate, 1 protease inhibitor 
cocktail tablet (Roche Complete) / 25-50ml. 
 
RIPA buffer: 25mM Tris-HCl, pH 7.2, 150mM NaCl, 1% Triton X-100, 0.1% SDS, 1% 
deoxycholate, 1mM Na2EDTA, 20mM NaF, 100uM orthovanadate, 1 protease inhibitor 
cocktail tablet (Roche Complete) / 25-50ml. 
 
Stripping buffer: 20ml of 10% SDS, 12.5ml 0.5M Tris HCl pH 6.8, 67.5 ml ultra pure 






TBS: 5mM Tris-HCl, 75mM NaCl, pH 7.4. 
 
TBS-T: 5mM Tris-HCl, 75mM NaCl, 0.05-0.1% Tween-20 v/v, pH 7.4. 
 




Table 2.1 General PCR primers 
 
Code Sequence (5' →3') Description 
Skin A forward TCATCACTGAGCCGGATCTGGAG
TCTGG 
214 bp 5' of mouse Ercc1 
exon1 
Skin B reverse GTTCCCCGCTCTAACTCCTC 57 bp 5' of mouse Ercc1 
exon1 
Skin C reverse GAAGTGAGTCTAGCAGGAGTTG
TG 
Within mouse Ercc1 exon1 
Exon 2 reverse ATGGACCCTGGGAAGGACGAGG Within mouse Ercc1 exon2 





Exon 3a reverse AGAACCCCAGCCAGACCCT Within mouse Ercc1 exon3 
M13 Forward GTAAAACGACGGCCAGT Forward sequencing primer 
M13 Reverse CATGGTCATAGCTGTTTCC Reverse sequencing primer 
 
 
Table 2.2 RT-PCR primers 
 
Code Sequence (5' →3') Description 
Novel promo GCTGAGTCGTCGCTGCCTTA For 11kb putative promoter 
Novel promo b GGAAGCGCTGAGTCGTCG For 11kb putative promoter 
Novel promo rev TTGTGAGGGGCTCAGACGAG For 11kb putative promoter 
Novel promo rev b ACGAGCAGCCATTGGAGATG For 11kb putative promoter 
ERC1 NP + 57 ACCGCGGCTAAGTTTAGAGG For 2.5kb putative promoter 
ERC1 NP + 65 TAAGTTTAGAGGCGGGTGGGG For 2.5kb putative promoter 
 
Table 2.3 5'RACE primers 
Code Sequence (5' →3') Description 
Oligo dT anchor GACCACGCGTATCGATGTCGACTT
TTTTTTTTTTTTTTV  (V= A,C or G) 
Anchor primer 







CAGGCATCGCCATGGGTCAC Neo control primer 
Control primer 
neo2/rev 
GCTGCCTCGTCCTGCAGTTC Neo control primer 
Control primer 
neo3/for 
GATTGCACGCAGGTTCTCCG Neo control primer 
 
 
Table 2.4 Bisulfite sequencing primers 
Code Sequence (5' →3') Description 
BIS CpG#1 FWD CCCAGTGGACACATTGAGGTGCA
GTAGTAG 
CGI#1 forward primer 
BIS CPG#1 RVS TTGATACAGGAGGAAGAAAC CGI#1 reverse primer 




CGI#1 internal forward 
primer 




CGI#1 internal reverse primer 
BIS CGI#2 FWD ACAGAAAGCAAACTTGGGGATGC
TG 
CGI#2 forward primer 
BIS CGI#2 RVS GATACCTTTGCCCTGTGGGAGAA CGI#2 reverse primer 
BIS CGI#3 FWD GCCTTGGAACACAACTACTTGAA
GTCAAAG 
CGI#3 forward primer 
BIS CGI#3 RVS GAAAGACCAGGTGAGTTTTGGCA
GT 








2.1.6.1 Primary antibodies 
Table 2.5 List of primary antibodies used in this study 
Code Target * kDa Supplier Dilution 
SC-10157 ERCC1 (m) 33 Santa Cruz 1:1000 
SC-17809 ERCC1 (m/h) 33/35 Santa Cruz 1:1000 
FL-297 ERCC1 (h) 35 Santa Cruz 1:1000 
ab2356 ERCC1 (m/h) 33/35 Abcam 1:300 
AB-5 (51) XPF (m) 102 Lab Vision 1:1000 
NA27 MSH2 (h) 105 Calbiochem 1:500 
SC-10789 MSH6 (h) 160 Santa Cruz 1:200 
51-1327GR MLH1 (h) 84 BD Biosciences 1:500 
ab6046-200 Beta-tubulin (m/h) 50 Abcam 1:6000 
015K-4821 Beta-actin (m/h) 42 Sigma 1:5000 
MAB375 GAPDH (m/h) 36 CHEMICON 1:10000 
SC-7907 PCNA (m/h) 36 Santa Cruz 1:3000 
*m:mouse protein; h:human protein 
 
2.1.6.2 Secondary antibodies 
 
Secondary antibodies were sourced from Dako and Santa Cruz. HRP-conjugated forms 





(P0449 1:4000) and rabbit anti-mouse (P0260 1:2000) antibodies were from Dako. A 
HRP-conjugated form of bovine anti-goat (SC-2305 1:3000) antibody was from Santa 
Cruz. 
 
2.1.7 Cell culture reagents 
 
Autogen Bioclear: Stem cell factor. 
 
Beckman-Coulter: Coulter counter, FACScan machine, Isoton®II diluents. 
 
BioRad: Chelex® 100 resin. 
 
Greiner Bio One: Cellstar® cell culture flasks, cell culture dishes, cell culture plates, 
pipettes, cell scrapers. 
 
Invitrogen: GIBCO® Dulbecco's Modified Eagle's Medium without calcium (No 
calcium DMEM, Cat. 21068-028), Dulbecco's Modified Eagle's Medium (DMEM, Cat. 
10938-025), RPMI-1640 (Cat. 21875), Glasgow's Modified Eagle's Medium (GMEM, 
Cat. 21710), 400mM L-glutamine, 100X non-essential amino acids (NEAA), 100 mM 






LONZA: Fetal calf serum (FCS). 
 
New Biowest: New-born calf serum (NCS). 
 
Sigma: beta-mercaptoethanol, Tetradecanoylphorbol acetate (TPA), cholera toxin, 
DMSO, endothelin, epidermal growth factor, penicillin G, streptomycin. 
 
PBS: 140mM NaCl, 3mM KCl, 2mM KH2PO4, 10mM Na2HPO4 
 
Trypsin-EDTA: 10 trypsin (Cambrex) diluted in PBS to 0.25% (w/v) trypsin, 1mM 
EDTA. Stored at -20C. 
 
2.1.8 Mammalian cells and culture media 
 
 
Table 2.6 List of mammalian cell lines used in this study 
Human cell lines: 
Cells Source Description 
HERMES 1 Prof. D. Bennett. St. Georges' 
Hospital Medical School, London 
Human melanocytes 






HERMES 4a Prof. D. Bennett. St. Georges' 
Hospital Medical School, London 
Human melanocytes 
immortalised with a telomerase 
expressing retrovirus 
A375 The European Collection of Cell 
Cultures (ECACC) 
Human malignant melanoma 
C32 ECACC Human malignant melanoma 
EDMEL_3 Melton group Human malignant melanoma 
G361 ECACC Human malignant melanoma 
HBL Gentaur. Brussels, Belgium Human malignant melanoma 
WM115 ECACC Human malignant melanoma 
PEA1 Dr. G. Sellar. Cancer Research 
Centre, The University of Edinburgh 
Human ovarian tumour cell 
line 
PEA2 Dr. G. Sellar. Cancer Research 
Centre, The University of Edinburgh 
Cisplatin-resistant derivative 
line of PEA1 
PEO1 Dr. G. Sellar. Cancer Research 
Centre, The University of Edinburgh 
Human ovarian tumour cell 
line 
PEO4 Dr. G. Sellar. Cancer Research 
Centre, The University of Edinburgh 
Cisplatin-resistant derivative 
line of PEO1 
PEO6 Dr. G. Sellar. Cancer Research 
Centre, The University of Edinburgh 
Cisplatin-resistant derivative 
line of PEO1 
PEO14 Dr. G. Sellar. Cancer Research 
Centre, The University of Edinburgh 
Human ovarian tumour cell 
line 
PEO23 Dr. G. Sellar. Cancer Research 
Centre, The University of Edinburgh 
Cisplatin-resistant derivative 







Mouse cell lines: 
Cells Source Description 
Keratinocyte 
ERCC1 WT 





Melton group Spontaneously immortalised 
Ercc1 deficient mouse 
keratinocytes 




PF20 Melton group Spontaneously immortalised 
Ercc1wild-type mouse 
embryonic fibroblasts 
PF24 Melton group Spontaneously immortalised 
Ercc1-deficient mouse 
embryonic fibroblasts 
3-1-1 T1a Melton group Spontaneously immortalized 
mouse melanocyte cell line 
containing a non-recombined 
Ercc1 floxed allele 
3-1-1 T1a #5 Melton group Ercc1 deficient derivative of 3-
1-1 T1a mouse melanocytes by 
deletion of the Ercc1 exon 3-5 
region 
HM1 Melton group Mouse ES cell line 
DNMT3- Nick Gilbert. Cancer Research 
Centre, The University of Edinburgh 
DNA methyltransferase 3 
deficient mouse ES cell line 
 
Our undifferentiated Ercc1 wild-type and deficient keratinocyte cultures were 





becoming differentiated (Lawrence et al. 2009). Differentiated keratinocyte cultures 
were maintained in normal DMEM. Medium was supplemented with 8% (v/v) chelex 
treated FCS (to minimize Ca2+) for undifferentiated keratinocytes or 8% (v/v) normal 
FCS for differentiated  keratinocytes, 10ng/ml epidermal growth factor or 10ng/ml 
keratinocyte growth factor, 4mM L-glutamine, 25U/ml penicillin and 25ug/ml 
streptomycin. 
 
PAM212 keratinocyte cells were maintained in RPMI media with 10% FCS, 25U/ml 
penicillin and 25ug/ml streptomycin (Tani et al. 1992). 
 
Immortalised Ercc1 wild type mouse embryonic fibroblast (PF20) and Ercc1 deficient 
mouse embryonic fibroblast (PF24) cultures were maintained in GMEM media supplied 
with 10% (v/v) FCS, 1mM NaPy, 25U/ml penicillin and 25ug/ml streptomycin (Melton 
et al. 1998). 
 
Immortalised Ercc1 wild type and deficient mouse melanocyte cell lines were 
maintained in RPMI-1640 with 10% FCS, 200nM TPA, 25U/ml penicillin and 25ug/ml 
streptomycin (unpublished). 
 
Mouse wild type ES cell line HM1 was isolated directly from HPRT-deficient strain 129 
mice by previous group work (Magin et al. 1992). HM1 and DNMT3- cultures were 
grown in GMEM supplemented with 5% FCS, 5% New-born calf serum (NCS), 1X 
NEAA, 1mM NaPy, 0.1mM beta-mercaptoethanol, leukaemia inhibitory factor, 25U/ml 






Human melanocytes, Hermes 1 and Hermes 4 cultures were grown in RPMI-1640 
supplemented with 10% FCS, 4mM L-glutamine, 10ng/ml SCF, 200nM TPA, 200pM 
cholera toxin, 10nM endothelin and 25U/ml penicillin and 25ug/ml streptomycin (Gray-
Schopfer et al. 2006). 
 
Human melanoma cell cultures were maintained in RPMI media with 10% FCS, 25U/ml 
penicillin and 25ug/ml streptomycin. 
 
Human ovarian tumour cell cultures were maintained in RPMI-1640 media with 10% 
FCS, 25U/ml penicillin and 25ug/ml streptomycin. 
 
2.1.9 Bacterial strains  
 
Sub-cloning Efficiency™ DH5α™ Competent Cells were sourced from Invitrogen, and 
were grown on/in LB medium at 37°C. 
 
2.1.10 Bacterial culture media and related reagents 
 
Ampicillin stock solution: 50mg/ml ampicillin in dH2O. 0.2µm filter sterilised and 






Blue/white lacZ screen LB agar plates: For DH5α 20µl of 40mg/ml X-gal was spread 
over LB agar plates containing the antibiotic ampicillin. The plates were dried at room 
temperature before being used. 
 
X-gal stock solution: 40mg/ml X-gal in dimethylformamide (DMF). Stored at -20°C and 
protected from light. 
 
2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Mammalian cell culture 
 
All cells were cultured using appropriate media in an incubator at 37°C with 5% CO2. 
Flasks were medium changed at least every second day, using aseptic technique inside a 
category II biological safety hood. When required, medium was aspirated (along with 
dead, floating cells), cells were passaged using trypsin-EDTA solution and counted 







2.2.1.2 Liquid nitrogen frozen stock 
 
For long term storage, cells were frozen in liquid nitrogen using the appropriate culture 
medium supplemented with 10% DMSO and 20% FCS.  
 
2.2.1.3 Counting of cells 
 
Cells were diluted 1:100 in isoton and counted using the Coulter Counter Z series 
(Beckman Coulter). 
 
2.2.1.4 Ultraviolet-C irradiation of cells 
 
Ultraviolet-C (UVC) irradiation was carried out using a UV lamp (Mineralight Lamp 
UVGL-58, UV Products.), emitting 0.5Jm-2s-1 from a fixed position. Cells were plated 
out 24 hours before irradiation in 100mm Petri dishes with 10ml of medium, or in 35mm 
Petri dishes with 2ml of medium before UVC irradiation. For irradiation, the medium 
was aspirated from dishes and a small amount of sterile PBS was applied (0.1ml/35mm 
dish) to prevent the cells from drying out. After the UVC irradiation, medium was 







2.2.1.5 Drug treatments of cells 
 
Drug (Cisplatin, MG132 or cycloheximide) was directly added to the cell culture 24-
hours post plating to give a designed final concentration. Treated cells were then 
incubated under standard conditions before being harvested at appropriate time points. 
 
2.2.1.6 Colony forming assay 
 
An optimal number of cells were plated in 6ml of complete media in 60mm Petri dishes. 
Duplicates or triplicates were set up in each assay. 24 hours later cultures were UV-
irradiated or cisplatin treated as described above. Cultures were then incubated and were 
monitored for growth using an inverted microscope. At the time of good primary colony 
formation (7 to 30 days in culture), dishes were fixed with Carnoy fixative (3:1 
methanol: glacial acetic acid) and stained with 0.25% (wt/v) Crystal Violet. Stained 
dishes were imaged using the Gel-Doc 2000 (Bio-Rad) system and colonies were 
counted using the Quantity One software (Bio-Rad). 
 
2.2.1.7 Cytotoxicity screening by Sulforhodamine B assay 
 
Cells were plated in a 96-well plate with 150ul of medium per well at the appropriate 
seeding density and incubated under normal conditions (DAY 0). 50ul of medium with 
cisplatin was added to the cell culture 24 hours following the plating to give the 





96-hour (DAY 5), 120-hour (DAY6) and 144-hour (DAY 7) following the drug 
treatment. For the assay, the medium was replaced with 50ul of 10% (wt/v) TCA, and 
incubated at 4°C for 1h fixation. Plates were washed with slow-running tap water for 
four times and air-dried at 40°C in an oven. 100ul of 0.057% (wt/v) SRB solution was 
added, incubated at room temperature for 30 min and quickly rinsed four times with 1% 
(vol/vol) acetic acid to remove unbound dye. 100ul of 10mM Tris-base solution (pH 
10.5) was added to each well after the plates were air-dried, and then incubated at room 
temperature for 30min with agitation to solubilise the protein-bound dye. The O.D value 
at 510nm was measured using a plate reader. 
 
2.2.1.8 Preparation of genomic DNA from mammalian cell lines 
 
Cells were harvested by trypsinisation and pelleted by centrifugation at 1,300 rpm for 5 
minutes. The pellet was resuspended in PBS and digested overnight at 37oC in 750l 
DNA isolation buffer supplemented with proteinase K to a final concentration of 
280g/ml. The supernatant was extracted twice with 750l PCA and vigorous shaking 
and subsequently with 750l CA to remove traces of phenol. The DNA was precipitated 
for 10 minutes at room temperature by addition of 750l of isopropanol. Following 10 
minutes centrifugation, the nucleic acid pellet was washed twice with 70% ethanol, 
dried, resuspended in 200l sterile distilled water and stored either at 4oC in the short 







2.2.1.9 Protein extraction from mammalian cell lines 
 
Cells were washed with cold PBS, scraped into 1ml of cold PBS in a 1.5ml 
microcentrifuge tube and centrifuged at 3000rpm for 3min. PBS was removed and the 
cell pellet was resuspended in 100 to 200ul of RIPA lysis buffer. The cell lysates were 
then incubated on ice for 15 minutes before being centrifuged at 13000rpm for 15 
minutes. The supernatant was recovered as cleared cell lysate and stored at -70°C. 
 
2.2.1.10 Protein extraction from tissues 
 
Fresh tissues were wrapped with foil and snap-frozen in liquid nitrogen. The frozen 
tissues were smashed into small pieces and then homogenised in 2ml of ice-cold 
modified-RIPA buffer for 1min, and then incubated on ice for 30 minutes before being 
centrifuged at 13000 rpm for 15 minutes. The supernatant was recovered as cleared cell 
lysate and stored at -70°C. 
 
2.2.1.11 Generation of xenografts 
 
Cells were grown in standard culture dishes and then trypsinised and counted. 107 cells 
were resuspended in 0.1ml DMEM media with 0.1ml of matrigel and injected 





each mouse had an injection on either flank. Xenograft growth was monitored over a 16 
week period.  
 
2.2.2 Molecular Biology Methods 
2.2.2.1 DNA ligation of PCR products into pGEM®-T Easy Vector 
Systems 
 
DNA ligation reactions were performed in a 10ul volume using reagents from the 
pGEM®-T Easy Vector Systems. The ligation reactions contained 5ul of 2X Rapid 
Ligation Buffer, 1ul of T4 DNA ligase (3 Weiss units/μl) and 50ng vector DNA. A 3:1 
molar ratio of insert DNA to vector DNA was present in each reaction. DNA ligation 
reactions were incubated for either 1h at room temperature or at 4°C overnight to ligate 
the T-tailed pGEM®-T Easy vector with the Taq polymerase generated A-tailed PCR 
products. 
 
2.2.2.2 Transformation of bacteria by heat shock 
 
50µl of DH5α competent bacterial cells were thawed on ice. 10-100ng of plasmid DNA, 
or 5l of a ligation reaction, was added to a tube of competent bacterial cells, and mixed 
gently. A positive control consisting of pUC19 plasmid DNA (250pg), and a negative 





transformations. The mixture of cells and DNA was incubated on ice for 30min, before 
being heat shocked in a 42C water bath for 20s. Following 2min incubation on ice, 1ml 
LB broth was added and the transformations were incubated at 37C for 1h with shaking 
(225rpm). After that, 100μl of the transformations were then plated out onto warm LB 
agar plates containing the antibiotic ampicillin. The plates were inverted and incubated 
at 37C overnight.     
 
2.2.2.3 Amplification of plasmid DNA using DH5α 
 
A single colony of transformed DH5α bacteria was used to inoculate 5 ml of LB 
medium containing ampicillin, and then incubated at 37°C at 225 rpm for 6-8 hours to 
amplify the plasmid DNA containing bacteria. 
 
2.2.2.4 Purification of plasmid DNA 
 
Plasmid DNA was isolated from DH5α bacteria using Qiagen® plasmid DNA Mini or 
Maxi Kits. For Miniprep, the starter culture was used directly according to the 
manufacturer's instructions. For Maxiprep, the starter culture was diluted 1:500 in 250 
ml of LB medium with antibiotic and then incubated overnight at 37°C at 225 rpm. Cells 
were centrifuged at 6000 rpm for 10 minutes at 4°C and plasmid DNA was isolated 
according to the manufacturer's instruction. In brief, the protocol is based on a modified 
alkaline lysis procedure, followed by binding of plasmid DNA to resin columns under 





Plasmid DNA is eluted in a high-salt buffer and then concentrated and desalted by 
isopropanol precipitation. Isolated plasmid DNA was resuspended in nuclease-free 
dH2O and stored at -20°C. 
 
2.2.2.5 Quantification of DNA/RNA 
 
The concentration of plasmid DNA/RNA was determined by spectrophotometry at 
260nm using the Nanodrop Spectrophotometer (ND-1000, Medrano Lab). After 
blanking, 1.5µl of samples was loaded for quantification by measuring absorbance at 
260nm, and for an estimate of purity by measuring the 260:280 absorbance ratios. Pure 
preparations of DNA and RNA have 260:280 ratios of 1.8 – 2.0. Concentrations were 
calculated on the basis that 50mg/ml of double-strand DNA or 40mg/ml of RNA give an 
OD260nm of 1.0.  
 
2.2.2.6 Restriction digestion 
 
Restriction digests contained 4U restriction enzyme (New England BioLabs)/g DNA 
and the appropriate reaction buffer, and were supplemented with 100g/ml bovine 
serum albumin (BSA) if required. Restriction digests were incubated at the appropriate 






2.2.2.7 Polymerase chain reaction 
 
Amplification of specific DNA molecules from a DNA template was performed by the 
polymerase chain reaction (PCR). Routine PCRs reactions contained Taq PCR buffer 
(Promega), 2.5mM MgCl2, 1U Taq DNA polymerase (Promega), 0.5 forward and 
reverse primers, 0.25mM dNTPs and 100ng genomic DNA template and dH2O in a total 
volume of 25ul mix. A no template DNA negative control was also prepared. The PCR 
cycling conditions were as follows: initial DNA denaturation at 94C for 3 min, then 30-
38 cycles of DNA denaturation at 95C for 60s, primer annealing at 50-65C for 60s, 
and DNA polymerase extension at 72C for 1min/kb PCR product. The primer 
annealing temperature was based on primer-specific recommendations from the 
oligonucleotide supplier and empirical observations. After PCR cycling, the PCRs were 
incubated at 72C for 10min to extend any remaining incomplete PCR products. PCR 
products were stored at 4°C before analysis. 
 
2.2.2.8 DNA sequencing 
 
All sequence analysis was performed by the Sequencing Unit at the MRC Human 
Genetics Unit, Edinburgh and using the BigDye Terminator v3.1 Cycle Sequencing kit 
(ABI). DNA sequencing reactions contained 2ul BigDye Terminator v3.1, 3.2pmol 
primer and 50-300ng DNA template in a 10ul volume. The sequencing reactions were 
performed using the following conditions: initial DNA denaturation at 96°C for 1min, 
then 25 cycles of DNA denaturation at 96°C for 10s, primer annealing at 50°C for 5s, 





temperature for 15 minutes by mixing the reaction with 2.5ul of 125mM Na2EDTA and 
30ul of 100 % (v/v) ethanol. After that, DNA fragments were centrifuged at 13000rpm 
at 4°C for 20 minutes, the solution was removed and precipitated DNA was washed 
again with 70 % (v/v) ethanol. The ethanol was removed following centrifugation at 
7500rpm for 15min and the precipitated DNA was air-dried in the dark at room 
temperature, and stored at -20°C before sequence analysis. 
 
2.2.2.9 Separation of DNA fragments by electrophoresis 
 
DNA fragments were separated by gel electrophoresis using 1-2% (w/v) agarose in TBE 
with 0.5mg/ml ethidium bromide for visualization. Loading dye was added to the DNA 
samples to a final concentration of 20%. DNA Hyperladder I was used to provide size 
markers with which to compare the band sizes. Electrophoresis was carried out in a 
horizontal tank, with a TBE buffered system, with a voltage of 75-150V run through the 
system. UV irradiation was used to visualize the DNA fragments and the gel image 
captured using Gel Doc EQ software. 
 
2.2.2.10 Purification of DNA from agarose gels 
 
DNA fragments required for cloning were resolved by agarose gel electrophoresis and 
were purified using the QIAquick gel extraction kit (QIAGEN) according to the 
manufacturer’s instructions. In brief, an agarose gel piece containing the DNA fragment 





were removed by a medium-salt wash and the DNA fragment was eluted in a high-salt 
buffer.   
 
2.2.2.11 5' RACE assay 
 
Characterisation of the 5' end of the Ercc1 cDNA was performed using the 2nd 
Generation 5'/3' RACE Kit (Roche) following the manufacturer's protocol (Figure 2.1). 
Ercc1 specific primers were used in the procedure with all other reagents supplied by the 
manufacturer. The NEO RNA from the kit was used as a control for the assay. The first 
strand of cDNA was synthesised from total RNA using an Ercc1-specific primer Ex2b 
rev with reverse transcriptase and deoxynucleotides. The resultant cDNA was then 
purified using High Pure PCR Product Purification Kit (Roche) to remove the 
unincorporated primers and deoxynucleotides. A homopolymeric A-tail was added to the 
3' end of the cDNA using terminal transferase. The tailed cDNA was then amplified by 
PCR using a second Ercc1-specific primer Skin RT rev C and oligo dT-anchor primer. 
Thic cDNA was amplified with a further round of nested PCR using internal primers 















2.2.2.12 Preparation of RNA 
 
Total RNA was extracted from cultured mammalian cells using RNAzolTMB. Cultured 
cells in 100mm culture dishes were lysed directly by the addition of 5ml of RNAzolTMB. 
The RNA was solubilised by pipetting the lysate several times and extracted by the 
addition of 1ml of chloroform followed by vigorous shaking of the mixture for 30 
seconds. The mixture was then centrifuged at 12000g for 15 minutes at 4oC and the 
aqueous phase was transferred to a fresh tube and an equal volume of isopropanol was 
added. RNA was allowed to precipitate at room temperature for 10 minutes and then 
pelleted by centrifugation at 12000g for 5 minutes, then washed in 70% ethanol and 
centrifuged at 7500g for 5 minutes. The pellet was air-dried at room temperature before 
being resuspended in 50l of RNase-free dH2O for storage at -70oC. 
 
2.2.2.13 Electrophoresis of RNA in agarose gels 
 
The separation of RNA on the basis of molecular weight was achieved by the 
electrophoresis of RNA denatured in a formaldehyde-formamide sample buffer in 
denaturing agarose gels. RNA samples were electrophoresed on denaturing 1.4% (w/v) 
agarose gels containing 0.5g/ml ethidium bromide, 1X MOPS and 0.66M 
formaldehyde. 20g of total RNA in 20l of sterile distilled water was added to an equal 
volume of formamide sample buffer and ¼ volume of 5X sample buffer. Samples were 
heated for 5 minutes at 65oC and snap chilled on ice immediately prior to loading. 






2.2.2.14 Randomly primed labelling method (Northern Blotting) 
 
The mouse Ercc1 mRNA was detected by northern blot using an Ercc1 cDNA probe 
(Selfridge et al. 2001). Radioactively labelled DNA was obtained using a randomly 
primed DNA labelling method, which is based on the hybridisation of a mixture of many 
different nonamer nucleotides to the DNA which allows small amounts of DNA to be 
labelled to high specific activities. The complementary strand is synthesised from the 
3'OH termini of the primer using Klenow polymerase, simultaneously incorporating 
radiolabelled dCTP into the newly synthesised DNA strand. Approximately 10ng of 
DNA was dissolved in 28l of dH2O and denatured by boiling for 5 minutes. 10l of 
labelling buffer, 50Ci of -32PdCTP and 2 units of Klenow polymerase were then 
added and incubated at 37oC for 15 minutes. 
 
2.2.2.15 Separation of unincorporated radionucleotides 
(Northern Blotting) 
 
Unincorporated nucleotides were separated from the labelled DNA by chromatography 
on a NICK R Column (Pharmacia). The labelling reaction was added to TE equilibrated 
column, then 400l of TE was added and the labelled DNA was eluted by the addition 







2.2.2.16 Hybridisation (Northern Blotting) 
 
Membranes onto which RNA had been transferred were blocked by prehybridising in 
30ml of 6X SSC, 1% (wt/v) SDS and 10% (wt/v) dextran sulphate with 3.5mg of 
denatured sonicated herring sperm DNA for two hours at 60°C in a hybridisation bottle. 
Hybridisation was then performed by addition of denatured radiolabelled probe to the 
prehybridisation mixture, and further incubated at 60°C for 12 to 24 hours. After the 
hybridisation, non-specifically RNA bound molecules were removed by immersing the 
membrane in 2X SSC at room temperature for 5min with agitation, and then twice in 2X 
SSC, 1% (wt/v) SDS for 30min at 60°C. Finally the membrane was rinsed in 0.1X SSC 
for 10min before being sealed in a plastic bag, and then visualised by phosphorimager 
(Molecular Dynamics). Signals were analysed with ImageQuant TL software (GE 
Healthcare Life Science). 
 
2.2.2.17 Reverse transcription of RNA 
 
Total RNA samples were treated with DNase 1 to ensure removal of contaminating 
DNA using a DNA-free Kit (Ambion) prior to reverse transcription. cDNA was prepared 
from RNA using the Retroscript Kit (Ambion) following manufacturer’s instructions. In 
brief, 2g of total RNA was mixed with 2l of random decamers, mixed and then 
denatured at 70oC for 3 minutes. 2l 10 x RT buffer, 4l dNTPs, 1l RNase inhibitor, 
and 1l reverse transcriptase enzyme were then added, incubated at 42oC for 1 hour and 






2.2.3 Protein Detection 
2.2.3.1 Protein quantification 
 
Protein concentrations were determined using the BCATM Assay Kit (Pierce) in a 96-
well plate. Protein samples were diluted 10-fold in dH2O to a total volume of 25ul. dH2O 
was used as a blank control. After 200ul of working reagent was added to each sample 
and incubated at 37°C for 30min, the protein concentration was determined at 562 nm 
using a plate Spectrophotometer (MRX, Dynatech). Concentrations of samples were 
calculated using the standard curve generated from the known BSA standards and were 




Immunoprecipitation of protein was performed using the Protein G Immunoprecipitation 
Kit (Roche Applied Science). 50ul of the homogeneous protein G-agarose beads (25ul 
bed volume) was add to 1ml of protein samples and incubated for at least 3 h or 
overnight at 4°C on a rocking platform prior to the immunoprecipitation to reduce 
background caused by non-specific adsorption of irrelevant cellular proteins. Beads were 
pelleted by centrifugation at 12,000 × g for 20 s in a microfuge. Supernatants were 
transferred to fresh tubes and incubated with an appropriate amount of the specific 
antibody for 1 h at 4°C with gently rocking. After that 50ul of the homogeneous protein 
G-beads were added to the mixture and incubated for at least 3 h or overnight at 4°C on 
a rocking platform. Beads were collected by centrifugation at 12,000 × g for 20 s and 





the removal of the wash buffer, the immunoprecipitated proteins were heated at 95-
100°C for 5 minutes in sample buffer to denature the protein and separate it from the 
protein G beads before analysis by western blotting. 
 
2.2.3.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
The separation of proteins on the basis of their molecular weight was achieved by 
discontinuous SDS-PAGE. SDS-PAGE at appropriate polyacrylamide concentrations 
was prepared using a Mini-PROTEAN3 electrophoresis system (Bio-Rad). 
Concentration of polyacrylamide in the resolving gel was determined by the molecular 
weight of the protein tested. Proteins with molecular weight from 30kDa to 200kDa 
were separated by 10% to 12% resolving gel (10% - 12% Acrylamide, 390 mM Tris-
HCl pH 8.8, 0.1 % SDS, 0.1 % APS, polymerisation was initiated by adding 0.08 % 
TEMED). The resolving gel was overlaid with isopropanol to remove air bubbles and 
flatten the top surface before being left to polymerise at room temperature. After that 
isopropanol was removed and the stacking gel (5 % Acrylamide, 123 mM Tris-HCl 
pH6.8, 0.1 % SDS, 0.1 % APS, 0.1 % TEMED) was added with either a 10-well or 15-
well comb. After the stacking gel was set, the comb was removed and the gel cassette 
was assembled with the Mini-PROTEAN3TM electrophoresis module and immersed in 
running buffer (192mM Glycine, 25 mM Tris, 0.1 % (w/v) SDS). Appropriate amounts 
of protein samples were prepared with 5X SDS sample buffer and were heated at 95°C 
for 5 minutes before loading onto the gel with 12ul of the Prestained Protein Ladder 
(Invitrogen). Protein samples were separated by electrophoresis in running buffer at 80V 






2.2.3.4 Western immunoblotting 
 
Following the SDS-PAGE, the resolved proteins were transferred electrophoretically to 
a methanol rinsed Immobilon-P PVDF transfer membrane (Millipore, Billerica, 
Massachusetts) with transfer buffer according to the method of Towbin (Towbin et al. 
1979). The transfer was completed by using a Mini Trans-Blot system (Biorad) at 100V, 
constant voltage at 4oC with an ice block for 1 hour, or at 20mA, constant current at 4oC 
overnight. After the transfer, the membrane was rinsed in TBS/T for 5 minutes before 
the filter was blocked with 5 % (w/v) dried skimmed milk diluted in TBS/T for 1 hour. 
The membrane was then incubated with the primary antibody diluted in 5 % (w/v) milk-
TBS/T for 1 hour at room temperature or overnight at 4°C, washed with TBS/T three 
times 10 minutes each at room temperature, and incubated with the appropriate diluted 
secondary antibody diluted in 5 % (w/v) milk-TBS/T for 1 hour at room temperature. 
Unbound antibodies were removed with three 10 minutes washes in TBS/T. The 
membrane was then overlaid with enhanced chemiluminescence solution (ECL) or ECL-
Plus (Amersham Biosciences, Buckinghamshire, UK) for 1 minute. Excess ECL solution 
was drained before membranes were exposed to HyperfilmTM ECL (Amersham 
Biosciences). 
 
2.2.3.5 Fluorescent ECL plus western blot detection with Storm 
image analysis system 
 
For accurate quantitative analysis of western blotting results, fluorescent ECL plus 
western blot detection with the Storm 840 phosphorimager (Molecular Dynamics) was 





incubated in ECL Plus detection reagent for 5 min. Excess reagent was drained and the 
wet membrane was placed in an open, low-fluorescence plastic hybridization bag. The 
membrane was covered slowly to avoid trapping air bubbles. The membrane was 
scanned using the Blue Fluorescence/Chemifluorescence scan mode of Storm model 840 
with a PMT voltage setting of between 650 and 800 V. The intensities of bands on the 
western blot were measured and analysed using the ImageQuant TL software (GE 
healthcare life science). 
 
2.2.3.6 Stripping nitrocellulose membranes 
 
Membranes were stripped to remove primary and secondary antibodies from the 
membrane before they were re-probed with additional antibodies. The membrane was 
incubated with pre-warmed 100ml of stripping buffer in a tightly sealed plastic box for 
up to 45 minutes at 50°C. The membrane was then rinsed under a running water tap for 
1-2 hours and treated for 1min of methanol rehydration before the blocking stage. 
 
2.2.3.7 Coomassie Brilliant Blue staining 
 
Resolving gels were washed 3 times in water, for 5 minutes each time with agitation.  
After that, water was replaced with EZblue stain reagent. Gels were incubated in the 
stain reagent for 1 hour with agitation, and then washed with water for 1 hour or 
overnight until the protein bands became visible and the gel background was clear. 







Characterization of ERCC1 protein expression in mouse 





3.1   Introduction 
 
This chapter addresses the investigation of ERCC1 protein expression in mouse 
keratinocytes and tissues. 
 
The nucleotide excision repair (NER) pathway has evolved primarily to repair UV-
induced DNA damage and is also active against a broad range of endogenously 
generated oxidative lesions (de Boer and Hoeijmakers 2000). NER consists of two 
subpathways in mammals, global genome repair (GGR) and transcription-coupled repair 
(TCR), according to the initial recognition stage. GGR can remove DNA lesions 
throughout the genome, while TCR mainly deals with lesions in the transcribed strand of 
actively transcribed genes (Leadon and Lawrence 1991; Lombard et al. 2005). The NER 
pathway involves about 30 distinct proteins. ERCC1 is essential for NER where it acts in 
a complex with XPF protein to make the incision 5' to the DNA lesion (Newman et al. 
2005). In the NER pathway, the TFIIH complex, including XPB and XPD is recruited to 
the damage site to unwind the DNA helix (de Laat et al. 1999). After that, XPG and 
XPF/ERCC1 access the damaged site to make the dual incision. XPG cuts on the 3' side 
while XPF-ERCC1 makes the 5' side incision (Mu et al. 1996; de Laat et al. 1999). Once 
the oligonucleotide containing the lesion has been removed, the gap is filled by two 
polymerases, using the intact strand as a template. The ends are then joined by DNA 
ligase. 
Because skin receives the greatest exposure to UV it is reasonable to expect that the 
expression of NER proteins may display different properties in the skin in an attempt to 
deal with a more demanding role in that tissue. As described in the Introduction chapter, 
we have identified the skin-specific 1.5kb Ercc1 mRNA as the major transcript in skin in 
terms of abundance. This novel Ercc1 transcript was found at much higher levels in 





a mechanism to enhance the level of repair in albino mouse skin which would not be 
protected against UV-induced DNA damage by melanin pigment. One of the main aims 
of this chapter was to investigate this hypothesis. 
 
3.2 Optimization of western blotting and selection of 
appropriate antibodies for ERCC1 and loading controls in cells 
and tissues 
 
Before investigating the level of ERCC1, we first tested several anti-ERCC1 antibodies 
against mouse and human ERCC1 protein. The commercial antibodies SC-17809, SC-
10157 and FL-297 were obtained from Santa Cruz biotech. The R540 is an "in house" 
ERCC1 antibody used previously for ERCC1 detection on mouse tissues by our group. 
According to the manufacturer’s datasheet, antibodies SC-17809 and FL-297 could 
detect the ERCC1 protein in both mouse and human species while SC-10157 could only 
react against the mouse ERCC1.  
 
The western blotting results using the optimal primary and secondary antibody dilutions 
are shown in Figure 3.1. We first tested all antibodies using a cell panel of ERCC1 wild-
type and deficient mouse embryonic fibroblasts, named PF20 and PF24 respectively. 
SC-17809, SC-10157 and R540 all detected a band at the expected position of 33kDa in 
the PF20 lane that was missing in the PF24 lane (Figure 3.1.A). All three antibodies 
picked up one or more cross-reacting bands in both PF20 and PF24 lanes in western 
blotting analysis. Antibody SC-17809 mainly cross-reacted with a protein at the 
molecular weight of 30kDa, while antibody SC-10157 only cross-reacted with one 





proteins and generated a dirty background in western blotting. The crossing-reacting 
band detected by SC-17809 was very close to the target band of ERCC1 and was much 
stronger than the ERCC1 band in terms of abundance. Thus, the antibody SC-10157 was 
chosen for western blotting of mouse samples.  
 
An investigation of the cross-reacting band generated by SC-10157 was performed to 
identify whether the cross-reactivity was specific (ie. ERCC1-related) or not. This is 
described later in this chapter. 
 
For ERCC1 detection in human samples, similar antibody selection was performed. 
Three human melanoma cell lines G361, WM115 and A375 were used in this 
investigation. Figure 3.1.B showed that the antibody SC-17809 could detect the target 
ERCC1 protein (35kDa) but also detected a cross-reacting protein underneath the main 
ERCC1 band. Because the molecular weight of human ERCC1 is 2kDa larger than 
mouse ERCC1, the separation between human ERCC1 and this cross-reacting band was 
much better. Whole cell protein lysate of mouse ERCC1 deficient keratinocyte cells was 
used in this western blotting as a negative control because no human ERCC1 deficient 
cells were available in the lab. The membrane was then probed with anti-beta-tubulin as 
a loading control. FL-297 also gave a clean result in western blotting of human samples. 
FL-297 normally generated a higher background compared to SC-17809. However after 
a higher dilution of the primary antibody plus extensive washing with TBS-T, the dirty 
background could be removed. Figure 3.1.C shows a western blotting result using 
optimized conditions for FL-297. Only the target human ERCC1 protein was detected at 
the expected position of 35kDa. Note that in Figure 3.1.C the loading may not be 
matched as neither the BCA assay nor a loading control re-probing was performed in 





Figure 3.1: Tests of different ERCC1 antibodies for detection of mouse and 
human ERCC1 by western blotting. 
 
            
            
A. Western blotting on mouse embryonic fibroblast cell lines PF20 (ERCC1 wild-type) and PF24 (ERCC1 
deficient) using different antibodies against ERCC1. SC-17809 and SC-10157 are the commercial 
antibodies from Santa Cruz biotech, R540 is the “in house” antibody used for previous 
investigations.  
B. Western blotting using anti-ERCC1 antibody SC-10789 on human melanoma cell lines G361, WM115 
and A375. Human ERCC1 bands at the position of 35kDa are indicated with red arrows. Cross-
reacting bands and loading control band of beta-tubulin are indicated with black arrows. Mouse 
ERCC1 deficient keratinocyte cell line was used as a negative control in this panel. Protein ladders 
are labelled to the left of the membrane. 
C. Western blotting using anti-ERCC1 antibody FL-297 on human melanoma cells lines G361, WM115 
and A375.  The identical ERCC1 bands are indicated with red arrows.  Protein ladders are labelled to 
the left of the membrane.  
A. 
B. C. 





analysis of human samples. The FL-297 could be ideal for immunohistochemistry 
applications.  
 
To measure the ERCC1 protein level quantitatively, good loading controls are essential 
to make sure the samples are equally loaded. Several loading control antibodies were 
tested for quantitative western blotting analysis. There were three important points for 
selecting a good loading control in this investigation. First, the loading control antibody 
should be specific and able to produce a clean western blotting result. Thus, most of the 
popular loading control antibodies raised in mouse cannot be used for western blotting 
on mouse samples, especially on mouse tissues due to secondary antibody cross-
reactivity with mouse immunoglobulins. Second, the band generated by the loading 
control antibodies should be as far as possible from the target ERCC1 band and cross-
reacting bands. Good separation is required to measure the intensity of different bands 
using the phosphorimager. Finally, levels of the ideal loading control protein should be 
independent of the biological status of the cell or tissue. For example, changing the 
culture conditions could potentially induce proliferation. As a result, a commonly used 
loading control such as PCNA would not be suitable for such an investigation. 
 
Beta-actin, beta-tubulin, TBP-like protein, GAPDH and PCNA were tested in western 
blotting using mouse cells and tissue and human cells. Beta-actin was not suitable for 
western blotting on mouse samples because most beta-actin antibodies were raised in 
mouse. However the beta-actin antibody could be used for loading control determination 
on human samples.  
 
Anti-GAPDH is a mouse antibody which detects a band at the position of 37kDa. It was 





detection because the GAPDH band would be too close to the ERCC1 band at 33kDa to 
35kDa. With human samples, GAPDH detected only one band of GAPDH specifically, 
thus it was reasonable to use the GAPDH loading control for quantitative detections of 
proteins of different molecular weight. For example, GAPDH could be used for XPF, 
MSH2, MSH6 and MLH1 quantitative measurements, which were part of our 
investigation of DNA repair in human melanoma and ovarian tumour cells in Chapter 5. 
 
The loading control antibody beta-tubulin from abcam was finally selected for the 
quantitative measurement of ERCC1 protein by western blotting. Firstly, this antibody 
detected a single clean band at 50kDa representing beta-tubulin with very low 
background. Secondly, because it was a rabbit polyclonal antibody, there was no 
problem of cross-reacting with mouse or human immunoglobulin. Thirdly, the position 
of the band at 50kDa was far away from the ERCC1 band and cross-reacting bands. It 
was also well-separated from other DNA repair proteins in our investigation. Figure 3.2 
shows the result of using the beta-tubulin loading control in different investigations. In 
the Figure 3.2.A, B and C, whole protein lysate of two mouse keratinocyte cell lines, 
two mouse melanocyte cell lines and two mouse skin samples were separated by SDS-
PAGE and then probed with the antibody SC-10157 against mouse ERCC1. After that 
the filters were re-probed with the loading control beta-tubulin antibody. The three 
bands, beta-tubulin, cross-reacting and mouse ERCC1 from the top to the bottom as 
indicated on the membrane were separated well enough for the next step of 
phosphorimager scanning.  In the Figure 3.2.D, whole cell protein lysate of two human 
melanoma cell lines, A375 and WM115, were probed with the antibody SC-17809 
against human ERCC1. As indicated on the figure, human ERCC1 and a cross-reacting 
band were detected at their expected position. Then the membrane was probed with 
beta-tubulin. The clear band detected by beta-tubulin was specific and identical in both 





Figure 3.2: Tests of loading control antibody anti-beta-tubulin in different 
applications by western blotting analysis 
 
   
 
   
Whole cell protein lysates were separated by SDS-PAGE and transferred to PVDF membranes for probing. 
Membranes were blocked and then probed with anti-ERCC1 antibody SC-10157 (mouse) or SC-17809 
(human). After that membranes were reprobed with the loading control antibody against beta-tubulin.  
A. Western blotting of mouse keratinocytes.  B. Western blotting of mouse melanocytes. C. Western 







To determine if the cross-reacting band detected by the anti-ERCC1 antibody SC-10157 
in mouse samples was specific or not, an immunizing peptide blocking experiment was 
performed. The primary antibody SC-10157 was neutralized by pre-incubation with its 
blocking peptide at different concentrations for 1 hour before being applied to the 
membrane for detection. By doing this neutralization, the antibody that was bound to the 
blocking peptide should no longer bind to the epitope present in the target protein on the 
western blotting analysis. The neutralized SC-10157 antibody was then used side-by-
side with the normal untreated SC-10157 antibody, and the results were compared. By 
comparing bands from the blocked antibody versus the untreated antibody, the 
specificity of the antibody recognition could be determined: specifically-recognized 
bands would be absent from the western blot performed with the neutralized antibody. 
 
Without neutralization by the blocking peptide, the SC-10157 antibody detected both 
ERCC1 and the cross-reacting protein. The cross-reacting bands were slightly stronger 
compared to ERCC1 bands in terms of the intensity. Once the SC-10157 antibody was 
neutralized by 0.0001ng/ml of blocking peptide, ERCC1 bands were only barely 
detectable. The intensity of cross-reacting bands was only slightly reduced by SC-10157 
antibody neutralization. The membrane strips were then probed with the loading control 
beta-tubulin to make sure the loading was matched (Figure 3.3). The neutralization of 
SC-10157 prevented recognition of ERCC1 more efficiently than it prevented 
recognition of the cross-reacting protein, supporting the conclusion that the detection of 






Figure 3.3 Investigation of the specificity of binding of the SC-10157 




Mouse skin protein lysates were separated by SDS-PAGE and transferred to the membrane, then blocked 
with 5% milk in TBS-T buffer. Duplicates of the blocked membrane strips were then probed with 
untreated anti-ERCC1 antibody SC-10157 on its own or anti-ERCC1 SC-10157 neutralized by blocking 
peptide. Membrane strips were then probed with secondary antibody and protein bands were visualized 
by ECL-PLUS on film. After that, strips were washed and then re-probed with loading control beta-
tubulin.  
 
A. Western blotting using anti-ERCC1 SC-10157 alone.  
B. Western blotting using neutralized anti-ERCC1 SC-10157 by pre-incubation with 0.0001ng/ml 






3.3 Western blotting of ERCC1 WT and knockout samples of 
mouse embryonic fibroblasts, keratinocytes, melanocytes and 
skin tissues 
 
Having optimized conditions for western blotting analysis, we then tested all of our 
stock cells and animals. As shown in the Figure 3.4, a panel of whole protein lysates of 
ERCC1 wild-type and deficient mouse keratinocyte cells (KER WT and NULL), 
embryonic fibroblast cells (PF20 and PF24), skin samples (SKIN WT and SKIN NULL) 
and mouse melanocyte cells (Melanocyte ERCC1 WT and Melanocyte ERCC1 NULL), 
and also a human melanoma cell line A375 were separated by SDS-PAGE and then 
transferred to the PVDF membrane for ERCC1 detection.  
 
The anti-ERCC1 antibody SC-10157 detected the expected mouse ERCC1 bands in the 
ERCC1 wild-type tracks at the position of 33kDa. A single clear band was detected by 
the SC-10157 in the human melanoma cell line A375 track as well at the position of 
35kDa. In lanes of ERCC1 deficient samples, there was no ERCC1 band detected. A 
cross-reacting band at about 40kDa was detected in every mouse sample lane. There was 
a second higher cross-reacting band at about 80kDa in the ERCC1 deficient mouse 
melanocyte lane. This band had appeared randomly before in mouse samples by western 
blotting detection using anti-ERCC1 SC-10157, but the frequency was very low. 
Loading control GAPDH indicated that the loading was equally matched. 
 
The western blotting demonstrated that we could detect ERCC1 protein expression in 
wild-type mouse keratinocytes, embryonic fibroblasts, melanocytes and mouse skin and 






Figure 3.4 ERCC1 protein expression pattern in our ERCC1 wild-type and 





A. Western blotting assay using panel of ERCC1 wild-type and ERCC1 null mouse keratinocytes, 
fibroblasts, skin samples, melanocytes and ERCC1 wild-type human melanoma cell line A375. The 
anti-ERCC1 antibody SC-10157 detected bands, indicated as Mouse ERCC1, at the expected 
molecular weight of 33kDa in ERCC1 wild-type samples but not in ERCC1 deficient samples. An 
expected band at 35kDa in human melanoma cell line A375 is labelled as Human ERCC1. Cross-
reacting bands at 42kDa in all tested protein samples are labelled as Cross-reacting. 








3.4 ERCC1 protein levels were consistent with Ercc1 mRNA 
levels in various mouse tissues except skin 
 
A panel of tissues from a wild-type Balb/C adult male mouse was analysed previously 
by northern blot using an Ercc1 cDNA probe by Dr. Jim Selfridge (unpublished 
observations). The normal 1.1 kb Ercc1 transcript as identified in human, was evident in 
all tissues examined (Figure 3.5.A).  The level of expression of this transcript was lowest 
in the liver and generally low in all other tissues except for the testis, where the level of 
expression of this transcript was much higher than elsewhere.  The pattern of expression 
seen in the skin was clearly different from any other tissue.  In addition to the normal 
Ercc1 transcript, a second larger transcript of 1.5kb was evident. In terms of abundance 
the novel Ercc1 transcript was the major transcript in skin. Since skin receives the 
greatest exposure to UV, it might require more DNA repair capability. Thus we 
hypothesized that the skin-specific 1.5kb Ercc1 transcript might have a special 
biological function to help skin deal with the increased DNA lesions and the expression 
of NER proteins may display different properties in the skin to deal with a more 
demanding repair role. 
 
Based on the northern blotting result, we performed a western blotting using the same 
panel of tissues, but from 4 different mouse strains. The Balb/C and CD1 strains were 
albino while the 129/Ola and C57BL/6 strains were pigmented.  
 
Because this western blotting involved several different tissues, it was difficult to use a 
loading control antibody to check the matched loading because we found that protein 
expression levels of loading controls varied significantly between different tissues from 





membrane with ink as a control to check the general loading levels. As shown in the 
Figure 3.5.C, the ink control indicated that the loading of each lane was generally 
matched, despite the presence of some highly-expressed and tissue-specific bands. 
Beside the ink control, a duplicate of the SDS-PAGE gel with the same loading of 
protein samples was stained with coomassie blue. The coomassie blue staining results 
were the same as the ink control (data not shown). The expression of ERCC1 protein 
was detected by anti-ERCC1 antibody SC-10157 (Figure 3.5.B).  
 
First, it is evident that the size of the ERCC1 protein is the same in skin as in other 
tissues examined (33kDa). This suggests that differential transcription in skin has no 
effect on the size of the ERCC1 protein product. This result agrees with a previous 
western blotting analysis using a Balb/C tissue panel probed with a different home-made 
R540 anti-ERCC1 antibody for ERCC1 detection (Andrew Winter, unpublished). The 
result is also in agreement with a previous RT-PCR assay using primers in exon2 to 
exon10, which suggested that the coding region of the skin-specific Ercc1 transcript was 
no different to that in the normal Ercc1 transcript (Andrew Winter, unpublished).  
 
Second, all strains examined showed a similar tissue pattern of ERCC1 protein level, 
which matched the tissue pattern of Ercc1 transcript. The level of ERCC1 was highest in 
testis, followed by brain. Skin and kidney showed a lower level than testis and brain. 
Liver had the lowest level of ERCC1. The duplicated ERCC1 bands in the 129 strain 
panel might be due to some degradation of protein samples. The protein level of ERCC1 
was not elevated in skin compared to other tissues, suggesting that the novel 1.5kb skin-











         
  
A. Northern blotting analysis using a panel of wild-type mouse tissues from strain Balb/C. The normal 
1.1kb Ercc1 transcript and novel 1.5kb skin-specific Ercc1 transcript are indicated by arrows on the 
right side.  
B. Western blotting using the same mouse tissue panel. The ERCC1 protein expression in different 
tissues was also tested in 3 other mouse strains CD1, 129/Ola and C57BL/6 as indicated on the left. 
C. Due to the difficulty of using a loading control for different tissues, the western blotting filters were 
inked before probing to determine whether the loading was matched. The ink control of the 
C57BL/6 western blotting filter stain indicated that the loading was generally well-matched. The ink 







Northern blotting for Ercc1 was carried out by a previous group study on RNA extracted 
from the skin of adult mice of inbred albino strains Balb/c, FVB, MF1, the outbred 
albino strains, MF1 and CD1, and the inbred pigmented strains C57Bl/6, DBA/2, 
CBA/Ca and 129/Ola (Figure 3.6.A) (Andrew Winter, unpublished). These results show 
that every pigmented strain had barely detectable levels of the novel transcript originally 
observed in BALB/c mice.  However, the novel transcript was seen in two other strains 
of albino mice, CD1 and MF1.  The albino strain FVB was the only albino strain to have 
the same expression pattern as pigmented mice. Because the albino strains did not have 
pigment in their skin, they are at great risk of UV-induced DNA damage, so we 
hypothesized that the 1.5kb novel Ercc1 transcript may help the albino strains to deal 
with the DNA damage in skin. 
 
To investigate whether this novel transcript could indeed induce a different protein 
expression of ERCC1 in skin, a western blotting using different skin samples from 
albino and pigmented strains was performed. CD1 and Balb/C strains were chosen from 
the albino strains while C57Bl/6 and 129/Ola strains were chosen from the pigmented 
strains. Two to three pieces of back skin samples were cut from each animal. Four mice 
were used for CD1 and C57Bl/6 strains while three mice were used for Balb/C and 
129/Ola. The protein level in ERCC1 of all samples was detected by western blotting 
using antibody SC-10157 using the phosphorimager system. Membranes were re-probed 
with loading control beta-tubulin and scanned by the phosphorimager system as well. 
The quantified protein level of ERCC1 was then standardized by the level of loading 
control beta-tubulin (Figure 3.6.B).  
 
The Balb/C strain showed the lowest level of ERCC1 protein in skin. The CD1 and C57 
strains had a similar level of ERCC1, which was slightly higher compared to Balb/C. 





When the results for CD1 and Balb/C strains were plotted together (albino group) and 
compared to C57BL/6 and 129/Ola strains plotted together (pigmented group) the 
ERCC1 protein levels were much more similar. The level of ERCC1 was slightly lower 
in the albino group, but the difference was not statistically significant (p=0.085 by 
Mann-Whitney U test). Thus, we found no support for our hypothesis that the 1.5kb 
skin-specific Ercc1 transcript might result in increased ERCC1 protein level in the skin 
of albino strains. 
 
3.5 Stress treatment induced changes in levels of ERCC1 in 
mouse keratinocytes 
 
Previous group work had found no increase in levels of the 1.5kb skin-specific Ercc1 
mRNA in mouse skin after UV irradiation (Andrew Winter, unpublished observation). 
Although we had found no evidence that ERCC1 protein levels were affected by the 
level of the 1.5kb skin-specific Ercc1 transcript under normal conditions, we wished to 
explore the possibility that ERCC1 protein levels may change in skin in response to UV-
irradiation or other stresses. These experiments were most conveniently carried out in 
cultured keratinocytes, rather than in mouse skin. 
 
As another NER protein, XPC, was reported be modified by SUMO-1 and ubiquitin 
following UV irradiation (Wang et al. 2005), we investigated whether the level of 
ERCC1 protein might be post-translationally regulated. Initially a simple preliminary 
experiment was carried out on mouse keratinocyte cells following treatment with the 
proteasome inhibitor MG132. Proteasomes are large protein complexes that degrade 





Figure 3.6 The Ercc1 mRNA and ERCC1 protein expression pattern 






A. Northern blotting for Ercc1 was carried out on RNA extracted from the skin of adult mice of inbred 
albino strains BALB/c, FVB, the outbred albino strains, CD1 and MF1, and the inbred pigmented 
strains C57Bl/6, DBA/2, CBA/Ca and 129/Ola. The 1.5kb and 1.1kb Ercc1 transcripts are indicated 
with arrows. 
B. Whole protein lysates of independent mouse skin samples from CD1, Balb/C, C57BL/6 and 129/Ola 
strains were separated by SDS-PAGE and then probed with anti-ERCC1 SC-10157 and detected by 
the phosphorimager system. After that, the membranes were re-probed with loading control beta-
tubulin. Top panel shows the beta-tubulin bands and bottom panel shows the ERCC1 bands. 
C. Histogram shows mean level of ERCC1 protein in skin ±SEM standardized against beta-tubulin for 
individual albino and pigmented mouse strains. 
D. Histogram shows mean level of ERCC1 protein in skin ±SEM standardized against beta-tubulin for 









selective proteasome inhibitor (Ki=4nM), which inhibits NFkappaB activation by 
preventing IkappaB degradation. MG132 can be used to block degradation of short-lived 
proteins.  
 
Surprisingly, given that the published half-life of ERCC1 is not particularly short (a 
half-life of about 7 hours was reported in human tumour cells by McGurk, et al. 2006), 
MG132 induced a significant accumulation of ERCC1 in our keratinocyte cells. ERCC1 
wild-type and deficient keratinocyte cell lines were treated with MG132. Cells were 
harvested 6 hours following the treatment, lysed and analyzed by western blotting. As 
shown in the Figure 3.7.A, the protein level of ERCC1 was barely detectable in the 
ERCC1 wild-type keratinocyte cells without the proteasome inhibitor MG132. However, 
when treated with MG132, the level of ERCC1 was boosted dramatically. In the 
negative control ERCC1 deficient keratinocyte cells, no ERCC1 protein was detected. 
The cross-reacting bands detected by the anti-ERCC1 SC-10157 could be used as a 
loading control in the western blotting to show the loading was well-matched. This 
result was very interesting as it revealed that there might be a potential post-translational 
pathway to regulate the protein level of ERCC1 in keratinocytes. 
 
In addition to the proteosome inhibitor MG132 treatment, UV-irradiation was then 
performed on keratinocytes (Figure 3.7.B). ERCC1 was barely detectable in non-
irradiated cells and cells following 5Jm-2 UVC-irradiation. Following 50Jm-2 UVC-
irradiation, the level of ERCC1 protein had increased by 6 hours and was highest at 24 
hours post UV. UVC radiation induces two of the most abundant mutagenic and 
cytotoxic DNA lesions cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts 
(6-4PPs). This damage is repaired mainly by the NER pathway in cells (Sinha and Hader 
2002). As ERCC1 plays an essential role in the NER pathway, this result indicated a 





Figure 3.7 ERCC1 protein levels in mouse keratinocytes following various 
treatments by western blotting 
 












A. Proteasome inhibitor treatment. Elevated protein level of ERCC1 was seen in mouse keratinocytes 6 
hours following proteasome inhibitor MG132 treatment. ERCC1 wild-type and deficient 
keratinocytes are labelled as KER WT and KER Null, respectively.  
B. UV-irradiation.  ERCC1 wild-type keratinocytes were labelled as KER ERCC1 WT in red and deficient 
keratinocytes were labelled as KER Null in blue. Cells were treated with 5Jm-2, 50Jm-2 and no UV 
(0Jm-2) as indicated on the top of the gel. The different harvest time points following UV-irradiation 
are labelled on the top as well. Number 1 and 2 indicates duplicate samples. Top panel of gel shows 
bands of the loading control beta-tubulin and bottom panel shows bands of ERCC1, as indicated by 
the arrows on the right. 
C. Treatment with high Ca2+ containing medium. The high Ca2+ culture condition could also elevate the 
level of ERCC1. Normal low Ca2+ culture condition is labelled in blue under the gel. High Ca2+ culture 
condition is labelled in red. Cells were harvested at 6 hour and 24 hour following the medium 
change. The time points are labelled on the top of the gel. Number 1 and 2 indicates duplicate 
samples. Top panel of gel shows bands of the loading control beta-tubulin and bottom panel shows 





We also investigated whether the concentration of calcium in the culture medium could 
affect the level of ERCC1 protein (Figure 3.7.C). The differentiation programme of 
cultured keratinocytes is regulated by the Ca2+ concentration of the culture medium 
(Hennings et al. 1980). In low-calcium medium keratinocytes remain undifferentiated. 
Increasing the calcium concentration triggers the differentiation of keratinocytes 
(Darmstadt et al. 1998). With Ca2+ below 0.1mM, keratinocytes form a monolayer of 
basal epithelial-like cells, with a characteristic "crazy paving" appearance under the 
microscope. When Ca2+ rises above 0.1 mM, the cells begin to stratify and mature to 
fully differentiated squames. 
 
Our western blotting results showed that the level of ERCC1 increased significantly 6h 
following transition from low (concentration<0.1mM) to high (concentration=1.8mM) 
calcium. The ERCC1 level decreased 24h after the transition and returned to normal 72h 
after the high Ca2+ treatment started.  
 
In all the above experiments in section 3.5 with our ERCC1 wild-type mouse 
keratinocytes there was an unexpectedly low level of ERCC1 protein under normal 
culture conditions without any treatment. At the beginning of the year 2007, this 
situation changed. The ERCC1 protein level in untreated keratinocyte cultures increased 
such that we could no longer detect an increase following any of the treatments used.  
The keratinocyte samples analysed in earlier sections of this Chapter (shown in Figure 
3.2 and Figure 3.4) were prepared after this change had occurred. While we were 
investigating the reason for this change to our ERCC1 wild-type keratinocyte cultures 
we investigated our ERCC1 wild-type mouse embryonic fibroblast line and an 
independent mouse keratinocyte cell line to see if they showed treatment-related changes 





The same elevation of ERCC1 protein level was not seen in mouse embryonic 
fibroblasts. As shown in the Figure 3.8.A, the ERCC1 level was already high in the 
wild-type fibroblast line (PF20) without any treatment. After 6 hours of treatment with 
proteasome inhibitor MG132, the ERCC1 level remained the same as in untreated cells. 
The ERCC1 deficient fibroblasts (PF24) were a negative control for this experiment. As 
expected there was no ERCC1 band detectable in the PF24 lanes, no matter whether 
treated with MG132 or not. The loading control of beta-tubulin showed the loading was 
well-matched.   
 
We then tested the level of ERCC1 in the PAM212 cell line following changing culture 
conditions. The PAM212 cell line was another mouse keratinocyte cell line which had 
different culture conditions from the ones used by our group. PAM212 was normally 
cultured in high Ca2+ RPMI medium where the cells had the appearance of differentiated 
keratinocytes under the microscope. When changed to low Ca2+ culture conditions, the 
growth of PAM212 cultures slowed down significantly. A few cells died in the low Ca2+ 
condition but the majority cells remained alive.  
 
PAM212 cells were transferred to the low Ca2+ condition for 6 hours and 24 hours, then 
cells were harvested and ERCC1 protein was detected by western blotting along with 
controls cultured in normal high Ca2+ medium. The whole cell protein concentrations 
were measured by the BCA assay and equal amounts of protein were loaded on the gel 
and separated by SDS-PAGE. ERCC1 was detected by anti-ERCC1 SC-10157 and the 
cross-reacting band was used as loading control (Figure 3.8.B). The level of ERCC1 
increased slightly in PAM212 cells cultured for 6 hours in low Ca2+ medium. The band 
intensities were then measured by the Quantity One densitometry system (BIO-RAD). 
The level of ERCC1 was standardized against the cross-reacting band. The mean 





Figure 3.8 ERCC1 protein levels in mouse embryonic fibroblasts and 














A. Proteasome inhibitor MG132 treatment of mouse embryonic fibroblasts. Protein lysates from ERCC1 
WT mouse fibroblasts (PF20) and deficient mouse fibroblasts (PF24) either untreated or treated for 
6h with MG132 were separated by SDS-PAGE, transferred to the PVDF membrane and then probed 
with anti-ERCC1 SC-10157 and the loading control of beta-tubulin. The top panel shows bands of 
beta-tubulin while the bottom panel shows bands of ERCC1.   
B. Effects of different culture conditions on PAM212 cells.  PAM212 cells were transferred to low Ca2+ 
medium and harvested after 6 hours and 24 hours. PAM212 cells cultured under normal high Ca2+ 
conditions were used as control in the western blotting. Number 1 and 2 indicates duplicates of 
samples above the gel. Cross-reacting bands and ERCC1 bands are indicated by arrows on the right. 
C. Histogram showing mean level of ERCC1 protein in PAM212 standardized against the cross-reacting 
band. Mean level of ERCC1 in PAM212 cultured in low Ca2+ medium is plotted in blue columns.  Mean 
level of ERCC1 of PAM212 cultured in normal high Ca2+ medium is plotted in the black column. Time 
points are labelled under their relevant columns. Y-axis shows the mean ratio of ERCC1 against cross-






The ERCC1 level was slightly elevated 6 hours following the change to low Ca2+ 
medium, but had returned to normal (high Ca2+) levels after 24 hours in low Ca2+ 
medium. This difference was not considered large enough compared to the difference 
seen in our own keratinocyte cell line to justify further experiments with this cell line. 
 
3.6 Investigation of the reason for the loss of stress treatment 
induced changes in ERCC1 levels in keratinocytes 
 
As described in Section 3.5, an uncontrolled change in the ERCC1 expression levels in 
our keratinocytes occurred at the beginning of the year 2007. The level of ERCC1 
protein in untreated cultures increased from the very low level seen in our initial 
experiments to a higher level more equivalent to that observed in untreated embryonic 
fibroblast and PAM 212 keratinocyte cultures. Going back to the freezer for fresh stocks 
did not solve this problem. To investigate what had happened to our keratinocytes, a 
series of experiments were carried out.  
 
At the beginning we thought that the change of the ERCC1 protein level might be 
related to different cell densities. When keratinocytes are cultured at low density the 
appearance of cells changes and they look similar to differentiated keratinocytes. Thus 
we compared the level of ERCC1 protein in keratinocytes between low density and high 
density following different stress treatments. As shown in Figure 3.9.A, when 
keratinocytes were cultured at high density, which means nearly 100% confluence in 
dishes, control cells without any treatments showed the same high level of ERCC1 as 





Figure 3.9 Investigation of the reason for the loss of stress treatment 
induced changes in ERCC1 levels in keratinocytes. 
    
 











     
 
A. ERCC1 protein levels in mouse keratinocytes grown to a high density (100% confluence) or to a much 
lower density (50% confluence) as indicated below the gel. Cultures were either untreated (control), 
treated with MG132 for 6 hours, or treated with high Ca2+ medium for 6 hours as indicated at the top 
of the gel. Cross-reacting bands and ERCC1 bands are indicated on the right. 
B. ERCC1 protein levels in mouse keratinocytes harvested at different cell density and different time 
points following passage. The four different harvest time points of 6 hours, 24 hours, 48 hours and 
72 hours are indicated below the gel. Different starting cell numbers used to set up the cultures and 
the different cell densities reached at the harvest time point are indicated at the top of the gel. 
Cross-reacting bands and ERCC1 bands are indicated on the right. 
C. Histogram showing level of ERCC1 protein in mouse keratinocytes harvested at different cell density. 
The different harvest time points, starting cell numbers used to set up the cultures and cell densities 
reached at the harvest time point are indicated below the gel. In terms of the level of ERCC1, data 
are divided into two groups, namely high and low expression, as indicated above the histograms. 
Asterisk indicates a significant difference (p=0.007) between these two groups by Mann–Whitney U 
test.  
D. ERCC1 protein levels in stock and daily used keratinocyte cultures. Cultures were either untreated, or 
treated with MG132 for 6 hours, or cultured without fetal calf serum (FCS) for 24 hours as indicated 
at the top of the gel.  ERCC1 deficient keratinocytes were used as a negative control. Cross-reacting 






6 hours. Previously control cultures had shown a very low level of ERCC1. When cells 
were cultured at low density, which means about 50% confluence in dishes, the levels of 
ERCC1 were again similar between control cultures and cultures treated with MG132, or 
a high concentration of Ca2+. There was now no clear difference in ERCC1 level 
between control and treated keratinocytes at either cell density. 
 
We then set up another experiment to detect the level of ERCC1 in cells at different 
density and time points following passage (Figure 3.9.B). When passaging 
keratinocytes, four groups of dishes were set up. Each group contained three dishes, one 
with the normal number of cells, one with half the normal number of cells and one with 
a quarter the normal number of cells.  These four groups of dishes were harvested 6 
hours, 24 hours, 48 hours and 72 hours following the passage and the levels of ERCC1 
were detected by western blotting using anti-ERCC1 SC-10157. Before harvest, the cell 
densities were estimated under the microscope and recorded. 
 
The groups of keratinocytes harvested at 6-hour and 24-hour time points showed the 
same high level of ERCC1 irrespective of the cell density. In the group of keratinocytes 
harvested at the 48-hour time point, the two dishes which were set up using quarter and 
half the normal number of cells showed high levels of ERCC1. At this time point the 
dish set up using half the normal number of cells had reached 100% confluence. At the 
48-hour time point, the dish containing the normal number of cells plated showed a 
decreased level of ERCC1. In the last group, at the 72-hour time point, all the three 
dishes of keratinocytes were 100% confluent and all showed a low level of ERCC1 
protein in the western blotting analysis. Even allowing for the reduced levels of the 
cross-reacting protein in the 72-hour samples, there was a clear reduction in ERCC1 





course this does not explain the sudden change in the ERCC1 protein levels in our 
control cultures which were not maintained at confluent cell densities.  
 
The level of ERCC1 proteins were then standardized against the cross-reacting proteins 
and plotted on a histogram (Figure 3.9.C). The data were clearly divided into two groups 
in terms of ratio of ERCC1. Samples harvested at 6h and 24h, as well as the two samples 
harvested at 48h with lower starting cell numbers (1/4 and 1/2) had a high level of 
ERCC1. The sample harvested at 48h with high normal starting cell numbers and 
samples harvested at 72h showed a 3.3-fold lower level of ERCC1. Statistical analysis 
using Mann Whitney U test showed the level of ERCC1 in the group with longer culture 
time and higher cell confluence was significantly lower (P=0.007).  
 
We also compared the level of ERCC1 protein between our in use cultures and a new 
culture obtained by going back to the early passage frozen sotck. As shown in Figure 
3.9.D, the stock keratinocytes from liquid nitrogen showed a slightly lower level of 
ERCC1 compared to the daily used keratinocyte culture, but the ERCC1 levels in both 
untreated cultures were much higher than we had seen previously. The level of ERCC1 
didn't change in either keratinocyte culture following MG132 treatment. We also starved 
our stock culture by removing the fetal calf serum from the medium for 24 hours to stop 
the cell growth. By analogy with the experiments described above (Figure 3.9.B), we 
expected that the ERCC1 protein level would be decreased by serum starvation, but the 
effect was the opposite and a slight increase was seen. ERCC1 deficient keratinocytes 
were used as a negative control in this western blotting. 
 
In summary, neither changing the keratinocyte cultures, nor manipulating the growth 





that we observed in our initial experiments. Consequently we were forced to terminate 




The expression of a gene is largely determined by the biological function and demand on 
the protein that the gene encodes. The NER pathway mainly deals with UV-induced 
DNA lesions and is also active against a broad range of other DNA damage. In wild type 
mouse, Ercc1 transcripts could be detected in all organs (van Duin et al. 1988). The level 
of Ercc1 expression was lowest in the liver and generally low in all other tissues except 
for the testis, where the level of expression of this transcript was much higher than 
elsewhere (Selfridge et al. 2001).   In addition ERCC1 expression is also relevant to 
cancer; a low level of ERCC1 expression correlated with better response to 
chemotherapies and longer survival. For example, in gastric cancer, survival for patients 
with low ERCC1 levels was significantly longer than in those with high levels (15.8 vs 
6.2 months; P<0.0001) (Lord et al. 2002; Wei et al. 2008). The same correlation was 
found in some other cancer types, such as non-small cell lung cancer (Olaussen et al. 
2006; Wang et al. 2008), colorectal cancer (Shirota et al. 2001) and ovarian cancer 
(Selvakumaran et al. 2003).  
 
In skin, the NER pathway removes the majority of the DNA adducts induced by UVB-
irradiation.  It has been reported that the mRNA level of ERCC1 was elevated in human 
keratinocytes at 6 hours post UV-irradiation (Murakami et al. 2001). However, previous 
group work had found no increase in levels of the 1.5kb skin-specific Ercc1 transcript in 





considered that the elevated level of the 1.5kb skin-specific Ercc1 transcript in albino 
strains could lead to an increased level of protein to protect the skin against UV-induced 
DNA damage.  
 
To investigate this hypothesis, we first tested the ERCC1 protein expression pattern in 
different tissues using a panel of mouse tissues from wild-type Balb/C, CD1, 129/Ola 
and C57BL/6 strains. All strains showed similar tissue patterns and levels of ERCC1 
protein, which matched the tissue pattern of Ercc1 transcripts apart from skin. In skin 
although the larger 1.5kb transcript predominated over the normal 1.1kb transcript found 
in other tissues, the size of the ERCC1 protein was the same in skin as in other tissues 
examined. This result agrees with our previous RT-PCR assay using primers in exon2 to 
exon10, which suggested that the skin-specific Ercc1 transcript had the same ERCC1 
protein coding region as the normal transcript. We further tested the ERCC1 protein 
levels in skin between albino and pigmented strains. Although the Ercc1 mRNA 
expression pattern was entirely different, there was no significant difference in terms of 
the ERCC1 protein level in skin between albino and pigmented strains.  
 
In addition, we had previously identified that the Ercc1 expression pattern in mouse skin 
was determined by the Ercc1 gene sequence and not by the coat colour (Andrew Winter, 
unpublished observations). A cross between BALB/c and C57BL/6 mice was performed 
to segregate the Ercc1 gene from those determining coat colours. F2 mice were 
genotyped for the strain of origin of the Ercc1 gene using a polymorphism in the 5' 
UTR.  Northern analysis revealed that skin from recombinant white mice which are 
homozygous for the C57BL/6 Ercc1 gene have the expression pattern found in C57BL/6 
mice, and recombinant black mice which are homozygous for the BALB/c Ercc1 gene 
have the expression pattern found in BALB/c mice. As expected, non-recombinant F2 






Combining these results together, we found no support for our hypothesis that the 1.5kb 
skin-specific Ercc1 transcript might result in increased ERCC1 protein level in the skin 
of albino strains. However, we found an interesting different sequence pattern between 
albino and pigmented strains in the region 1kb 5' of the known Ercc1 promoter. The 
regulatory elements in this region might be linked with the altered Ercc1 expression 
observed. This will be discussed in more detail in Chapter 4. 
 
The rapid change in ERCC1 protein levels that we observed in our cultured mouse 
keratinocytes in the absence of changing Ercc1 transcript levels suggested to us that 
there may be post-translational regulation of ERCC1. Protein modification by ubiquitin 
and SUMOylation has been observed for a number of DNA repair proteins, which has 
been reviewed recently (Bergink and Jentsch 2009). For example, the NER protein XPC 
is reported to be modified by ubiquitin and SUMO-1 following UV irradiation (Wang et 
al. 2005). DNA damage usually activates the DNA repair or damage-avoidance 
pathways, and often induces a checkpoint response that triggers cell-cycle arrest for the 
repair of DNA lesions, referred to as the DNA-damage response (DDR) (Harrison and 
Haber 2006; Branzei and Foiani 2008). Some repairs need to assemble large protein 
assemblies, which needs to be disassembled when the repair is completed. Therefore, the 
reversible modification of proteins by conjugation of ubiquitin, or its relative 
SUMOylation is ideally suited for regulatory purposes. 
 
Compared to our other mouse cell lines, untreated cultures of our Ercc1 wild type mouse 
keratinocytes showed a very low level of ERCC1 from 2005 to 2007. This level 
increased rapidly following exposure to UV, or to a proteasome inhibitor, or by moving 
cells from their normal low Ca2+ medium to a high Ca2+ medium which induced 





keratinocyte cultures increased so that the previous treatments were now ineffective at 
stimulating responses. After the ERCC1 protein changed from a low level to a high level 
in our keratinocyte cultures, we did a series experiments to investigate the cause of the 
change. We confirmed that the high level of ERCC1 protein in untreated cultures was 
due to the culture conditions as going back to the liquid nitrogen stock cells had no 
effect. The epidermal growth factor (EGF) used in the culture medium was considered to 
be a candidate to affect ERCC1 protein levels as EGF-mediated induction of ERCC1 
expression through the ERK2 and MAPK pathway in human carcinoma cells has been 
reported (Adly Yacoub 2003; Andrieux et al. 2007). However, changing the EGF 
concentration in culture medium had no effect. We further tried using keratinocyte 
growth factor (KGF) instead of EGF but the level of ERCC1 protein remained at the 
same high level in our cultures. Other conditions like cell density and confluence, 
calcium concentration, trypsinization and possible UV-irradiation were investigated but 
no cause of the elevated ERCC1 protein could be found. It is important to stress that 
after the change in our keratinocyte cultures, the level of ERCC1 was similar to that in 
our mouse embryonic fibroblast and another widely used keratinocyte cell line PAM212. 
Thus, this increase in ERCC1 protein level could be regarded as a kind of "recovery" in 
our keratinocytes. From 2005 to 2007 it might be that an undefined different culture 
condition was acting to reduce ERCC1 expression. We lost this culture condition and 
then the ERCC1 protein level was returned back to its normal level. During the course of 
our investigation into the reason for the changing ERCC1 levels in untreated 
keratinocyte cultures we did see clear evidence that the level of ERCC1 protein dropped 
in cultures maintained at high density. Presumably there is less requirement for DNA 
repair in non proliferating cells. In retrospect we should have passaged these high 







Chapter 4:  
Are upstream CpG islands the source of the novel 












4.1 Investigations of the novel 1.5kb mouse Ercc1 skin-specific 
transcript and potential upstream Ercc1 promoters.  
 
Previous group work has identified a novel 1.5kb skin-specific mRNA transcript for 
Ercc1 in mice. It was shown by RT-PCR and RACE that this transcription of Ercc1 in 
skin was driven by an alternative upstream promoter not utilised in other tissues. 
However, the accurate position of the promoter region was still unclear. 
 
Based on the previous results, a further investigation was carried out in an attempt to 
identify the promoter for the 1.5kb skin-specific Ercc1 transcript. A series of computer-
based promoter prediction programmes were used to identify candidate promoter 
regions. 
 
As shown in the Figure 4.1, the Ensembl Genscan program, a joint project to develop a 
software system which produces and maintains automatic annotation on selected 
eukaryotic genomes, reported one potential transcript in mouse (labelled as TSS No.2). 
This transcript could possibly contain two potential exons about 11kb upstream of the 
known Ercc1 transcript spliced onto Ercc1 exon 2 to exon 10.  
 
Another potential Ercc1 transcript (labelled as TSS No.1) is predicted in both human and 
mouse by several computer prediction programs, and has been reported in the literature 
(Wilson et al. 2001). The putative promoter regions containing regulatory elements, 
located 2.5kb upstream of the Ercc1 gene in mouse and 5kb upstream of ERCC1 in 
human, were analyzed by several promoter-predicting programs including PROMOTER 





McPromoter/), and Tfsitescan (www.ifti.org/). A conserved GC-rich region with 77% 
GC content was found in this promoter region to share 81% identity with the mouse and 
human. Within this promoter region, an 112bp gap-free region with a sequence identity 
of 93% between species contains a conserved TATA box and a GC box. Other classical 
elements and putative regulatory elements were found as well. A computer predicted 
gene, located very close to the 2.5kb upstream Ercc1 putative promoter and generating a 
putative transcript in the opposite direction to the Ercc1 transcript, was noticed in mouse 
by NCBI BLAST search (Gene: D830036C21, Figure 4.1). There was no known protein 
product of this putative gene and a BLAST search in human did not show this gene. 
Thus, this putative promoter region, conserved in mouse and human, was a strong 
candidate to be the source of the 1.5kb skin-specific Ercc1 transcript. 
 
4.2 RT-PCR showed no positive evidence that the two potential 
upstream Ercc1 promoter regions were active. 
 
As described before, there were two potential upstream promoter regions for Ercc1. We 
first investigated the 11kb upstream promoter which was an Ensembl Genscan predicted 
Ercc1 transcript (Genscan ID: GENSCAN00000061823). The Ensembl Genscan 
program predicted this Ercc1 transcript with two putative exons at its 5' end. According 
to the Ensembl Genscan result, the putative exon 1 was 166bp and putative exon 2 was 
208bp with a 1.5kb intron between them. The putative exon 2 spliced into the middle of 
known Ercc1 exon 2 and skipped the known exon 1. The known Ercc1 exon 3 to exon 
10 remains the same and the size of this putative Ercc1 transcript is 1278bp. Although 
this transcript is about 200bp smaller, it was considered a reasonable match to the 1.5kb 





Figure 4.1: A schematic diagram of the investigation of potential promoter 







Mouse chromosome 7 and human chromosome 19 are shown as a black and white line. Red rectangles 
show putative Ercc1 exons predicted by Ensembl Genscan and other computer programmes. Black 
rectangles show known Ercc1 exons recorded in the database. Purple rectangles show putative exons of 
other genes. Dark blue rectangles show CpG islands around promoter regions. The grey rectangle shows 
unpublished sequence in the novel Ercc1 exon. Known and putative Ercc1 transcription start sites are 





(Figure 4.2.A). However, this transcript was not compatible with the previous RACE 
and RT-PCR work, which had shown that the 1.5kb Ercc1 transcript contained sequence 
immediately upstream of the normal Ercc1 exon1. 
 
Analysis of the DNA sequence of the 11kb upstream region revealed a CpG island and a 
possible transcriptional start site. The presence of these promoter elements gave support 
to this prediction. To investigate the possibility that this 11kb upstream Ercc1 promoter 
was functional, RT-PCR analysis was performed on mouse embryonic fibroblasts and 
keratinocytes. 
 
Novel primers were designed located in these putative exons, as shown in the Figure 
4.2.A. These primers should generate 1.6kb (approximately) PCR products on 
keratinocyte DNA, and 237bp to 257bp PCR products on keratinocyte cDNA (Figure 
4.2.B).  
 
Total RNA from mouse keratinocyte cells was reverse transcribed using an oligo-dT  
primer to generate a pool of cDNA. Skin A forward primer in combination with Ex2b  
reverse primer, which we had tested before and which generated 382bp PCR products on 
keratinocyte cDNA and 791bp products on keratinocyte DNA, were used as a control 
reaction for Ercc1 cDNA synthesis (Figure 4.2.B). PCR using Skin A and Ex2b rev on 
the pooled mouse keratinocyte cDNA generated a single clear band at the expected 
position of 382bp, indicating that the Ercc1 cDNA quality was good and that there was 
no DNA contamination (Figure 4.2.C). PCRs using different combinations of novel 
primers were then performed on the wild type fibroblast DNA, keratinocyte DNA and 
pooled keratinocyte cDNA to amplify the sequence between putative upstream Ercc1 





Figure 4.2 No evidence by RT-PCR assay for activity from the 11kb 
upstream promoter (No.2) detected by the Ensembl Genscan program. 
 
 





























A. A schematic diagram of RT-PCR investigation. Potential exons predicted by Ensembl Genscan are 
showed in green. Known Ercc1 exons are shown in orange. Additional sequence present in the 
1.5kb transcript upstream of exon 1 is shown in yellow. Primers used in the RT-PCR are labelled 
along exons in light green. Intron between potential exons is labelled in blue.  
B. Predicted sizes of RT-PCR products on mouse keratinocyte cDNA and DNA.  
C. PCR using primers SKIN A and Ex2b rev on mouse keratinocyte cDNA. A product at the size of 
382bp indicates the cDNA is working well in this RT-PCR.  
D. PCR using primers for the predicted upstream exons. The RT-PCR showed no positive evidence 
to support this Ensembl Genscan predicted promoter. The positive controls on mouse DNA 
showed the predicted bands at the size of 1.6kb. No product could be detected from RT-PCR 
using mouse cDNA. 
E. PCR using primers for the predicted upstream exon together with Ercc1 exon 2. The positive 
controls using Skin A with Ex2 rev on mouse cDNA showed the predicted bands at the size of 
340bp. No product could be detected from RT-PCR using novel primers for the Ensembl Genscan 






visualized by ethidium bromide staining. As shown in the Figure 4.2.D, clear bands at 
the predicted 1.6kb size were detected in both fibroblast and keratinocyte DNA lanes, no 
matter which combination of novel primers were used in the PCR. This result indicated 
that the novel primers were working well in this analysis. However, no PCR product 
could be detected in Ercc1 cDNA lanes, suggesting that the Ensembl Genscan Ercc1 
transcript may not be real (Figure 4.2.D). 
 
As these novel primers were all located in the putative exons, the above RT-PCR assay 
had no connections between the putative exons and known Ercc1 exons. Moreover, it 
was possible that there were mistakes in the Ensembl Genscan prediction. For example, 
the length, position and numbers of the putative exons could be different in reality. Thus 
it was possible that the negative RT-PCR result may be due to prediction mistakes rather 
than to lack of promoter activity. Therefore, another RT-PCR was performed using the 
novel forward primers with a reverse primer Ex2 rev which is located in the known 
Ercc1 exon2 and 42bp upstream of the Ex2b rev primer (Figure 4.2.E). Forward Skin A 
primer and the Ex2 rev primer were used in this RT-PCR as a control for Ercc1 cDNA. 
Because the Ex2 rev primer had not been tested before, a RT-PCR using Ex2 rev only 
was performed as another control to test for spurious PCR amplification. The two novel 
primers paired with Ex2 rev didn't show any band in the RT-PCR. Skin A primer and the 
Ex2 rev primer produced a band at the expected size of 340bp indicating good cDNA 
quality. No band was detected by Ex2 rev on its own. 
 
From these two RT-PCRs results we did not find any evidence that the skin-specific 
transcript initiates from this Ensembl Genscan promoter region 11kb upstream of the 






The second putative promoter region we investigated was predicted by several computer 
programs. This putative promoter region was located 2.5kb upstream of Ercc1 in mouse 
and 5kb upstream of ERCC1 in human. The Figure 4.3.A shows the sequence of this 
putative promoter region in mouse (C57BL/6 strain). The sequence labelled as "Potential 
Novel Promoter" shared 81% identity in the mouse and human. Classical promoter 
elements, such as a GC box and a TATA box were detected in this region. The potential 
transcriptional start site was predicted to be 23bp downstream of the TATA box. 
Furthermore, two CpG islands were detected around the putative promoter. The CpG 
Island 1 covered the whole promoter region while the CpG Island 2 was located about 
400bp downstream of the putative promoter.  
 
Two forward primers (ERC1 NP+57 and ERC1 NP+65), located 57bp and 65bp 
downstream of the potential transcriptional start site, were designed for RT-PCR assay 
with the Ex2b reverse primer. Skin A with Ex2b rev was used as positive control for 
Ercc1 cDNA. For PCR product size prediction (Figure 4.3.B), Skin A and Ex2b rev 
should generate 382bp PCR products on keratinocyte cDNA and 791bp products on 
keratinocyte DNA. ERC1 NP+57 and ERC1 NP+65 should generate 3358bp and 3350bp 
PCR products, respectively, with the Ex2b reverse primer on keratinocyte DNA. For 
PCR products using the novel forward primers with Ex2 rev on Ercc1 cDNA, firstly,  
there was 29bp from the start of Ercc1 exon 2 to the Ex2 reverse primer and 479bp from 
the end point of Dr. Selfridge's old 5'RACE result to the end of Ercc1 exon 1, thus the 
minimum size of RT-PCR product should be 508bp. Secondly, as it was 382bp from the 
5'RACE end point to the start of Ercc1 exon 1, and the skin-specific 1.5kb transcript was 
about 400bp larger than the normal 1.1kb transcript, the 5'RACE end point identified by 
Dr. Selfridge should be very close to the real end of the Ercc1 cDNA. Therefore the RT-
PCR product should not be much larger than 508bp. Using the same argument, genuine 





Figure 4.3 No evidence by RT-PCR that the skin-specific transcript initiates 
from another computer-predicted promoter region 2.5kb upstream of the 
normal Ercc1 transcript. 
 
  







        
A. Computer program predicted 2.5kb upstream ERCC1 promoter region (TSS No.1) in mouse. The 
computer-predicted promoter region is labelled as "Potential Novel Promoter". Classical TATA 
box and GC box are marked in red boxes. The putative transcription start site is indicated with a 
black star shape.  Novel forward primers ERC1 NP+57 and ERC1 NP+65 used in RT-PCR and two 
computer-detected CpG islands (CGI #1 and CGI #2) are labelled above the sequence.  
B. A schematic diagram showing the minimum size of genuine Ercc1 RT-PCR products using 
different primer combinations. Predicted products' sizes are labelled on the top. The 5' end, 
exon 1 and exon 2 sequences are illustrated in green dash-line, red line and purple line 
respectively. The PCR size predictions on DNA are illustrated in orange lines. Primers are 
labelled at the relevant end of sequence. The different scales used for cDNA and DNA are 
indicated. 
C. RT-PCR using various combinations of primers to investigate the possible activity of the 2.5kb 
upstream potential promoter region. The primers Skin A and Ex2b rev were used as a positive 
control to show cDNA quality. A weak band at the position of about 280bp could be detected 
using primer pair ERC NP+65 and Ex2b rev. 
D. Gradient RT-PCR performed on keratinocyte cDNA using ERC NP+65 with Ex2b rev. Forward 
primer Skin A and reverse primer Ex2b rev were used as control for quality of cDNA. Three main 
products detected, sized 200bp, 400bp and 1kb are indicated by arrows on the right. The 
product at 280bp seen in Figure 4.3.C was also present at a low level. Primer pairs used in 
reactions are labelled.  
E. Final round of RT-PCR performed on keratinocyte cDNA and DNA using annealing temperature 
at 57°C according to the result of gradient PCR. As previous result, three main products sized 
200bp, 400bp and 1kb were detected. An expected 382bp product was detected in cDNA 
control lane. Primers and template type are labelled on the top. Sizes of the PCR products are 
indicated on the right. 









should be only slightly bigger than 550bp, and only slightly bigger than 760bp by novel 
forward primers with Ex3a reverse primer. 
 
The PCR was performed under normal conditions with an annealing temperature at 
62°C. PCR products were electrophoresed on 1.2% agarose (Figure 4.3.C). The novel 
forward primers with Ex3a and Ex2 reverse primers didn't generate any product. There 
was no product generated by ERC1 NP+57 with Ex2b rev either. The PCR using ERC1 
NP+65 with Ex2b rev showed a very faint band at the size of 280bp. The positive 
control using Skin A with Ex2b rev generated a clear single band at 382bp indicating 
that the cDNA quality was good and there was no DNA contamination.  
 
Though this 280bp band generated by primers ERC1 NP+65 with Ex2b was too small to 
be the expected PCR product related to the 1.5kb Ercc1 transcript, it suggested that this 
primer pair could work on the Ercc1 cDNA. A gradient PCR with lower annealing 
temperatures to 55°C was then performed using ERC1 NP+65 and Ex2b rev on the 
Ercc1 cDNA to investigate this possibility further (Figure 4.3.D). Beside the very faint 
band at the size of 280bp detected previously, other major bands at about 200bp, 400bp 
and 1000bp were detected. The same PCR was repeated using the annealing temperature 
at 57°C to produce the 400bp and 1000bp products as well as to control the background 
non-specific bands to the minimum (Figure 4.3.E). The 400bp product was potentially 
interesting because of its size though it was slightly smaller than the 550bp PCR product 
size prediction. However, as the size of 1.5kb skin-specific transcript was measured by 
northern blotting before, the size might not be accurate. The control reaction using Skin 
A and Ex2b rev primers on keratinocyte cDNA generated a band at 382bp indicating 
good Ercc1 cDNA quality. Another control reaction using NP+65 and Ex2b rev on the 
keratinocyte DNA didn't generate the expected band at 3350bp, possibly due to the 





There were some non-specific bands detected in the DNA control reaction in which the 
two main bands were at 200bp and 360bp. This indicates that the 200bp product in the 
RT-PCR reaction was probably due to the contamination of genomic DNA in the 
keratinocyte cDNA preparation. 
 
The 400bp and 1kb products were cloned into the p-GEM T-EASY vector using the lacZ 
blue white screen. 5 positive clones of each fragment were sequenced. However, the 
sequencing showed that neither 400bp nor 1kb products were Ercc1 related. 
 
To sum up, no evidence was found by RT-PCR that the skin-specific transcript initiates 
from computer-predicted promoters 2.5kb and 11kb upstream of the normal mouse 
Ercc1 transcript. 
 
4.3 Investigation of the methylation status of CpG islands 
around putative and normal Ercc1 promoters. 
 
Because the methylation status of CpG islands can have a major impact on gene 
expression, we studied the methylation status of the CpG islands detected around the 
putative and normal Ercc1 promoters for any possible evidence to support the activity of 
the putative promoters in the production of the Ercc1 skin-specific transcript. We mainly 
focused on the 2.5kb upstream promoter region in mouse as it had more classical 
promoter elements than the 11kb upstream promoter and was conserved in human. There 





(Figure 4.4.A). These CpG islands were named CGI #1 to CGI #4. Normally, the CpG 
island around the active promoter region of the gene is unmethylated. Therefore our 
hypothesis was: In mouse skin cells, if the larger 1.5kb skin-specific transcript was 
driven by this upstream promoter, then CpG islands CGI #1 and CGI #2 that are located 
around the putative 2.5kb upstream promoter should be unmethylated, while CpG 
islands CGI #3 and CGI #4 that are around the normal Ercc1 promoter should be 
methylated. In contrast, in other tissues where the normal 1.1kb Ercc1 transcript was 
transcribed, the methylation status of these CpG islands around the 2.5kb upstream 
region and normal promoter region should be the opposite of the situation in skin. 
 
Besides the mouse keratinocytes and fibroblasts, where the 1.5kb transcript is the major 
Ercc1 transcript, two different mouse ES cell lines, HM1 and DMNT3-, were used to 
investigate the methylation patterns. HM1 was a wild-type ES cell line, while DNMT3- 
was a DNA methyltransferase 3 deficient ES cell line. The skin-specific Ercc1 transcript 
was not detected by northern analysis in HM1 cells by previous group study. According 
to the hypothesis, the methylation patterns of the putative and normal Ercc1 promoters 
should be opposite between mouse HM1 ES cells and skin cells. 
 
DNA from the different cell lines was freshly extracted before the bisulphite treatment. 
The bisulphite conversion was carried out using the kit from Cambridge Bioscience. 
Optimal amounts of DNA were converted according to the manufacturer's protocol to 
avoid incomplete conversion. After that, the converted DNAs were amplified by PCR 
using specially designed bisulphite sequencing primers for individual CpG islands. After 
the first round PCRs, samples of CGI #2 and CGI #3 generated the expected products at 
the positions of 272bp and 283bp, respectively, along with a heterogeneous smear of 
DNA (Figure 4.4.B). The sample of CGI #1 only generated a smear of DNA 





Figure 4.4 PCR amplification of bisulphite treated CpG islands around the 
putative and normal Ercc1 promoters in mouse keratinocytes, fibroblasts 




   
 
A. A schematic diagram showing the potential 2.5kb upstream promoter region and normal 
promoter region in mouse. Blue boxes show CpG islands with CpG/GpC contents greater than or 
equal to 60%. White boxes show known Ercc1 exons. Classic promoter elements are indicated: 
TATA box (red) and GC signal (green). The transcriptional start sites are labeled as TSS with an 
arrow.  
B. The bisulphite treated DNA from keratinocytes (KER), mouse embryo fibroblasts (PF20), DNA 
methyltransferase deficient mouse ES cells (DNMT3ˉ) and mouse ES cells (HM1) was amplified 
with bisulphite sequencing primers specific for individual CpG islands. PCR products were 







To improve the quality of the bisulphite sequencing PCR product of CGI #1, the smear 
regions were cut out, gel purified, and a second round of nested PCRs using internal 
primers were then performed on DNA fragments retrieved from the first round PCRs 
(Figure 4.4.B). The second round of nested PCR generated a much better quality of 
bands in all samples. Strong bands corresponding to the converted CGI #1 region were 
detected at the expected position of 424bp. The band sizes varied slightly among these 
four cell lines because of the sequence difference between the different mouse strains 
(described later in Section 4.5).  
 
At this stage all unmethylated cytosine residues should be converted to uracil residues 
by bisulphite treatment and then changed to thymine residues in the PCR step. The 5-
methycytosine residues of the dinucleotide CpG would be unaffected by the bisulphite 
treatment and then changed to cytosine in the PCR step. 
 
The expected PCR products for CGI #1, CGI #2 and CGI #3 for all four cell lines were 
then carefully cut out, gel purified and then cloned into p-GEM T-EASY vector using 
the lacZ blue white screen. At least 10 clones of each converted CpG island fragment 
were sequenced for analysis. 
 
The methylation status of CpG islands was analyzed by BiQ analyzer software, which 
worked out the methylation status by the following three steps: (a) align the CT 
converted sequence with the genomic sequence, (b), remove erroneous sequence, such 
as poor quality sequencing results and wrong sequence according to the input genomic 
sequence etc, and (c) compile information of the sequence identities relative to the 
genomic sequence, the sequences' conversion rates, methylation statistics and 





treatment efficiency were determined by calculating the C to T conversion rate for 
cytosine bases not in CpG dinucleotides.  
 
All three CpG islands in the four different cell lines we tested showed very good 
sequence conversion rates. The substantial majority of clones we sequenced had a 
conversion rate of 100%, while a few clones had slightly lower rates from 97% to 99%, 
according to the BiQ analyzer software. More than 90% of the clones were genuine 
products containing the target CpG island fragment. Therefore there was no negative 
effect from the bisulfite conversion and cloning procedure in this investigation. The 
methylation rates of individual CpG sites from different clones were calculated and 
aggregated representations of methylation data for the whole CpG islands are shown in 
the Figure 4.5.  
 
As predicted by our hypothesis, CpG island 2, located about 400bp downstream of the 
putative promoter was fully unmethylated in keratinocytes. There were 17 CpG sites in 
this island in the mouse keratinocytes and fibroblasts. The CpG sites 8, 16 and 17 were 
missing in the HM1 and DNMT3- cells because both ES cell lines were derived from a 
different mouse strain that lacked these sites. In the mouse fibroblasts, where the skin-
specific transcript is expressed, CGI #2 showed a very low level of methylation, at the 
overall rate of less than 4%. Three mouse fibroblast CGI#2 clones didn't have the CpG 
sites 8, 16 and 17 due to the heterozygosity of the Ercc1 allele. In contrast, the mouse ES 
cell line HM1 showed a much heavier methylation of the whole CGI #2 region at the 
overall rate of 52%. The CpG sites 15 and 14 were heavily methylated at the rate of 
73%. The methyltransferase deficient ES cell line DNMT3- was fully unmethylated as 






However, the CpG island 1, which had 35 CpG sites and was probably more important 
than CGI #2 as it covered the whole region of the 2.5kb upstream putative promoter 
region, showed an increased level of methylation at the beginning (CpG sites 1 to 7) and 
the middle (CpG sites 20 to 26) in keratinocytes (KER) compared to the other three cell 
lines. The CpG site 20 was 43bp downstream of the putative TATA box and 20bp 
downstream of the potential transcription start site. The CpG sites 22, 24 and 25 were 
73%, 67% and 64% methylated respectively. At the CpG sites 9, 27 and 29, one clone in 
fifteen was methylated. In mouse embryonic fibroblasts (PF20), the CGI #1 was 
predominantly unmethylated while some CpG sites showed a very low methylation rate 
around 10%. In HM1 mouse ES cells the CGI #1 was generally unmethylated. The CpG 
sites 7, 14, 17, 19, 30, 31 and 35 showed a weak methylation rate from 23% to 40%. 
Another two CpG sites 10 and 33 were methylated in one clone of the thirteen. As 
expected, the CGI #1 of the DNMT3- cell line was also largely unmethylated. However, 
unexpectedly there were still 4 CpG sites methylated in one or two clones of the eleven 
sequenced (Figure 4.5.B). 
 
The CpG island 3 located around the normal Ercc1 promoter had 15 CpG sites. The CpG 
site 10 was missing in mouse keratinocyte and fibroblast cells due to the different 
sequence between strains (Figure 4.5.C). This island was predominantly unmethylated in 
all four cell lines tested. There were 2 CpG sites in keratinocytes and one in fibroblasts 
that showed a very low methylation rate of less than 10%. One clone of the DNMT3- 
cell line showed a methylation at CpG site 1 as well.  
 
In summary, the methylation status of CpG island 2 fitted our hypothesis with a very 
low level of methylation in both cell lines (keratinocytes and fibroblasts) showing high 
levels of the 1.5kb transcript and heavy methylation in the ES cell line (HM1) that 





Figure 4.5 DNA methylation data for CpG islands around the 2.5kb 




























Aggregated representation of methylation data obtained by bisulphite sequencing. Unmethylated CpG 
positions are indicated in blue. Methylated CpG positions are indicated in yellow. A grey box indicates a 
CpG position that is not present in a particular cell line. For all cell lines, occasional failure of sequencing 
of a specific clone to detect a particular CpG position was registered as not present. 





supported by the methylation status of CpG island 1, which actually spanned the 
putative 2.5kb upstream promoter. This, correlated with the failure to find any 
significant levels of methylation around the normal promoter (CGI #3) in any of the cell 
lines tested, meant that we had no evidence from the methylation status that the 2.5kb 
upstream promoter was the source of the 1.5kb Ercc1 transcript. 
 
4.4 Northern blotting to investigate whether the 1.5kb Ercc1 
transcript is expressed in DNA methyltransferase 3 deficient ES 
cells 
 
As described in the previous section, CpG island 2, located about 400bp downstream of 
the 2.5kb upstream promoter, showed a different methylation pattern between the mouse 
ES cell line HM1 and keratinocytes. It was heavily methylated in HM1 but fully 
unmethylated in keratinocytes. Although this island did not span the putative promoter, 
it could still be involved in regulating expression of the skin-specific Ercc1 transcript. 
To investigate this possibility, a northern blotting analysis was performed on a panel of 
cell lines. The aim of the northern was to look at whether the skin-specific transcript 
could be detected in the methyltransferase deficient mouse ES cell line DNMT3-. As 
identified by the bisulphite sequencing, the CGI #2 was fully unmethylated in DNMT3-. 
This was the same pattern as keratinocytes. Therefore if CGI #2 is involved in the 
regulation of the putative promoter, the larger 1.5kb Ercc1 transcript may be detected in 






A panel of Ercc1 wild-type and deficient mouse keratinocytes and fibroblasts, ES cell 
line HM1, methyltransferase deficient ES cell line DNMT3- and mouse melanocyte cell 
line Melan A were screened by northern blotting for the 1.5kb Ercc1 transcript (Figure 
4.6). Total RNA was freshly isolated from cells, separated by electrophoresis, 
transferred on to a nylon membrane and the Ercc1 transcript was detected by 
hybridisation to a mouse Ercc1 cDNA probe. 
 
The ethidium bromide staining of the gel indicates that the loading of RNA was 
generally well matched. As expected, the skin-specific 1.5kb Ercc1 transcript was 
present in both Ercc1 wild-type mouse keratinocyte and fibroblast lanes. No bands were 
detected in the Ercc1 deficient cells. The normal 1.1kb transcript was present in HM1, 
DNMT3- and Melan A lanes. No hint of the 1.5kb transcript was detected in the 
DNMT3- lane.  
 
Thus, there was no correlation between non-methylation of CpG island 2 and expression 
of the 1.5kb Ercc1 transcript. 
 
4.5 5' RACE to reinvestigate the origin of the skin-specific Ercc1 
transcript 
 
We performed the 5'RACE analysis on mouse keratinocytes to re-investigate and 
characterise the 5' end of the skin-specific 1.5kb Ercc1 transcript. Previous 5'RACE 





Figure 4.6 No evidence for the presence of the 1.5kb novel Ercc1 transcript 






Northern analysis of mouse cell lines with an Ercc1 cDNA probe. Ercc1 wild type and deficient 
keratinocytes are labelled as KER WT and KER NULL. Ercc1 wild type and deficient mouse embryo 
fibroblasts are labelled as PF20 and PF24. HM1 is a mouse ES cell line. DNMT3ˉ is the DNA 
methyltransferase 3 deficient mouse ES cells. Melan A, mouse melanocyte cell line. Upper panel, 
ethidium bromide staining of the gel with 18S rRNA band indicated. Lower panel, Ercc1 mRNA detection 






to a position 389nt upstream of the normal start site of mouse Ercc1 (unpublished 
observations). We repeated the 5'RACE using improved RACE technology to 
investigate whether this position really corresponded to the beginning of the transcript.  
 
Figure 4.6.A shows a schematic representation of the 5'RACE analysis. The Neo RNA 
came from the 5'RACE kit and was used as control according to the manufacturer's 
protocol. PCR product size prediction is shown in Figure 4.6.B. Total RNA was freshly 
isolated from Balb/C mouse keratinocytes for the 5'RACE.  
 
The first strand cDNA synthesis was carried out using gene specific primers, neo/rev1 
for NEO and Ex2b rev for Ercc1 respectively. The synthesised Neo cDNA was 
amplified using neo3/for in combination with neo2/rev and Ercc1 cDNA was amplified 
using primers Skin A in combination with Ex2b rev (Figure 4.6.C). PCR products were 
electrophoresed on a 1.5% agarose gel. Strong bands at the expected position of 157bp 
in the NEO lane and at 382bp in the keratinocyte lane indicated that the efficiency of 
first strand cDNA synthesis was good and that there was no contamination from DNA. 
 
The cDNA was then purified using the high pure PCR product purification kit, a 
homopolymeric A-tail was added to the 3' end and then it was PCR amplified using 
Oligo-DT anchor primer in combination with gene specific reverse primers: Neo2 for 
the NEO and Skin RT rev C for Ercc1. The PCR products were then separated by 
electrophoresis on a 1.5% agarose gel and visualised by ethidium bromide staining 
(Figure 4.6.D). The NEO control showed a single band at 293bp indicating that the 
quality of the cDNA synthesis and efficiency of the dA-tailing reaction of the purified 
cDNA was good. In the Ercc1 cDNA lane, a diffuse band at the position of 600bp and a 





Figure 4.6 Re-investigation of the origin of the 1.5kb skin-specific Ercc1 












































A. A schematic representation of the investigation of the potential upstream Ercc1 promoter using 
5' RACE.  
B. Predicted sizes of different PCR products on control Neo cDNA, mouse keratinocyte cDNA and 
DNA.  
C. After reverse transcription using exon 2B rev primer and addition of a homopolymeric poly(A)-
tail, PCR was performed on the first strand cDNA. The Ercc1 cDNA was amplified by forward 
primer SKIN A and reverse primer Ex2b rev. The control NEO cDNA was amplified by NEO3 and 
NEO2 according to the manufacturer's protocol. An expected PCR product at the size of 382bp 
was detected in Ercc1 the cDNA lane. The PCR on control NEO cDNA produced an expected 
product at the size of 197bp.  
D. The tailed Ercc1 cDNA was amplified using OligodT-anchor forward primer and skin RT rev C 
reverse primer. The PCR product was visualized and the positions of bands at 400bp and 600bp 
in the mouse keratinocyte track are indicated in black. The expected band generated by           
dT-Oligo anchor and NEO2 primers at 293bp in the positive control Neo cDNA track is indicated 
in red. 
E. A further round of nested PCR was performed using PCR anchor forward primer and either skin 
RT rev B or skin RT rev C reverse primers showing two bands of 400bp and 460bp respectively.  
F. A further round of nested PCR was performed on the gel purified 600bp PCR product in Fig C. 
Bands of 600bp were detected from PCR using reverse skin RT rev C. Bands of 400bp, 500bp, 
560bp and 800bp were detected from PCR using an internal reverse primer skin RT rev B.  
G. Digestion with restriction enzyme EcoR1 on the sequenced plasmids retrieved from purified 
500bp, 560bp and 800bp PCR products showing various size inserts. Asterisks indicate clones 






keratinocyte lane was cut out, gel purified and analyzed later. Meanwhile, a further 
round of PCR was carried out using primers PCR-anchor in combination with Skin RT 
rev C and another internal primer Skin RT rev B.  PCR products at about 460bp using 
Skin RT rev C and 400bp using Skin RT rev B were detected by electrophoresis (Figure 
4.6.E). This was unexpected because if Oligo dT-anchor primer with Skin RT rev C 
generated a product at about 600bp then using primers PCR-anchor with Skin RT rev C 
should have generated a product only slightly shorter. We gel purified the 400bp 
fragment produced. Fragments were cloned into p-GEM T-EASY vector by the lacZ 
blue white screen. 10 positive clones from each fragment were sequenced in order to 
map the end point of the Ercc1 mRNA in mouse skin. The sequencing analysis of 400bp 
fragments showed the same result as Dr. Selfridge's previous 5'RACE (Figure 4.8). 
When the sequence was numbered with the A of the translational start (ATG) being +1, 
a homopolymeric A-tail added by terminal transferase to the end of the Ercc1 cDNA 
was detected at nt position around -500. The 5' end sequence was dominated by 150bp 
of CT repeats. The new 5'RACE result from the 400bp fragment didn't extend any 
further 5' compared to the old 5'RACE result. 
 
The 600bp fragment from the first round of PCR using Oligo dT-anchor primer in 
combination with Skin RT rev C was then amplified by a further round of PCR using 
forward primer PCR-anchor with reverse primers Skin RT rev C and Skin RT rev B. A 
single clear band at slightly bigger than 600bp was detected in the PCR-anchor with 
Skin RT rev C lane (Figure 4.6.F). This product should be the same fragment as the 
600bp one detected in the first round of PCR as the same primers were used in each 
reaction. The 600bp band was then gel purified and cloned into p-GEM T-EASY vector 
using the lacZ blue white screen. 8 positive clones were sequenced and analyzed. The 
sequencing results showed that this 600bp band was not Ercc1 related. It was just an 





The second round of PCR on the gel purified 600bp fragment using PCR-anchor with 
Skin RT rev B showed several bands. One main abundant band was detected at 400bp. 
This 400bp product was considered to be the same as the one described before in Figure 
4.6.E. Besides the 400bp band, 3 other bigger bands were detected at 500bp, 560bp and 
800bp respectively. All these bands were cut out, gel purified and cloned for sequence 
analysis as described in this section before. The results showed that the 560bp and 800bp 
fragments were artificial products which contained fragments from other mouse 
chromosomes fused to Ercc1 sequence. The sequencing results of the 500bp fragments 
showed that 4 clones of the 8 were genuine Ercc1 5'RACE clones. Sequence analysis of 
these clones is explained later.  
 
The DNA plasmids expected to contain the 500bp, 560bp and 800bp fragments that we 
used in sequencing were investigated by restriction enzyme digest to determine the 
actual inserts sizes (Figure 4.6.G). The digest result showed that most of the inserts were 
not of the expected size, especially for the 800bp group which contained no fragment at 
the expected size. We conclude that many of these low abundance PCR products that we 
were trying to clone were artefactual products generated by multiple rounds of PCR 
rather than true Ercc1 RACE products. 
 
10 genuine sequences of 5'RACE clones from 400bp, 460bp and 500bp fragments were 
mapped along with Dr. Selfridge's old RACE result to the 5' flanking sequence of 
keratinocyte Ercc1 DNA. In the Figure 4.8.A, the longest 5'RACE clone is labelled as 
"New RACE". All end points from other genuine RACE clones are indicated by a black 
arrow above this sequence. The translational start site (ATG) is numbered as +1. It was 
evident that five of the 10 new RACE clones had an end point which was very close to 
Dr. Selfridge's old RACE end point at -502 nt, within a region of 30nt. Four new RACE 





















A. The sequence of the longest new 5'RACE clone determined using mouse keratinocyte RNA, Dr. 
Selfridge's old Skin 5'RACE result and unpublished keratinocyte DNA sequence from Balb/C 
mouse strain are aligned using the Invitrogen AlignX software. Identical sequence is indicated in 
black.  Mismatched sequence is indicated in red. The PCR anchor primer and Skin RT rev B 
primer used in the 5'RACE are labeled with purple and blue boxes respectively. All other end 
points of shorter genuine new 5'RACE clones are mapped above the "New RACE" sequence by 
black arrows. The translational start site of mouse Ercc1 is considered as the "+1" base pair. 
 
B. A different 5'RACE result from the 500_3 clone showed a small new exon 482bp upstream of 
known Ercc1 exon1 and then spliced to 203bp upstream of Ercc1 exon1. Dr. Selfridge's previous 
5'RACE end point is indicated with a black asterisk in the figure. The PCR anchor primer and Skin 
RT rev B primer used in the 5'RACE are labeled with purple and blue boxes respectively. The 








The longest 5'RACE clone contained 79bp upstream of the old RACE result. However, 
this additional sequence did not align with the corresponding Ercc1 DNA sequence, nor 
did it align with any sequence up to 10kb upstream of the Ercc1 gene. Blast search using 
National Center for Biotechnology Information (NCBI) BLAST programme reported 
that there was no significant similarity found in the mouse genome to this additional 
sequence (Ye et al. 2006). There was no evidence for an acceptor splice site at the 
junction between the genuine 5' Ercc1 sequence and the extra sequence either.  
 
Therefore, we considered the longest RACE clone to be another spurious artefactual 
PCR product. Thus, the new RACE result confirmed our old 5'RACE results and 
identified that the 5' end of the Ercc1 mDNA in mouse skin was at nt position 
502, 382 nt upstream of the normal transcriptional start site. The alignment between the 
RACE result and 5' flanking sequence of Ercc1 in keratinocytes was perfectly matched, 
except for a single base mismatch at nt position -347. In the new RACE clone the nt at 
this position was a C, compared with a T in the keratinocyte DNA sequence. 
 
There was another 5'RACE clone from the 500bp fragment that showed a very 
interesting result (Figure 4.8.B).  This clone was labelled as "500_3" and aligned with 
keratinocyte DNA. A new short 21nt exon was detected in this clone from nt position  
-595 to -574 and 47bp upstream of the previous RACE end point. The sequence was 
then spliced into nt position -307 and continued to the known exon 1. Note that although 
this clone had a more 5' start point than the other RACE clones, the presence of the 
intron meant that it would only contain 217 nt upstream of the normal transcriptional 
start site, compared to 382 nt for the consensus RACE end point. There was only one 







Figure 4.9 Sequence alignment of the region 5' of the normal Ercc1 


















Sequence alignment of 129/Ola, C57BL/6 and Balb/C DNA for the Ercc1 flanking region. Identical 
sequence is indicated in black.  Mismatched sequence is indicated in red. CT repeats are labelled with 
purple frame. Ercc1 exons are labelled with green frame with Ercc1 intron omitted. The end points of the 
5'RACE are indicated by black arrows. Novel exon detected by RACE is labelled in blue frames. Potential 
transcriptional start site, normal transcriptional start site, splice donor and acceptor are all labelled 
above the sequence. The translational start site of mouse Ercc1 is considered as the "+1" base pair. 
Sequence elements: direct-repeat (dark underline), SINE/B2 (light blue boxes), LINE/L2 (light orange 






We further analyzed the 5' flanking sequence of the mouse Ercc1 gene. About 1.3kb of 
sequence from albino strain (Balb/C), the source of the keratinocytes used for the RACE 
determination, and pigmented strains (129/Ola and C57BL/6) were aligned together and 
properly labelled with the upstream and normal transcriptional start site, the 5'RACE 
end points and known exons (Figue 4.9). The translational start site (ATG) is numbered 
as +1.  
 
There were two main differences between Balb/C and the pigmented strains. Firstly, the 
presence of an extra 185bp in Balb/C, around 1kb upstream of the normal Ercc1 
transcriptional start site, that was not present in the pigmented strains. The sequence was 
analyzed using RepeatMasking (http://www.repeatmasker.org/) and this service 
indicated that the 185bp extra sequence in Balb/C was a SINE/B2 element. Secondly, a 
CT repeat region immediately downstream of the upstream transcriptional start site was 
longer in Balb/C (174bp) than in pigmented 129/Ola (78bp) and C57BL/6 (58bp) strains. 
A potential TATA box was found at the nt position -904, which was about 400bp 5' of 
the RACE end point. A potential CAAT box was found 52bp upstream of the TATA 
box. The LINE/L2 element was detected in all three tested strains and was located 
between the TATA box and CT repeats. 
 
The potential promoter activity of this region in the three strains was analysed using the 
McPromoter programme, which is a program aiming at the exact localization of 
eukaryotic RNA polymerase II transcription start sites (http://tools.genome.duke.edu 
/generegulation/McPromoter/). To better understand how this programme worked, we 
first tested a well-studied promoter, the mouse ß-globin gene. The ß-globin gene has a 
classical promoter at the size of approximately 200bp located immediately upstream of 
its exon 1. Classical promoter elements like the CAAT box and TATA box were found 





sequence of the mouse ß-globin gene plus its exon 1 sequence was analysed by the 
McPromoter programme. The McPromoter promoter activity curve was then aligned 
with the ß-globin sequence (Figure 4.10.A). The promoter activity was generally less 
than 0 before the promoter region, but then peaked over the promoter region itself with 
the highest score of 0.02 at the TATA box. 
 
After that we tested potential promoter activity of the Ercc1 gene in Balb/C, C57BL/6 
and 129/Ola mouse strains (Figure 4.10.B, C and D). For Ercc1 in all three strains there 
were peaks at the normal transcriptional start site and the region immediately 
downstream of CT repeats. Troughs associated with the CT repeats themselves were 
detected in all three strains. There was no strong peak associated with CAAT/TATA or 
LINE/LE region in all three strains. However, in Balb/C there was a strong peak around 




To understand the mechanism of transcriptional regulation of Ercc1, it is essential to 
identify and characterize its promoter. The genomic structure of Ercc1 has been 
characterized in human and mouse and the promoter region, just at the 5' side of exon 1 
is characterized by the absence of classical promoter elements, such as TATA and 
CAAT boxes (van Duin et al. 1987; van Duin et al. 1988). However, transcript analysis 
of human ERCC1 ESTs revealed a 5' variant containing a differentially spliced exon 1 
(genebank association number: BG333187), which spans the entire previously 





may initiate further upstream (Wilson et al. 2001). Our group also identified a novel 
larger 1.5kb Ercc1 transcript in mouse skin, which is due to initiation of transcription 
upstream of the normal transcription start site (unpublished observations). These results 
suggest that there should be another Ercc1 promoter upstream of the normal promoter 
and additional upstream elements could play a key role in Ercc1 expression in both 
human and mouse.  
 
We have investigated two computer predicted putative 11kb and 2.5kb upstream Ercc1 
promoters in mouse but could not find any evidence to support their activity. RT-PCR 
assays were performed to detect activity from both putative promoters. We did not get 
any positive result but more primers should be tried. The splice pattern might be 
different from the computer prediction so the novel primers designed to be in the 
putative exons might actually be skipped by splicing. As our 5'RACE result is very close 
to the 5' end of the mouse Ercc1 transcript in skin as determined by northern analysis, if 
other further upstream novel exon(s) exist then their size should be very small. Thus it is 
very difficult to design new primers to identify such exon(s) because of the limited 
sequence. In addition, the putative promoters are in a highly GC-rich region that makes 
new primer design very difficult.  
 
The 11kb upstream putative promoter has now been removed from the Ensembl 
Genscan website, which suggests a lower possibility of it being a real promoter. The 
2.5kb upstream putative promoter, which is 5kb upstream in human, could still be 
interesting as it is highly conserved between mouse and human, as well as containing 
classical promoter elements (Wilson et al. 2001).  It has been suggested that the lower 
than normal ERCC1 expression obtaining by placing the strong SV40 promoter in front 
of ERCC1 cDNA might indicate the synergistical regulation of ERCC1 expression by a 
combination of the 5kb upstream region and the normal ERCC1 promoter (van Duin et 





Figure 4.10 Alignment of sequence elements and promoter activities in 




Promoter activities predicted by McPromoter are shown as a red curve. The McPromoter output is shown 
as the vertical axis. The McPromoter output is aligned with the DNA sequence elements which are shown 
underneath. 
A. Alignment of sequence elements and promoter activities of the mouse ß-globin gene. The reported 
promoter is indicated as a bold blue arrow. TATA signal and CAAT signal are labelled with yellow and 
red squares. Exon 1 is indicated as a green box. 
 
B, C, D.  Alignment of sequence elements and promoter activities of mouse Ercc1 gene in 129/Ola, 
C57BL/6 and Balb/C. SINE/B2, LINE/L2, CTs and exons are indicated as blue, orange, purple and green 
boxes, respectively.  The 5' end of the analyzed sequences are indicated in red pentagon boxes. TATA 
signal and CAAT signal are labelled with yellow and red squares. 
 
 






      
      








the upstream promoters in mouse from our study, further investigation of this putative 
promoter in human would be worthwhile. 
 
A new genomic perspective of the Ercc1 gene reported that the region approximately 
1kb to the 5' side of the known promoter was also conserved between human and mouse. 
This region contains transposable elements (TEs) LINE/L1 and LINE/L2, as well as the 
classical regulatory elements, CAAT and TATA boxes (Wilson et al. 2001). 
Transposable elements (TEs) are sequences of DNA that move from one location in the 
genome to another (Kidwell 2005). Recently these mobile elements were reported to be 
possibly involved in endogenous gene regulation, determining which genes are turned 
on and when this activation takes place (Pennisi 2007). The CAAT signal is considered 
to be the binding site for an RNA Pol II transcription factor and is normally located 75-
80 bases upstream of the transcription initiation site. The TATA signal is normally 
bound by the TATA Binding Protein (TBP) in the process of transcription. Therefore 
this 1kb 5' region might play some kind of regulatory role in Ercc1 expression. 
 
We investigated the sequence 5' of the normal Ercc1 promoter region between the albino 
and pigmented strains. The CAAT signal, TATA signal, LINE/L2 element and CT 
repeats were found from 264bp to 841bp upstream of the normal promoter in all 
investigated strains. The CAAT box was found 52bp upstream of the TATA box. 
Interestingly in the albino Balb/C strain only, beside these above regulatory elements, 
we found a SINE/B2 element 1023bp upstream of the normal promoter, which is about 
300bp to the 5' side of the CAAT signal. The SINE/B2 element is reported to provide 
mobile RNA polymerase II promoters and is responsible for the production of the 
endogenous laminin alpha (Lama3) transcript in mouse (Ferrigno et al. 2001). Analysis 
among 20,193 gene promoter regions indicated that TEs have a big potential to influence 





signals. When inserted in promoter regions, they can alter gene expression patterns by 
contributing transcription factor binding sites previously not present in promoters of 
specific genes (Thornburg et al. 2006). Therefore it is possible that the insertion of this 
SINE/B2 element could be involved in the altered Ercc1 gene expression between albino 
strains and pigmented strains. As the 1.5kb Ercc1 transcript is highly expressed in albino 
strains but not in pigmented strains, and the SINE/B2 element as well as the CT repeats 
are the only major differences in the 5' flanking sequence between the different mouse 
strains examined, it is proposed that the SINE/B2 element may interact with downstream 
elements to regulate the expression of this 1.5kb Ercc1 transcript synergistically. This 
hypothesis is also in agreement with the promoter activity prediction which shows an 
increased activity at the position of the SINE/B2 element in the Balb/C strain. 
 
In previous experiments carried out after the skin-specific Ercc1 mRNA was discovered, 
but before the correlation between this transcript and mouse strain was understood, a 
previous postgraduate student, Yvonne Simpson (unpublished observations), had studied 
the expression of an Ercc1 minigene constructed by Dr Jim Selfridge (unpublished 
observations). This minigene, shown schematically in Figure 4.11.A, contained the 
normal Ercc1 promoter region and upstream sequence from strain 129Ola DNA shown 
in Figure 4.9. When transfected into Ercc1 deficient mouse keratinocytes it conferred 
UV resistance. RT-PCR analysis using primer pairs to detect skin-specific Ercc1 
transcripts and all Ercc1 transcripts indicated that pooled keratinocyte clones containing 
the correcting Ercc1 minigene showed the same pattern of Ercc1 initiation as wild type 
keratinocytes (Figure 4.11.B). This suggests that this promoter region was capable of 
directing expression of the skin-specific Ercc1 transcript in this transfection assay in 
cultured keratinocytes despite lacking the SINE element that appears to be important for 












               
This experiment was carried out by Yvonne Simpson 
A. The Ercc1 minigene used in our previous study is shown. The plasmid backbone is shown as a thin 
line. Ercc1 exons are shown in black. 1.2 kb of 5' flanking sequence of 129/Ola strain is shown in 
yellow. Regulatory elements LINE/L2 and CT repeats are shown in Orange and purple respectively. 
Primers are indicated by black arrows under the minigene. 
B. RT-PCR analysis of RNA extracted from Ercc1-null keratinocytes pools transfected with Ercc1 
minigene. Total RNA was prepared and reverse transcribed using oligo-dT primers. Three PCR 
reactions were performed on cDNA using the following forward primers; primer 'A' and primer 'B' 
are specific to a region upstream of the normal transcriptional start site and primer '2' is specific to 










In addition to our results, two mouse Ercc1 transcripts which contain the similar exon 1 
as identified in the 1.5kb skin-specific transcript were published on a comprehensive 
cDNA-supported gene and transcripts annotation AceView, NCBI (Thierry-Mieg and 
Thierry-Mieg 2006). These two Ercc1 transcripts were reconstructed from cDNA clones 
of different mouse tissues and both have the exon 1 reconstructed from only a mouse 
visual cortex clone. The Ercc1 transcript variant cSep07 had a transcriptional start site 
just 18bp  upstream of the end point of our 5'RACE result and had the same exon1 
sequence as the 1.5kb Ercc1 transcript, except for the additional 18bp sequence at the 5' 
side. The cSep07 variant also has an alternative exon 8 which contains the known exon 
8, intron 8 and exon 9 of Ercc1. An "opal" stop codon TGA was found in the intron 8, 
which might lead to a truncated ERCC1. Another Ercc1 transcript variant bSep07 had a 
slightly shorter exon 1 at the 5' side compared to the 1.5kb Ercc1 transcript and also had 
a 132bp longer exon 10. As both these transcript variants had the exon 1 reconstructed 
from the mouse brain tissue, we don’t think these transcripts are as important as the 
1.5kb Ercc1 transcript found in skin. Our northern blotting showed only a barely 
detectable hint of the 1.5kb Ercc1 transcript in tissues other than in skin. However, these 
two Ercc1 variant provide extra evidence that the 1.5kb Ercc1 transcript could be driven 
by the region just 5' of the normal Ercc1 promoter rather than by a promoter located 
much further upstream. 
 
In conclusion, we believe that the source of the Ercc1 skin-specific transcript is most 
likely to be a promoter region adjacent to the RACE endpoints that we have mapped 
some 400bp upstream of the normal transcriptional start site, rather than at the more 






Chapter 5:  












5.1   Introduction 
 
Melanoma is a malignant tumour of melanocytes that causes the majority of skin cancer 
related deaths. It is characterized by high resistance to chemotherapy and to date there is 
still no effective therapeutic regime. Cutaneous melanoma is the eighth most common 
cancer in the UK and the incidence is rising rapidly. Patients with early-stage melanoma 
have good long-term survival following simple surgical resection, but patients with 
metastatic disease, especially distant metastases, are generally considered incurable. The 
long-term survival rate for patients with metastatic melanoma is only 5% (Brown and 
Nelson 1999). Therefore, investigations are essential to improve and develop more 
effective prevention strategies and prognostic markers of melanoma. 
 
As DNA repair deals with both environmental and anti-cancer drug induced DNA 
lesions, a better understanding of the functional role of DNA repair pathways could not 
only benefit the prevention but also the chemotherapy of melanomas. Analysis of 
differential gene expression was carried out to identify the gene-profile signature for 
human primary malignant melanoma associated with recurrence (ie. metastasis). 48 
DNA repair genes, among a list of 234 genes, were found to be associated with 
metastatic progression, of which 44 genes were overexpressed (Kauffmann et al. 
2008).This overexpression of DNA repair genes covers multiple repair pathways 
including BER, NER, MMR and HR and can potentially explain the cause of high 
resistance of metastatic melanoma to chemotherapy (Kauffmann et al. 2008). Our study 
with 596 Scottish melanoma patients and 441 population-based controls also found that 
polymorphisms in the NER genes ERCC1 and XPF were significantly associated with 






The hypermethylation of the hMLH1 gene promoter could induce the loss of DNA 
mismatch repair which occurs at a high frequency in a number of human tumours. This 
loss of MMR is reported to be associated with resistance to a number of clinically 
important anticancer drugs, including the platinum-based chemotherapy drug cisplatin. It 
is reported that re-expression of the MLH1 gene in the MLH1 null mouse cells leads to 
sensitization to DNA damaging agents (Buermeyer et al. 1999). 
 
In ovarian cancer, hMLH1 promoter methylation is observed at a higher frequency in 
tumours following chemotherapy treatment compared with tumours before treatment. 
The majority of cisplatin-resistant derivatives of ovarian tumour cell lines lacked MLH1 
expression because of the methylation of its promoter (Strathdee et al. 1999). In vitro, 
the cisplatin-resistant variants became drug sensitive following re-expression of MLH1, 
or treatment with demethylating agents (Durant et al. 1999; Strathdee et al. 1999). In 
MMR-deficient human ovarian tumour xenografts, re-expression of MLH1 by prior 
demethylating agent treatment also resulted in sensitization to cisplatin (Plumb et al. 
2000).  
 
Therefore, the protein level of MLH1, as well as two other MMR proteins, MSH2 and 
MSH6, was investigated in this thesis. 
 
In this investigation, levels of several different DNA repair proteins, including two NER 
proteins ERCC1 and XPF, three MMR proteins MSH2, MSH6 and MLH1, were 
quantitatively measured and compared using a panel of human melanoma, melanocyte 
and ovarian tumour cells in an attempt to identify any correlation between DNA repair 
capability and resistance to DNA damaging agents. Six melanoma cell cultures A375, 





Hermes 1 and Hermes 4a and seven ovarian tumour cell lines were used in the 
investigation. PEO4 and PEO6 are cisplatin-resistant derivatives of PEO1, PEO23 and 
PEA2 are cisplatin-resistant derivatives of PEO14 and PEA1, respectively (Langdon et 
al. 1988).  
 
 
5.2   Comparison of expression of NER proteins ERCC1, XPF 
and mismatch repair (MMR) proteins MSH2, MSH6, MLH1 in 
human melanoma cell lines, melanocytes and human ovarian 
tumour cell lines 
 
Levels of two NER proteins, ERCC1 and XPF, and three MMR proteins, MSH2, MSH6 
and MLH1, in human melanoma, melanocytes and ovarian tumour cells were 
determined by western blotting. Target protein bands were first detected using ECL-plus 
on high performance autoradiography film (Figure 5.1.A-5.5.A), and then immediately 
scanned with the phosphorimager STORM 840 system. Band densities, which correlate 
with the target protein level in cells, were quantified using the ImageQuant™ TL 
software. The levels of proteins were normalized to the loading control Tubulin or 
GAPDH. Experiments were repeated at least 3 times (MSH6 protein level in all cell 
lines and ERCC1 protein level in human melanocytes were tested twice only). The mean 
ratio of target protein against loading control in the melanoma group was set as 1, and 
then relative levels of proteins in each individual line were plotted (Figure 5.1B-5.5.B). 







It was clear that the protein level of ERCC1 was significantly higher (>2-fold) in the 
melanoma group compared to the ovarian tumour group (P=0.004, Mann-Whitney U 
test)(Figure 5.1). In the melanoma group, the WM115 cell line showed the highest level 
of ERCC1, about two times higher than the C32 cell line, which has the lowest level of 
ERCC1. Interestingly, mean level of ERCC1 protein was also higher in melanocytes 
compared to ovarian tumours, though this was not statistically significant (p=0.380). 
This may be due to more DNA repair being required in skin to deal with UV-induced 
DNA damage. In the melanoma cell lines the level of ERCC1 was 60% higher than in 
non-transformed melanocytes (P=0.046). This could contribute to the extremely high 
resistance to chemotherapy of melanoma. 
 
However, surprisingly there was no consistent correlation between ERCC1 protein 
levels and the chemotherapy resistance in ovarian tumour cultures. The cisplatin 
sensitive culture PEA1 has the lowest level, while the resistant culture PEO6 has the 
highest level of ERCC1. However, the cisplatin sensitive culture PEO14 showed a very 
similar high level of ERCC1 as PEO6. All other cultures generally showed similar 
protein level of ERCC1 irrespective of their cisplatin resistance or sensitivity.  
 
ERCC1's partner, the XPF protein showed the same significant increased level in 
melanomas compared to the ovarian tumours and melanocytes (Figure 5.2). The level of 
XPF was 1.5 times higher in the melanoma group than the ovarian tumour group 
(P=0.022). However, different from ERCC1, XPF showed a lower protein level in 
human melanocytes, which is 31% compared to melanomas (p=0.046) and 44% 
compared to ovarian tumours (p=0.040), respectively. The trend of the XPF protein level 
in tested samples was very similar to the ERCC1 protein level. In melanomas, the C32 
had the lowest level of both ERCC1 and XPF, while A375 and WM115 showed high 





Figure 5.1 Expression pattern of NER protein ERCC1 in human melanoma, 





A. ERCC1 protein levels in human melanoma, melanocytes and ovarian tumour cells. Top panel shows 
bands of ERCC1, while the bottom panel shows bands of loading control tubulin. Figure is made from 
an autoradiograph. 
B. Histogram showing mean level of ERCC1 in each individual cell line ±SEM standardized against the 
loading control tubulin. The ERCC1/Tubulin ratios are normalized to the mean level in all melanoma 
cell lines. Melanoma, melanocytes and ovarian tumour cultures are plotted in orange, purple and 
green columns, respectively.  The cisplatin sensitive and resistant ovarian cell lines are indicated 
underneath, with black arrows showing original and daughter cell lines. There is no error bar for 
human melanocytes as they were tested only twice. Data from phosphorimager. 
C. Histogram showing mean level of ERCC1 in each cell type ±SEM standardized against tubulin. 
Melanoma, melanocytes and ovarian tumour cultures are plotted in orange, purple and green 














































Figure 5.2 Expression pattern of NER protein XPF in human melanoma, 





A. XPF protein levels in human melanoma, melanocytes and ovarian tumour cells. Top panel shows 
bands of XPF, while the bottom panel shows bands of loading control GAPDH. Figure is made from an 
autoradiograph. 
B. Histogram showing mean level of XPF in each individual cell line ±SEM standardized against the 
loading control GAPDH. The XPF/GAPDH ratios are normalized to the mean level in all melanoma cell 
lines. Melanocytes and ovarian tumour cultures are plotted in orange, purple and green columns, 
respectively.  The cisplatin sensitive and resistant ovarian cell lines are indicated underneath, with 
black arrows showing original and daughter cell lines. Data from phosphorimager. 
C. Histogram showing mean level of XPF in each cell type ±SEM standardized against GAPDH. 
Melanoma, melanocytes and ovarian tumour cultures are plotted in orange, purple and green 










































ERCC1 and XPF, while PEO6 had the highest levels of both two proteins. 
 
We further tested three different MMR proteins MSH2, MSH6 and MLH1 using the 
same protocol as described above. There was no significant difference in MSH2 levels 
between the three cell types (Figure 5.3). As expected, there was no obvious correlation 
between cisplatin-resistance and MSH2 protein level, either. 
 
The MSH6 protein showed a slightly higher level in the ovarian tumours cells compared 
to the melanoma lines, but this difference was not significant (Figure 5.4). Different 
from the MSH2, the level of MSH6 was much lower in melanocytes, about 40% of the 
level in melanomas and ovarian tumours. Within the cell types there was no obvious 
correlation between MSH2 and MSH6 protein levels.  
 
Interestingly, another MMR protein, MLH1, showed an elevated level in melanomas 
compared to melanocytes (P=0.046) and ovarian tumour cells (P=0.003) (Figure 5.5). 
This is opposite to the previous investigations from the literature, which suggest that 
tumour cells with reduced MLH1 expression seem to have a survival advantage during 
combined chemotherapy and loss of MLH1 may relate to the drug resistance in breast 
and esophageal cancers (Mackay et al. 2000; Kishi et al. 2003). Melanoma is more 
resistant to chemotherapy compared to ovarian cancer, but the level of MLH1 in 
melanoma cell lines was nearly 1.5 times higher. The protein level of MLH1 was also 
higher in the cisplatin-resistant ovarian tumour cell lines compared to the sensitive ones. 
The mean MLH1 expression ratio was 0.74 and 0.57 in cisplatin-resistant and sensitive 
ovarian tumour cell lines, respectively, though this difference was not statistically 






Figure 5.3 Expression pattern of MMR protein MSH2 in human melanoma, 





A. MSH2 protein levels in human melanoma, melanocytes and ovarian tumour cells. Top panel shows 
bands of MSH2, while the bottom panel shows bands of loading control GAPDH. Figure is made from 
an autoradiograph. 
B. Histogram showing mean level of MSH2 in each individual cell line ±SEM standardized against the 
loading control GAPDH. The MSH2/GAPDH ratios are normalized to the mean level in all melanoma 
cell lines. Melanoma, melanocytes and ovarian tumour cultures are plotted in orange, purple and 
green columns, respectively.  The cisplatin sensitive and resistant ovarian cell lines are indicated 
underneath, with black arrows showing original and daughter cell lines. Data from phosphorimager. 
C. Histogram showing mean level of MSH2 in each cell type ±SEM standardized against GAPDH. 
Melanoma, melanocytes and ovarian tumour cultures are plotted in orange, purple and green 
















































Figure 5.4 Expression pattern of MMR protein MSH6 in human melanoma, 





A. MSH6 protein levels in human melanoma, melanocytes and ovarian tumour cells. Top panel shows 
bands of MSH6, while the bottom panel shows bands of loading control GAPDH. Figure is made 
from an autoradiograph. 
B. Histogram showing mean level of MSH6 in each individual cell line ±SEM standardized against the 
loading control GAPDH. The MSH6/GAPDH ratios are normalized to the mean level in all melanoma 
cell lines. Melanoma, melanocytes and ovarian tumour cultures are plotted in orange, purple and 
green columns, respectively.  The cisplatin sensitive and resistant ovarian cell lines are indicated 
underneath, with black arrows showing original and daughter cell lines. There are no error bars for 
MSH6 proteins due to this test being repeated only twice. Data from phosphorimager. 
C. Histogram showing mean level of MSH6 in each cell type ±SEM standardized against GAPDH. 
Melanoma, melanocytes and ovarian tumour cultures are plotted in orange, purple and green 


















































Figure 5.5 Expression pattern of MMR protein MLH1 in human melanoma, 





A. MLH1 protein levels in human melanoma, melanocytes and ovarian tumour cells. Top panel shows 
bands of MLH1, while the bottom panel shows bands of loading control Tubulin. Figure is made 
from an autoradiograph. 
B. Histogram showing mean level of MLH1 in each individual cell line ±SEM standardized against the 
loading control Tubulin. The MLH1/Tubulin ratios are normalized to the mean level in all melanoma 
cell lines. The MLH1 protein level in melanomas is set to the ratio 1. Melanoma, melanocytes and 
ovarian tumour cultures are plotted in orange, purple and green columns, respectively.  The 
cisplatin sensitive and resistant ovarian cell lines are indicated underneath, with black arrows 
showing original and daughter cell lines. There is no error bar for human melanocytes as they were 
tested only twice. Data from phosphorimager. 
C. Histogram showing mean level of MLH1 in each cell type ±SEM standardized against Tubulin. 
Melanoma, melanocytes and ovarian tumour cultures are plotted in orange, purple and green 














































5.3 Colony forming survival assay following UV-irradiation in 
human melanoma cell lines and human ovarian tumour cell 
lines. 
 
To investigate whether the increased level of ERCC1 and XPF proteins relate to a higher 
DNA repair capability in melanomas, a colony forming assay was performed to study 
the long-term survival rate of different types of tumour cells following UV-induced 
DNA damage. 
 
Preliminary studies were carried out on the majority of our melanoma and ovarian 
tumour cell lines to determine the appropriate cell densities for plating, the culture 
conditions and plating efficiency of each cell line. To avoid the subjective bias of 
manual enumeration of colonies, colonies were counted using the GEL-DOC 2000 
system with proper parameters for enumeration of each cell line. From the preliminary 
results, cell lines that did not form clear visible colonies were excluded from this assay 
and finally 2 melanoma cell lines, A375 and G361, as well as 2 cisplatin resistant 
ovarian tumour cell lines, PEO4 and PEO6 were selected (Figure 5.6). Appropriate 
numbers of cells were plated in 60mm petri-dishes 24 hours before the UV irradiation at 
doses from 0Jm-2 (control) to 200Jm-2, dishes were then cultured until good and clear 
colonies were formed before being fixed and stained with crystal violet. Triplicate dishes 
of A375 and duplicate dishes of G361, PEO4 and PEO6 were set up in the assay. The 
A375 cell line grew rapidly and normally took about one week to finish a single assay. 
The G361, PEO4 and PEO6 grew much more slowly and took about 3 to 4 weeks to 
finish one single assay.  
 
The D50 values (UV dose for 50% survival) for the melanoma cell lines were: A375, 













Relative plating efficiency is plotted on the Y-axis on a log scale. This is the plating efficiency at each UV 




















ERCC1 and XPF than the ovarian cell lines, but this did not correlate with increased UV 
survival. 
 
5.4 Comparison of cisplatin resistance between human 
melanoma and ovarian tumour cells by Sulforhodamine B (SRB) 
assay. 
 
Since some of the melanoma and ovarian cancer cell lines could not form good colonies 
we changed to using the SRB assay to test their resistance to the chemotherapy drug 
cisplatin. The SRB assay, based on the measurement of cellular protein content, is a 
widely used method for in vitro cytotoxicity screening (Skehan et al. 1990; Vichai and 
Kirtikara 2006). Generally, the SRB dye binds to protein components of trichloroacetic 
acid (TCA) fixed cells in a 96-well plate format, and then the amount of dye extracted 
from stained cells is measured at 510nm and the O.D value is directly proportional to the 
cell mass (Vichai and Kirtikara 2006). In our assay, 6 replicas of each cell line and 
cisplatin concentration were performed for each individual test to permit statistical 
analysis of the data.   
 
Starting cell density is important for the SRB assay as an improper cell-seeding density 
will result in exceeding the linearity range of the absorbance reading and lead to 
spurious cytotoxicity effects of cisplatin. Therefore, pilot assays with a range of starting 
cell densities were performed using 4 cell lines of both human melanomas and ovarian 
tumour cells (Figure 5.7). The starting cell density that produced O.D.s in the 
exponential increase phase range, but not exceeding the linearity range of the absorbance 






The day of setting up the plates was counted as day 0. Cells were harvested on day 4 to 
day 7. The A375 cell line grew very fast and achieved 100% confluence in the wells on 
day 6 using 1000 cells per well, though the O.D value was still within the linear range. 
Therefore 500 A375 cells per well was chosen for the cisplatin assay. For the rest of the 
cell lines, appropriate starting cell densities from 4K to 10K were chosen according to 
the pilot experiment (as shown in Figure 5.7 with the black arrow). 
 
Following the pilot experiments, SRB assays with cisplatin treatment were carried out 
using optimal starting cell densities. The 96-well plates were set up with 150ul of 
appropriate media in each well on day 0. 24 hours (day 1) following the plating, the 
desired amount of cisplatin was mixed into 50ul of culture media and added to each well 
directly to make a total volume of 200ul of media with a final concentration of cisplatin 
ranging from 0.3uM to 10uM. For the controls, 50ul of culture media without cisplatin 
was added to each well. After that, plates were incubated for another 48 hours (day 2 
and day 3) under the proper culture conditions. The first plate was harvested on day 4, 
which is 72 hours following the cisplatin treatment, and the last plate was harvested on 
day 7. Cisplatin was kept continuously in the media until the harvest of the plate.  
 
For each individual cell line, the relative growth with different concentration of cisplatin 
treatment on each day was analyzed and plotted using a histogram. As cisplatin induces 
the ICL DNA lesions which interrupt the DNA replication and finally induce apoptosis 
(Pillaire et al. 1995), the long-term effect of its cytotoxicity should be obvious in this 
assay.  
 










Histogram showing the O.D value at 510nm of pilot experiments for the SRB assay. Y-axis shows the O.D 
value while X-axis shows different starting cell densities used in the pilot assay for each individual cell 



























































































































melanomas, HBL and WM115 were more sensitive to the cisplatin treatment compared 
to A375 and G361, as 0.3uM of cisplatin reduced growth by 30% for HBL and WM115 
cells while the same concentration of cisplatin hardly had any effect on A375 and G361. 
In the ovarian tumour cells, the PEA1 and PEO1 cells were more sensitive to cisplatin 
compared to PEO4 and PEO6. 1uM of cisplatin reduced the growth to 70% in PEA1 and 
40% in PEO1, while the same treatment has nearly no effect on PEO4 and PEO6. This 
result is reasonable because PEO4 and PEO6 are cisplatin-resistant derivatives of PEO1.  
 
When compared to the melanoma cells, PEO4 and PEO6 cells showed a very similar 
cisplatin resistance to G361 cells, but they were more resistant than the other 3 
melanoma cell lines tested. Therefore this suggests that there is no correlation between 
the level of NER protein ERCC1 and cisplatin resistance. For instance, A375 had a 2 
times higher level of ERCC1 than PEO4 and PEO6 (Figure 5.2.B), but was less resistant 
to the cisplatin treatment. With 10uM of cisplatin, A375 cells showed a relative growth 
at less than 5% compared to 40% in PEO4 and PEO6 cells. The cisplatin resistance did 
not correlate with levels of other DNA repair proteins we tested either.  
 
When all cell lines were combined together by tumour type, there was no statistical 
significance between the cisplatin resistance of the melanoma and ovarian tumour 
groups (Table 5.1.A).  However, the in-group test showed that the cisplatin sensitive 
ovarian tumour cells had a significantly lower relative growth compared to the 








Figure 5.8 SRB assays of human melanoma and ovarian tumours cells 





Histogram showing the relative growth following cisplatin treatment on day 6. Y-axis shows the relative 
growth while X-axis shows concentrations of cisplatin used on each individual cell line. Melanomas are 
shown in green histograms and ovarian tumours are shown in blue. Starting cell densities and the 

















































































































































The human melanoma cell lines had a higher level of ERCC1 and its partner, XPF, than 
the ovarian cancer cell lines we investigated, but they did not show the expected 
increased resistance to UV- and cisplatin-induced DNA damage. Although resistance to 
DNA damaging agents is only an indirect measure of DNA repair levels, we did not 
consider that our results justified measuring levels of DNA repair directly in the 
different cell lines. Instead, we turned to a system where we could manipulate the levels 
of ERCC1 directly and measure the consequences for melanoma growth and resistance 
to cisplatin. For this we used an immortalized mouse melanocyte cell line isolated from 
our mouse strain containing a floxed ERCC1 allele that was described in Chapter 1. This 
cell line grows as a xenograft in immunocompromised mice with the histological 






Table 5.1 Statistical analysis of the cisplatin resistance between human 
melanoma and ovarian tumours cells 
 
Table 5.1.A 
 D4 0.3uM D4 1uM D4 3uM D4 10uM D5 0.3uM D5 1uM D5 3uM D5 10uM 
Mean of melanomas 84% 81% 59% 32% 84% 80% 53% 19% 
Mean of ovarian tumours 98% 90% 73% 44% 94% 79% 53% 28% 
Significance 0.468 0.149 0.149 0.564 0.248 1.000 1.000 0.564 
 D6 0.3uM D6 1uM D6 3uM D6 10uM D7 0.3uM D7 1uM D7 3uM D7 10uM 
Mean of melanomas 85% 73% 47% 10% 91% 76% 49% 7% 
Mean of ovarian tumours 95% 78% 43% 16% 97% 76% 37% 13% 
Significance 0.309 0.773 0.773 0.309 0.564 0.885 0.564 0.309 
 
Table 5.1.B 
 D4 0.3uM D4 1uM D4 3uM D4 10uM D5 0.3uM D5 1uM D5 3uM D5 10uM 
Mean of cisplatin sensitive 
ovarian tumour cells 94% 79% 61% 22% 80% 60% 34% 13% 
Mean of cisplatin resistant 
ovarian tumour cells 102% 102% 86% 66% 107% 99% 71% 43% 
Significance 0.006 0.003 0.018 0.001 0.001 0.018 0.065 0.729 
 D6 0.3uM D6 1uM D6 3uM D6 10uM D7 0.3uM D7 1uM D7 3uM D7 10uM 
Mean of cisplatin sensitive 
ovarian tumour cells 89% 59% 35% 7% 91% 57% 57% 7% 
Mean of cisplatin resistant 
ovarian tumour cells 102% 96% 55% 24% 104% 96% 47% 19% 
Significance 0.015 0.001 0.038 0.001 0.001 0.001 0.001 0.001 
 
Significance (P value) by Mann Whitney U test using SPSS. D4, D5, D6 and D7 mean Day 4, Day 5, Day 6 
and Day 7, respectively. Table 5.1.A: Mean relative growth of melanomas and ovarian tumour cell lines. 





5.6 ERCC1-deficient melanoma xenografts are cured by 
cisplatin. 
 
3-1-1 T1a is the immortalised mouse melanocyte cell line that contains an Ercc1 floxed 
allele (Figure 5.9) and grows as malignant melanoma when xenografted in nude mice. 
An Ercc1 deficient derivative was isolated by cotransforming 3-1-1 T1a cells with 
pBT/MTneo and pMCreN plasmids. Transfectant colonies were selected by resistance to 
G418, while cotransfection with pMCCreN should result in expression of Cre 
recombinase and deletion of the Ercc1 exon 3-5 region, resulting in an Ercc1 deficient 3-
1-1 T1a melanocyte derivative. This experiment was carried out by Ann-Marie Ratchie. 
 
G418-resistant colonies were picked, expanded and screened by PCR and western 
blotting. 8 out of 13 colonies screened were Ercc1-deficent. On such clone (Ercc1 3-1-1 
T1a #5) is shown in Figure 5.9.B. The in vitro growth rates of both proficient and 
deficient mouse melanocytes were tested before the xenograft experiment (Figure 
5.9.C). Both cell lines grew at the same rapid dividing speed approximately once per 24 
hours. 
 
The Ercc1 proficient and deficient melanocytes were then transplanted into nude mice. 
Each animal received 107 cells plus matrigel into each flank. The Ercc1 proficient 
xenografts grew very rapidly (Figure 5.10). The curve stops at day 24 because at this 
stage the tumours in some animals had reached the maximum permitted size (1.44cm2) 
and the affected animals had to be culled. In comparison the Ercc1-deficient xenografts 
grew much more slowly taking 70 days before the largest tumours reached maximum 
permitted size. Thus although both cell lines grew equally well in vitro, Ercc1 was 





Figure 5.9 Generation of the ERCC1 deficient mouse melanocytes. 
 
     
 
 
A. Schematic representation of floxed and recombined Ercc1 alleles. Ercc1 exons are numbered. Black 
squares indicate the Ercc1 exons.  Red arrowheads represent loxP sites. 
B. Screening using western blotting indicating the ERCC1 deficiency in the mouse melanocyte line 3-1-
1T1a colony #5. Initial culture means the first culture from the colony. Extended culture indicates the 
same cells but with higher passage number. 11-1 and KER are ERCC1 deficient mouse melanocytes 
and keratinocytes, respectively. Cross-reacting bands and target ERCC1 bands are indicated by arrows 
on the right. 
C. In vitro growth comparison between 3-1-1 T1a and its ERCC1-deficient derivative. For each cell line 
5x104 cells were plated in 25cm2 flasks. Each time point is the mean of duplicate flasks. Y-axis shows 





































Growth of ERCC1 proficient and deficient xenografts in nude mice was measured. The red line represents 
the average of 5 mice with 2 ERCC1 proficient xenografts per mouse. The green line represents the 






























Figure 5.11 Growth rates of ERCC1 proficient and deficient xenografts 
following cisplatin treatment. 
 
 
Growth of Ercc1-proficient and deficient xenografts in nude mice. The red line represents the average 
relative volume without cisplatin treatments. The green line represents the average relative volume with 
6mg/kg cisplatin treatments. Volumes of all tested tumours are set to 1 on day 0. Y-axis indicates the 
relative tumour volume, which is calculated by dividing the measured tumour volume with the volume 
measured on day 0. X-axis indicates the time. It took X days before day 0 for xenografts to grow to the 
threshold volume for the treatment to start. Cisplatin treatments are indicated by black arrows under 
the X-axis A. Growth of Ercc1-proficient xenografts. Both control and treated groups have 5 mice with 2 
xenografts per mouse. B. Growth of ERCC1 deficient xenografts. Both control and treated group have 4 
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Once the tumours had reached a threshold size of 0.1cm3 mice with Ercc1 proficient and 
deficient xenografts were randomised into control and cisplatin groups and the mean 
tumour volume in each group was set at 1 and the day set at Day 0. In Figure 5.11, X is 
the number of day taken from injection to reach the starting size for cisplatin treatment 
at Day 0. X=12 for Ercc1 proficient and X=42 for Ercc1 deficient xenografts.  
 
The Ercc1-proficient tumours grew rapidly in the absence of cisplatin, with the mean 
volume increasing 10-fold in 21 days before all animals had been culled because their 
tumours had reached the maximum size. Cisplatin injection (6mg/kg, intraperitoneally) 
on days 0 and 7 resulted in initial shrinkage of  the Ercc1 proficient tumours, followed 
by regrowth that could not be prevented by two further cisplatin injections on day 21 and 
29. The drop of the relative tumour volume curve around 55 days and increased error 
bars were due to the loss of some animals because their tumours had reached the 
maximum permitted size. 
 
From day 0 in the ERCC1 deficient group, untreated control tumours grew as fast as the 
Ercc1-proficient group (Figure 5.11.B). The mean volume of tumours was 12 times 
bigger on day 24 and all animals had to be killed. However, very interestingly, the 
ERCC1 deficient tumours showed a hypersensitivity to the cisplatin treatment. Only two 
cisplatin treatments were performed on the ERCC1 deficient tumours, on days 0 and day 
7. Tumours stopped growing and rapidly shrank following the treatment. No regrowth 






5.7 The level of ERCC1 protein was elevated in xenografts 
following cisplatin treatments 
 
Cells were retrieved from the xenografts and cultured for further investigations.  First of 
all, the status of ERCC1 was identified by western blotting. Figure 5.12.A shows some 
of the cells retrieved from xenografts. In the Ercc1-proficient group, the untreated 
control tumour cells 425R and 767L showed a very similar level of ERCC1 as the input 
cells (3-1-1 T1a) used to generate xenografts. Interestingly, in lines 764R2 and 769R1, 
derived from the cisplatin-treated group, the level of ERCC1 was increased compared to 
the input and control cells. No ERCC1 protein was detected in both input cells and 
control xenograft cells in the ERCC1 deficient group, as expected. 
 
The ERCC1 protein was then detected in all retrieved cells and measured quantitatively.  
Level of ERCC1 was standardized by the loading control Tubulin (Figure 5.12.B). There 
were 5 samples in the input group (from independent 3-1-1 T1a cultures), 4 samples 
(from independent xenografts) in the control group and 8 samples (from independent 
xenografts) in the cisplatin group. The ratio of ERCC1/Tubulin in the control group was 
set to 1. There was no difference in ERCC1 levels between the input group and the 
control xenograft group, indicating that the transplanting of xenografts had no effect on 
ERCC1 expression. However, following the cisplatin treatment, the level of ERCC1 
increased 2.1 times compared to the control group (p=0.005). Every individual cell line 
retrieved from the cisplatin treated xenografts showed a higher level of ERCC1 than the 







Figure 5.12 Western blotting analysis of Ercc1-proficient and deficient 




   
A. ERCC1 protein levels in cells retrieved from xenografts experiments. 3-1-1-T1a is the mouse 
melanocyte line used to generate the Ercc1-proficient xenografts. 425R and 767L are cells retrieved 
from the Ercc1-proficient control xenografts, mouse ID 425, right side tumour and 767 left side 
tumours. 764R2 and 769R1 are cells retrieved from the Ercc1-proficient cisplatin treated xenografts, 
mouse ID 764, right side tumour and 769 right side tumour. 3-1-1#5 is the Ercc1-deficient mouse 
melanocyte line used to generate the ERCC1 deficient xenografts. 714L1R and 709L1 are cells 
retrieved from the ERCC1 deficient xenografts, mouse ID 714, left side tumour and 709 left side 
tumours. Upper bands are loading control tubulin while lower bands are ERCC1. 
B. Histogram showing the ERCC1 protein level in input Ercc1-proficient cells and cells retrieved from 
control and cisplatin xenografts, standardised against Tubulin and normalised for the  mean 



























Treatment of cancer using chemotherapy often fails due to the resistance of tumours to 
drugs used. Thereby, better understanding the mechanisms of resistance may contribute 
to improved treatment. Generally, the resistance to the anti-cancer drug cisplatin can be 
catalogued into two types, acquired resistance and intrinsic resistance. Acquired 
resistance develops both in patients undergoing chemotherapy and in cell lines exposed 
to increasing concentrations of cisplatin until they have reached a high tolerance, while 
intrinsic resistance is described when patient tumours are naturally unaffected by 
platinum treatment (Zamble and Lippard 1995).  
 
An increased level of DNA repair in tumour cells is suggested to be a main cause of 
resistance.  The enhanced expression of proteins involved in repair is suggested to be 
associated with the elevation of DNA repair. However, other mechanisms, such as 
inhibition of drug uptake, enhanced replicative bypass of the cisplatin-DNA adducts and 
changes in the concentration of regulatory proteins may also contribute to the cisplatin 
resistance (Zamble and Lippard 1995).  
 
ERCC1 is essential in the NER pathway that recognizes and removes cisplatin-induced 
DNA adducts (Zamble et al. 1996). ERCC1 also plays an important role in the repair of 
ICL in DNA and in recombination processes (Niedernhofer et al. 2004). It has been 
reported that the platinum resistance is linked with elevated expression of ERCC1 
mRNA in cell lines from ovarian, cervical, testicular, bladder, and non–small-cell lung 








In this thesis, we have detected the level of five DNA repair proteins, including two 
NER proteins, ERCC1 and XPF, as well as 3 MMR proteins, MSH2, MSH6 and MLH1, 
in human melanomas, melanocytes and ovarian tumour cells. In our study, we noticed a 
higher level of ERCC1 protein, as well as its partner the XPF protein in melanoma cell 
lines compared to ovarian tumour cell lines. This might contribute to the high resistance 
to chemotherapy in melanoma. One MMR protein, MLH1, also showed a higher level in 
melanoma cell lines, while the other two MMR proteins, MSH2 and MSH6, showed a 
similar expression in all tested cell lines. However, we found that the elevated DNA 
repair protein level was not linked to an increased DNA repair capability for either UV 
or cisplatin induced DNA damage. The ovarian tumour cell line PEO4, which only has 
half the ERCC1 level compared to the melanoma cell line A375, showed the best 
survival rate following UV irradiation. In the SRB assay for detecting cisplatin 
cytotoxity and resistance, the ovarian tumour cell lines PEO4 and PEO6, which had a 
lower level of ERCC1 compared to all melanoma cell lines used in the assay, showed 
higher resistance to cisplatin. 
 
Although only four cell lines were tested by colony forming assay, the result is in 
agreement with our previous data by short-term survival assay following UV irradiation 
(Ewan Brown, unpublished observations). The resistance to cisplatin in the ovarian 
tumours by SRB assay correlates with our previous IC50 data (Ewan Brown, unpublished 
observations). Combining all the data together, we found no evidence that the elevated 
level of DNA repair proteins in melanoma cell lines could be linked with increased 
DNA repair capabilities for UV or cisplatin induced damage. However, it is important to 







Also, an investigation comparing DNA repair between totally different cell lines itself is 
problematic. More samples of each tumour type may be needed to achieve any solid 
conclusions. However, if we just focus on the ovarian tumour group, the result is still 
quite interesting. 
 
As described before, PEO4 and PEO6 are cisplatin-resistant derivatives of PEO1, while 
PEO23 and PEA2 are cisplatin-resistant derivatives of PEO14 and PEA1, respectively 
(Langdon et al. 1988). According the western blotting analysis, a trend of slightly 
increased protein level was shown in three of five tested DNA repair proteins, ERCC1, 
XPF and MLH1, in derivative cisplatin-resistant cell lines. In terms of ERCC1 protein 
level, derivative PEA2 was 2 times higher than the original cell line PEA1, while 
derivatives PEO4 and PEO6 also showed an increased level of ERCC1. Only derivative 
PEO23 had a lower ERCC1 level than original cell line PEO14 (Figure 5.1). In terms of 
XPF, all derivatives showed an increased level compared to their original cell lines 
(Figure 5.2). In terms of MLH1, the majority of cisplatin-resistant derivatives had an 
increased protein level, except PEO6, which showed a slightly lower level of MLH1 
than PEO1. However, although there is a trend for the cisplatin-resistant ovarian lines to 
have higher levels of these repair proteins, the differences are small and none are 
significant. For the other two MMR proteins MSH2 and MSH6, there was no correlation 
between protein levels and cisplatin resistance. There was no evidence that cisplatin 
resistant derivatives had decreased expression of MMR genes as previously reported 
(Strathdee et al. 1999). 
 
In the colony forming assay, PEO6 showed an increased survival rate compared to 
PEO4. This could be due to the higher protein expression of both ERCC1 and XPF in 
PEO6 (Figure 5.6). In the SRB assay of cisplatin resistance (Figure 5.8), derivatives 





PEO1. PEO6 was more resistant to cisplatin than PEO4, as with the treatment of 3uM 
cisplatin, PEO6 showed a survival rate at more than 80% compared to less than 60% for 
PEO4. Although PEO1 had higher DNA repair protein levels than PEA1 (both cisplatin 
sensitive), it was more sensitive to cisplatin than PEA1. This might suggest that in tested 
cell lines, the level of DNA repair proteins following the treatment, rather than before 
the treatment, is more meaningful to predicting chemotherapy resistance of the tumour. 
The elevated level of DNA repair proteins after the cisplatin treatment might be linked 
with higher tumour cell survival and higher resistance, representing some kind of 
acquired resistance.  
 
As far as we are aware the melanoma cell lines we assayed had not been exposed to 
cisplatin previously, either in vivo or in vitro. The same applied to some of the ovarian 
tumour cell lines, while others had arisen as resistant derivatives following cisplatin 
treatment. Since the cisplatin resistant ovarian tumour cell lines were not maintained in 
cisplatin, any acquired resistance perhaps with associated increased levels of ERCC1 
and XPF may have been lost during extensive in vitro culture in non-selective 
conditions. Thus, our approach to attempt to correlate DNA repair protein levels with 
resistance to DNA damaging agents by comparison between different tumour cell lines 
with different histories of exposure to DNA damaging agents was problematic. A better 
approach could be to measure levels of DNA repair proteins simultaneously on a large 
collection of tumour samples on a tissue microarray and correlate this directly with data 
on intrinsic or acquired resistance of individual tumours to chemotherapeutic agents. 
 
Because of these limitations we switched to a different approach where we could study 
the consequence of altered levels of ERCC1 directly on melanoma growth in a series of 
isogenic immortalised mouse melanocyte cell lines. Xenografts of the Ercc1-proficient 





Cisplatin treatment caused an initial shrinkage of these tumours, but cisplatin resistance 
quickly appeared. Cell re-isolated from untreated xenografts had the same ERCC1 level 
as the input cell line, while cells from cisplatin-resistant tumours, had 2-fold elevated 
levels of ERCC1. This demonstrates in a direct functional assay that acquired resistance 
to cisplatin is associated with increased levels of ERCC1. 
 
While the Ercc1-deficient derivative of the mouse melanocyte cell line grew as rapidly 
as the Ercc1-proficient partner in vitro, for the first seven weeks after being xenografted 
into mice it grew very slowly. During the first week after xenografting slow growing 
tumours often show some shrinkage as the supporting matrigel is resorbed and this was 
the case with both the Ercc1-proficient and Ercc1-deficient melanocytes. However, 
while the Ercc1-proficient melanocyte xenografts then grew rapidly resulting in tumour 
size end points being reached within 4 weeks, it took 7 weeks before the Ercc1-deficient 
melanocyte tumours began to grow rapidly. 
 
It is very interesting to see that the lack of ERCC1 slowed the initial growth of 
xenografts in nude mice. Perhaps this results from greater exposure during the early 
stages of in vivo growth to endogenous DNA damage. During growth of tumours, a 
highly heterogeneous microenvironment, characterized by oxygen depletion, 
extracellular acidosis, elevated lactate levels, glucose deprivation, low energy status, and 
interstitial hypertension, can be developed (Vaupel et al. 1989). This hostile 
microenvironment could result in increased DNA damage that would normally be 
repaired by pathways requiring ERCC1. The physiological parameters of the 
microenvironment of tumours are mainly determined by the blood supply, which 
depends primarily on the vascular density (Vaupel 2004). At the initial growth stage of 
xenografts in mice, the vascular density will be very low, the blood supply of the tumour 





supply, the oxygen level in the tumour cells could increase rapidly resulting in elevated 
level of oxidative DNA damage that would be growth inhibitory to the DNA repair 
deficient xenografts.  
 
Another less likely possibility is that the Ercc1-deficient xenografts needed to acquire 
some new mutations before growth could commence in vivo. The Ercc1-deficient 
xenografts persisted in mice but only grew very slowly for a comparatively long period 
(more than 7 weeks) following the transplantation compared to the Ercc1-proficient 
xenografts. The Ercc1-deficient tumours then started to grow rapidly and this could 
potentially be linked to new mutations. This possibility could be investigated by 
performing microarray to identify gene expression changes between input Ercc1-
deficient melanocytes and cells subsequently reisolated from rapidly growing tumours. 
Any changes could then be compared with any identified in a similar comparison of 
input Ercc1-proficient melanocytes with cells reisolated from tumours (Pardo et al. 
2009). 
 
Once the Ercc1-deficient xenografts had established themselves they grew as rapidly as 
Ercc1-proficient xenografts. However, they were cured by cisplatin treatment, while 
Ercc1-proficient xenografts rapidly became resistant. These results demonstrate that, in 
this mouse melanoma xenograft model, ERCC1 is important for melanoma growth and 
is essential for resistance to cisplatin. This raises the possibility that an ERCC1 inhibitor 
could be used to enhance the effectiveness of cisplatin treatment. The melanoma 















Maintaining genetic integrity is essential for proper cellular functioning because the 
accumulation of DNA mutations may activate proto-oncogenes and inactivate tumour 
suppressors, leading to an increased risk of tumourigenesis. The nucleotide excision 
repair (NER) pathway plays an important role in repairing various types of DNA 
damage, especially UV-induced DNA lesions. Studies have identified that defects in 
NER are linked with several diseases such as XP, TTD and CS. ERCC1 with its partner 
XPF plays an essential role in the NER pathway as an endonuclease to make the 5' 
incision around the DNA lesions. However, the consequences of ERCC1 deficiency in 
in human have not been studied in-depth due to its extreme rarity. The first reported case 
of human inherited ERCC1 deficiency was associated with Cerebro-Oculo-Facio-
Skeletal (COFS) syndrome (Jaspers et al. 2007). The patient failed to pass any 
developmental milestones and died at the age of 14 months due to respiratory failure 
from bilateral pneumonia. Analysis on the patient is still going on but it is clear that in 
this case of ERCC1 deficiency in human there is a mild defect in NER and severe 
developmental failure. 
 
Due to the limitation of using human subjects for disease pathogenesis studies, the 
availability of genetically-engineered mouse models becomes a powerful tool for 
investigating the molecular pathology of ERCC1 deficiency. Our group was the first to 
successfully generate the ERCC1 knockout mouse which was associated with severe 
runting and a very short lifespan due to liver failure (McWhir et al. 1993; Selfridge et al. 
2001). We also created a mouse model with longer lifespan using a liver-specific 
transgene and a mouse model with tissue-specific ERCC1 knock out using an Ercc1 
floxed allele. These made a good platform to perform further investigations of ERCC1 






Previous group work has identified a 1.5kb skin-specific Ercc1 transcript which 
originates from an alternative upstream promoter in mouse skin (J.Selfridge, 
unpublished observations).  In skin, the 1.5kb novel transcript was the major transcript 
compared to the normal 1.1kb Ercc1 transcript.  This 1.5kb skin-specific transcript is 
more abundant in most albino mouse strains and is barely detectable in pigmented 
mouse strains. 
 
Since NER has evolved to deal with UV-induced DNA damage and most UV damage in 
the body occurs in skin, we hypothesised that the novel transcript might be linked with 
increased DNA repair capability. Therefore we decided to investigate whether the high 
levels of novel Ercc1 transcript expression in skin was linked with any functional role, 
especially any link with repair of UV-induced DNA damage and protecting the skin 
from skin cancer. 
 
It was important to find the source of the 1.5kb Ercc1 transcript as it is not possible for it 
to originate from the normal Ercc1 promoter. We found no evidence for the 11kb 
upstream and 2.5kb upstream potential promoter regions as the source of the 1.5kb skin-
specific Ercc1 transcripts. Meanwhile, we investigated the region approximately 1kb to 
the 5' side of the known Ercc1 promoter and found an interesting different sequence 
pattern within this region among Balb/C (albino), C57BL/6 (pigmented) and 129/Ola 
(pigmented) mouse strains (Chapter 4). A CAAT signal, TATA signal, LINE/L2 
transposable element and CT repeats were found in all investigated strains. However, in 
the albino Balb/C strain only, beside these above regulatory elements, we found a 
SINE/B2 element 1023bp upstream of the normal promoter. The CT repeats in the 
Balb/C strain were also longer than in the other two tested strains. As the insertion of a 
transposable element at the promoter region is known to be capable of altering gene 





(Thornburg et al. 2006), it was possible that the insertion of this SINE/B2 element in 
albino strains could relate to the altered Ercc1 gene expression. CT repeats in a promoter 
region have also been reported to be linked with an alternative transcription start site 
(Xu and Goodridge 1998).  It also has been reported that the CT repeats strongly 
regulate the human HMGA2 promoter with an activation pattern that correlates to its CT 
repeat length (Borrmann et al. 2003).  
 
Our 5'RACE result and some confirmed Ercc1 transcripts in an online database, which 
contain the same exon 1 as our novel 1.5kb skin-specific Ercc1 transcript, mapped the 
transcription start site to the 5' region just upstream of the known Ercc1 promoter. In 
addition, the UV resistance of Ercc1 deficient mouse keratinocytes could be corrected by 
using a minigene which contains just the 1.03kb of sequence upstream of the known 
Ercc1 promoter and directs expression of the 1.5kb Ercc1 transcript. Thus, we believe 
that the high level of the novel 1.5kb skin-specific Ercc1 transcripts is driven by the 
region immediately upstream of the normal Ercc1 promoter.  
 
The Ercc1 skin-specific transcript is expressed at a higher level in most albino strains 
analysed, but does it have a functional role? Firstly, we found that the size of the ERCC1 
protein was the same in skin as in other tissues examined. This was in agreement with 
our previous studies on this 1.5kb Ercc1 transcript where we found no difference in the 
coding regions between the 1.1kb and 1.5kb Ercc1 transcripts. Secondly, we found that 
ERCC1 protein levels were generally consistent with Ercc1 mRNA levels in all mouse 
tissues examined except skin.  
 
As the 1.5kb skin-specific transcript had a much higher level in most albino strains 





different mouse strains. As the 1.5kb Ercc1 transcript had a much higher level in albino 
mouse skin, we expected that this would produce higher protein expression of ERCC1 in 
albino skin. However, this was not what we found. Levels of this 1.5kb transcript were 
not increased in mouse skin and cultured mouse keratinocytes after UV irradiation. 
Perhaps this is because the level of the 1.5kb Ercc1 transcript mRNA is already high 
enough to maintain adequate level of ERCC1 protein to respond to UV-induced DNA 
damage. 
 
Unrepaired UV-induced DNA damage blocks RNA Pol II transcription. This could lead 
to reduced levels of DNA repair proteins at precisely the time when they are most 
needed. Could the 1.5kb transcript be involved in maintaining adequate levels of ERCC1 
in the presence of a UV-damaged template? Albino strains lacking pigment protection 
would be at a greater risk of UV-induced DNA damage than pigmented strains. The 
SINE/B2 elements could contribute additional transcription factor binding sites, while 
the longer CT repeats could contribute to a more stable level of transcription on a UV-
damaged template (Borrmann et al. 2003). Both CPDs and 6-4PPs lead to altered helical 
structure. After UV irradiation the CT repeats could be expected to have a higher level 
of damage and the altered conformation might act as a local monitor of damage around 
the Ercc1 gene favouring adjacent initiation by RNA Pol II. To sum up, the role of the 
1.5kb skin-specific Ercc1 transcript in albino strains may be to maintain Ercc1 
transcription on a UV-damaged template rather than to boost expression. This 
hypothesis could be investigated by run on transcription assays from the normal and 
upstream Ercc1 promoter on UV-damaged and non-irradiated templates. 
 
Chapter 5 investigated the functional role of ERCC1 in melanoma, especially its 
reported correlation with resistance to the widely used chemotherapy drug cisplatin. An 





prognosis in a number of different cancers, such as advanced colorectal cancer, non-
small cell lung cancer and oesophageal cancer (Lord et al. 2002; Wei et al. 2008; Kim et 
al. 2009). We determined the level of NER proteins ERCC1 and its partner XPF 
between human melanoma and ovarian cancer cells. As melanoma is more resistance to 
cisplatin, we expected the level of the NER proteins to be higher in melanoma compared 
to ovarian cancer cell lines. Both ERCC1 and XPF showed an elevated level in 
melanoma. However, further investigations by proliferation assays didn't show any 
increased survival following UV-irradiation or cisplatin treatment in melanoma cell lines 
compared to ovarian cancer cell lines. The mechanism of the elevated level of NER 
proteins in cisplatin-resistant cells need to be investigated further. It is possible that the 
upstream promoter might be involved in this production of elevated level of ERCC1 
mRNA in cancer. To investigate this, 5'RACE and northern blotting analysis should be 
carried out on RNAs from cisplatin sensitive and resistant tumours. 
 
To investigate the role of ERCC1 in melanoma more directly, we turned to a system 
where we could manipulate the levels of ERCC1 directly and measure the consequences 
for melanoma growth and resistance to cisplatin. To achieve this, immortalized ERCC1 
proficient and deficient mouse melanocyte cell lines isolated from our mouse strain and 
which grow as xenografts with the histological characteristics of malignant melanoma 
were transplanted into nude mice and some mice were treated with cisplatin. (D.Melton, 
unpublished observations). 
 
Using this mouse model we noticed a very interesting result that the lack of ERCC1 
slows down the xenograft growth rate significantly in nude mice. Although both cell 
lines grew at the same rate in vitro, the ERCC1 proficient xenografts grew very rapidly 
while the ERCC1 deficient xenografts showed nearly 3 times slower growth during the 






Cisplatin treatments on ERCC1 proficient and deficient xenografts also showed a 
significant difference. ERCC1 proficient xenografts rapidly became cisplatin resistant, 
but the growth of ERCC1 deficient xenografts was completely inhibited. This raises the 
possibility that ERCC1 may be used to enhance the efficiency of cisplatin treatment. 
Moreover, this melanoma xenograft system could be ideal to identify and test possible 
ERCC1 inhibitors. Up to date, most of the reported ERCC1 inhibitors, such as UCN-01, 
actually do not inhibit ERCC1 directly but affect the interaction between ERCC1 and 
other NER proteins (Jiang and Yang 1999). We are screening the reported Ercc1 
inhibitors, as well as searching for new potential drugs in vitro by proliferation assay 
now. Once some interesting drugs are found by in vitro assay, we can test them further 
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